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The Road goes ever on and on
Down from the door where it began.
Now far ahead the Road has gone,
And I must follow, if I can,
Pursuing it with eager feet,
Until it joins some larger way
Where many paths and errands meet.
And wither then? I cannot say.
J. R. R. Tolkien
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P-glycoprotein (P-gp) is a member of a family of energy-dependent
transport proteins. The expression of P-gp isoforms in different tissues has
been previously examined, but the physiological functions of the genes have
not yet been established. Three gene isoforms have been found in rodents.
These appear to be functionally distinct and only two of them are related to
the multidrug resistance (mdr) phenotype displayed by tumour cells refactory
to chemotherapy.
Gene specific probes for each mouse isoform has allowed an
analysis of mdr gene expression in normal mouse tissues. The major mdr
mRNA species expressed in mouse liver is a 4.5 kb transcript encoding mdr
2. The function and factors regulating expression of this gene are unknown.
Mdr 1 and mdr 3 are also expressed in mouse liver, but at lower levels.
The exogenous and endogenous factors controlling the expression of
mdr 1, 2 and 3 mRNA in mouse liver were examined. The regulation of mdr
genes in the rat liver by xenobiotics, including cytochrome P450 and
glutathione S-transferase (GST) inducers, was also studied. The
hepatotoxins 2-acetylaminofluorene, aflatoxin B-j and diethylnitrosamine
induced rat hepatic mdr gene expression. Diethylnitrosamine also induced
hepatic and renal mdr 1 expression in the mouse. The compound, 1,4-bis [
2-(3-dichlorpyridyloxy)] benzene (TCPOBOP) caused a suppression of
hepatic mdr 2 and mdr 3 levels in mouse whilst inducing cytochrome P450
levels to a high extent. Long-term suppression of mdr 2 levels was also
demonstrated. The anti-cancer drugs vincristine and etoposide, as well as
the phenolic antioxidant butylated hydroxyanisole, known to elevate GST
levels, induced mdr 2 gene expression in the mouse.
Using hypophysectomised animals, it was shown that the pituitary
regulates the expression of both mdr 2 and mdr 3 in mouse liver. Animal
models, in which specific pituitary hormones were ablated, demonstrated
that neither growth hormone nor thyroid hormone depletion reduces the
expression of mdr 2. Elevation or depletion of hormones produced by the
adrenal gland, using chemical treatment, also did not affect mdr 2 gene
expression. The regulation of mdr 2 and 3 gene expression by the pituitary
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appears to be complex and may involve more than one hormone.
Using a cell culture model, it was demonstrated that non-metabolised
carcinogens do not compete with known substrates for transport across the
plasma membrane.
All these findings are important in elucidating the
regulation of mdr genes in rodents.
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Cells protect themselves from toxic insults in a variety of ways. Use of
chemicals often results in their becoming ineffective due to cellular
resistance mechanisms and understanding such mechanisms has become
increasingly significant in medicine. Resistance may be both intrinsic or
acquired. Intrinsic resistance may be due to a variety of biochemical reasons
as shown in Table 1.1. For example, the mammalian lung copes with
oxygen-induced free radicals by producing antioxidants including
superoxide dismutase and glutathione peroxidase (Halliwell and Gutteridge,
1985). Drugs and toxins produce biochemical changes including enzyme
induction, DNA repair and increased detoxification capacity. Certain
bacteria produce dihydrofolate reductase in response to trimethoprim
treatment (Young and Amyes, 1986).
Environmental factors can elicit an adaptive response that also
confers chemical resistance. Prokaryotes have various stress response
mechanisms. Many proteins are regulated by stress and the responses may
inter-relate.
Heat-shock to cells causes the expression of three families of heat-
shock genes, Hsp 90, Hsp 70 and Hsp 20. Hsp 70 and Hsp 72 bind
peroxisome proliferators, for example clofibrate, which may inhibit their
activity (Alvares et al, 1990).
A fundamental association between adaptive response to
environmental stress and drug resistance seems to exist. The heat-resistant
Chinese hamster ovary (CHO) cell line over-expresses Hsp 70 and also
shows resistance to adriamycin and the epipodophyllotoxin VM-26 (Wallner
and Li, 1986). These are both well known substrates for P-glycoprotein (P-
gp), which is involved in the mdr phenotype. It has been shown that P-gp
expressing cells contain a heat-shock consensus sequence in their
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TABLE1.1 EXAMPLESOFINTRINSICRESISTANCE EXAMPLE Antibioticproducers Braintumours Chemoprevention Heatshock Poordebrisoquine metabolizersORGANISM Streptomycesgriseu Man Mammals Chinesehamster fibroblasts Man AdaptedfromH yesndWolf,1990
PROTEINORTH R FACTORS Aminoglycoside phospotranferase Sanctuarysi e Dietarymanipul tion Transienthyperthermia CytochromeP-450
TYPEDRUG Novelmetabo icStreptomycin inactivation DrugdeliveryAnticancerdrugs AdaptivechangCarcino n (aflatoxinB-|) Stressrespon eAdriamycin, ethanol Population polymorphismReduced sensitivityto carcinogens
promoter region (Chin et at, 1990). Carcinogens also induce heat-shock
proteins (Carr etal, 1986).
The second type of resistance, that ofacquired resistance, describes
the emergence of a population of previously drug-sensitive cells. The
development of cancer is a step-wise process that involves in part such a
selection. Major alterations are observed in the levels of drug metabolising
enzymes in hepatocyte nodules selected by exposure to carcinogens. The
changes include a decrease in the expression of the cytochrome P450 and
sulphotransferases and over-expression of glutathione-S-transferases
(GSTs), UDP glucuronyl transferase, epoxide hydrolase, DT-diaphorase, y-
glutamyl transferase and P-gp.
Such a diversity of events suggests the existence of a common
control mechanism responsible for coordinating the expression of these
enzymes. An initial mutation event, which could involve a stress response
regulatory gene, may initiate a cascade of events as described above. An
understanding of these enzymes is crucial to the prevention or treatment of
cancer.
Cytochrome P450s and glutathione S-transterases (GSTs) are
subject to regulation by a variety of endogenous and exogenous factors. The
aim of this project was to study the factors controlling the regulation of P-gp,
as well as trying to relate it s regulation to that of P450s and GSTs in order to
establish whether areas of common regulation exist.
In this introductory chapter, literature dealing with the properties of the
P-gp, cytochrome P450 and GST gene families in rodents will be discussed.
The regulation of cytochrome P450s and GSTs by xenobiotics and
endogenous substances will be briefly reviewed. Questions regarding the
regulation of P-gp will be raised and the strategy for answering them
described.
The following chapters will contain more detailed background
information regarding different aspects of the project and discuss the
findings of the experimental work conducted. The final chapter will
summarise the results and discuss them more fully in addition to suggesting
future topics for study.
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MULTIDRUG-RESISTANCE
1.2.1 THE MULTIDRUG RESISTANCE PHENOTYPE AND P-
GLYCOPROTEIN
Multidrug-resistance (mdr) describes the simultaneous expression of
cellular resistance to a wide range of structurally unrelated drugs. Such a
phenotype is frequently seen in clonal mammalian lines selected for
resistance to a single cytotoxic agent. The complexity of the mdr phenotype
is illustrated in Table 1.2, where it is shown that mdr cells can be cross-
resistant to structurally andfunctionallydistinct compounds.
TABLE 1.2







Gramicidin D -5000 NA
Methotrexate NA 3
vinbastine in the case of CEMA/LB100.
*
compared to parental wild-type cell line
NA not assayed
Adapted from Gerlach etal, 1986
Mdr cells frequently display collateral sensitivity to certain hydrophobic
compounds. Resistance appears to be due to a lower cellular accumulation
of the drugs involved.
Many mammalian cell lines selected for resistance to a single
cytotoxic agent, for example actinomycin D, adriamycin, colchicine or Taxol,
show an altered sensitivity to an unexpectedly wide range of cytotoxic
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compounds (Biedler et al, 1983; Gupta, 1983 a, b; Ling et al, 1983; Beck,
1984a; Curt et al, 1984). Usually, the cell lines display the highest degree of
resistance to the selecting agent and lower resistance to other compounds.
In general, among the anti-cancer drugs, resistance to the
anthracyclines, vinca alkaloids, podophyllotoxins, actinomycin D,
maytansine and Taxol are most often observed in mdr cell lines. Cross-
resistance to alkylating agents such as melphalan, nitrogen mustard and
mitomycin C and to anti-metabolites such as methotrexate occurs less
frequently and usually at a lower level.
Cytogenetic studies demonstrate the frequent presence of
homogeneously staining regions and double minutes in mdr cell lines
(Baskin et al, 1981), which are karyotypic features of gene amplification
(Cowell, 1982). Gene amplification of P-gp sequences in a variety of cell
lines has been noted (Riordan et al, 1985).
A reduced accumulation of drug has been a consistent feature of
many cell lines, relative to their drug sensitive counter-part (Beck, 1984;
Riordan and Ling, 1985). This may be effected by reduced influx, increased
efflux, altered compartmentalization or by a combination of these
mechanisms. A unifying model to account for all the observed reduced
accumulation events in these cell lines has not yet been conclusively
demonstrated.
Many studies have concentrated on elucidating the biochemical
differences between mdr and sensitive cells. The most consistent
biochemical change is the increased expression of a plasma membrane
glycoprotein, termed p-glycoprotein (P-gp). Only minor differences are
observed in the lipid constituents of the membranes of mdr cells (Bosman,
1971; Ling et al, 1977). However, changes in cytoplasmic components have
been noted. The most consistent of these is an increase in a small
cytoplasmic protein of 19 kD and isoelectric point (pi) of 5.7. This is present
in elevated amounts in Chinese hamster and mouse cells resistant to
vincristine (Meyers and Biedler, 1981; Meyers et al, 1985). This protein is
called VP19 and is phosphorylated (Biedler et al, 1983).
The association of P-glycoprotein with mdr was first described in
colchicine- resistant Chinese hamster ovary (CHO) cells and in actinomycin
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D-resistant Syrian hamster cells (Juliano and Ling, 1976). Similar alterations
were later described in many other drug resistant cell lines (Peterson and
Biedler, 1978; Garman and Center, 1982; Beck et al, 1979).
In isolated plasma membranes of highly resistant CHO cells, P-gp
was found to be the major membrane component (Riordan and Ling, 1979).
The reported molecular weight (Mr) for P-gp is 170,000 kD, but this can vary
from between 140,000-220,000 kD depending on the SDS-PAGE system ,
the solubilisation and electrophoresis conditions used. An Mr of 170,000 kD
was obtained using a modified Fairbanks system for SDS-PAGE (Fairbanks
et al, 1971; Debenham et al, 1982; Kartner et al, 1983 a, b). This buffer
system gives sharper resolution of glycoproteins than the more
conventionally used discontinuous systems such as that of Laemmli (1970).
The improved sensitivity of detection of P-gp by monoclonal
antibodies (Kartner etal, 1985) along with Western blotting (Towbin et al,
1979) made possible a comparitive study of different mdr cell lines (Kartner
et al, 1983a, 1985). It was found that homologous P-gps are expressed in
mdr cells of different origins and that the level of P-gp expression was
always elevated over drug sensitive parental levels by an amount consistent
with the degree of resistance.
Monoclonal antibodies have also been applied to the identification of
cDNA clones encoding P-gp. Riordan et al (1985) identified a 600 bp clone
from a ?igt11 library that was shown to code for three epitopes of P-gp. A 4.7
kb mRNA specific to mdr cells was found using this cDNA insert which was
consistent with the molecular size of the P-gp polypeptide. The amount of
message expressed also correlated with the level of P-gp expression in cell
lines with different degrees of mdr.
Using Southern blotting with P-gp genomic DNA from sensitive and
resistant cell lines, it has been shown that there is amplification of the
genomic DNA coding for P-gp in some mdr cells (Riordan et al, 1985).
Increased P-gp can also occur in the absence of gene amplification (Fuqua
et al, 1987).
Cloning P-gp genes was a major advancement in the understanding
of the structure and function of P-gp. The sequence of human P-gp (mdr 1
gene) encodes a molecule of 1280 amino acids and is tandemly repeated.
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Each half of the molecule consists of a hydrophobic domain containing
three pairs of membrane-spanning a-helices and a highly conserved
hydrophilic cytoplasmic domain containing an adenosine triphosphate (ATP)
binding site (Gros et al, 1986; Chen et al, 1986; Gerlach et al, 1986).
The transmembrane domains are thought to form a pore through
which P-gp effluxes drugs and endogenous substances. How energy is
transduced for transport is unknown although the binding of ATP analogues
to P-gp and the ATPase activity of the purified protein has been confirmed
(Cornwell et al, 1987; Hamada and Tsuruo, 1988). It has also been shown
that a mutation of one or both nucleotide-binding consensus sequences
results in a lack of drug resistance in mdr transfected cells (Rothenburg and
Ling, 1989). These sites may functionally interact to effect drug efflux.
The mechanism of drug binding is not yet known, but direct binding of
drugs to P-gp may be an important step. Choik et al (1988) reported a
mutation in a human mdr cell line that resulted in a change from valine to
glycine at position 185. Mutants displayed an increased resistance to
colchicine, etoposide (VP16) and a decreased resistance to vinblastine,
vincristine and actinomycin D. This finding infers that subtle alteration in
these sequences can produce significantly different mdr phenotypes.
Direct binding of drug analogues to P-gp has been studied.
Photoaffinity vinblastine analogues can label the protein and the binding is
inhibited by other drugs such as vincristine and daunomycin, as well as
chemosensitisers such as verapamil (Gottesman, 1988b). The conclusion
from these findings is that these compounds may be competing for a
common binding site.
It is possible that differential expression of mdr genes could alter the
profile of transported drugs. Co-amplification of other genes, as well as the
mdr genes, may also modify the profile. Van der Bliek et al (1986) reported
the co-amplification and overexpression of at least six classes of genes in
one CHO cell line. P-gp is phosphorylated at both serine and threonine
residues (Endicott and Ling, 1989) and changes in the extent of such
phosphorylation may also modulate activity.
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1.2.2 P-GLYCOPROTEIN AS PART OF A TRANSPORT SUPER-FAMILY
Both bacterial and eukaryotic transport proteins share extensive
sequence homology to P-gp, as displayed in Figure 1.1, and is therefore
considered a member of a super-family of proteins that transport a wide
range of substrates. Members of this family have high sequence homology
in the nucleotide binding consensus sequence (Walker et at, 1982).
The transporters fall into two general classes. The first represents
proteins which have linked hydrophobic and hydrophilic domains. P-gp
appears structurally most like this class and can be viewed as a tandemly
duplicated hemolysin B (Hly B)-like protein (Gros etal, 1986; Gerlach etal,
1986). The hydrophobic domains of P-gp and Hyl B-like proteins have low
sequence homology but their location and the number of membrane-
spanning helices argue for a similar membrane disposition and pore-
forming function. The brown and white loci of Drosophila are also part of the
Hyl B-like protein class but the order of the two domains is reversed
(Dreesen et al, 1988). The brown and white proteins import pteridine
pigment precursors into cells whereas the Hyl B class export substrates.
Riordan et al (1989) has recently described the cystic fibrosis gene
product, referred to as the cystic fibrosis transmembrane conductance
regulator (CFTR). This is also a member of this class of transporters and has
a tandemly duplicated structure.The CFTR protein is presumed to be
involved in the transport of anions across cell membranes.
The second group of transporters are members of multi-component
periplasmic protein binding permeases (PPBP) systems of bacteria. The
permease system is composed of a substrate binding protein that presents
the substrate to a membrane complex consisting of two integral membrane
proteins capable of forming several transmembrane helices and
a membrane associated cytoplasmic hydrophilic protein that binds ATP
(Ames, 1986). There is evidence that two ATP binding subunits might also
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1.2.3 THE P-GLYCOPROTEIN MULTI-GENE FAMILY
P-gp is a member of a small, highly conserved multigene family with
three genes in rodent and two genes in primates (Ng et al, 1989). The family
appears to have arisen from one or more gene duplication events (Van der
Bliek et al, 1988a). Each P-gp isoform is highly conserved in protein
sequence and genomic structure.
Analysis of the 3' untranslated region of various P-gp genes has
allowed identification of equivalent isoforms between species (Ng et al,
1989). Each gene within a species encodes a unique 3' untranslated region
but certain differences are conserved across species.
The P-gp isoforms can be grouped into three classes as shown in
Table 1.3.
TABLE 1.3
CLASSIFICATION OF THE P-GLYCOPROTEIN GENES
SPECIES CLASS I CLASS II CLASS III
Hamster pgp 1 pgp 2 pgp 3
Mouse mdr 3 mdr 1 mdr 2
Human mdr 1 - mdr 3 (mdr 2)
Redrawn from Juranka et al, 1989
Various studies indicate that transfection of class I and II P-gp can confer the
mdr phenotype (Guild et al, 1988;Ueda et al, 1987) whereas type III
transfection does not result in drug resistance (Rothenburg and Ling, 1989;
Gros et al, 1988). Structural features of this isoform clearly imply that it is a
membrane transport protein, similar to class I and II isoforms and it would be
interesting to determine the compounds it may transport.
Human class I and mouse class II P-gp genes have been studied to
determine their genomic intron/exon organization (Chen et al, 1989;
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Raymond and Gros, 1989). Both genes contain 27 exons with identical
relative location within the coding region (Ng etal, 1989; Chen etal, 1989;
Raymond and Gros, 1989). P-gp may have originated from a duplication
event or by the fusion of two closely related but independently evolving
genes.
The number of P-gp genes in vertebrates has been estimated (Ng et
al, 1989). Primates (human, rhesus monkey), rabbit, chicken and fish contain
two genes; rodents (hamster, mouse, rat) and cow contain three genes and
pig has five genes. Invertebrates also contain P-gp sequences. Drosophila
melanogaster contains two genes, and three genes have been cloned from
the nematode Caenorhabditas elegans. McGrath and Varshowsky (1989)
reported a P-gp gene in Saccharomyces cervisae. The P-gp cloned is the
product of the STE6 gene; a locus required for the secretion of the a-factor
mating pheromone.This represented the first identification of a normal
function for a P-gp gene product. STE6 is part of a signal sequence-
independent protein translocating system. This is shared by the products of
the bacterial Hly B, cya B and the Ikt B genes. The mammalian class III P-gp
gene may have a similar protein translocating function.
The malarial parasite, Plasmodium Falciparum, is known to have two
genes (pfmdr) (Foote et al, 1989; Wilson et al, 1989). The pfmdr is amplified
in some chloroquine-resistant Plasmodium cells. Resistance is associated
with increased drug efflux (Krogstad et al, 1987) and verapamil can reverse
such resistance.
1.2.4 EXPRESSION AND REGULATION OF P-GLYCOPROTEIN
Regulation of P-gp may occur at various levels including transcription,
translation and post-translation. Most regulation studies have been done in
cell lines but the mechanisms may also apply to normal and malignant
tissues.
Following early drug selection steps, human cell lines exhibit
increased levels of P-gp, mRNA and protein, but without increased gene
copy number. Control of transcription is suggested as the reason (Shen et
al, 1986). Bradley et al (1988) showed that P-gp may also be over-
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expressed in resistant human and rodent cell lines due to gene
amplification. Bradley et al {1989) has more recently reported increased P-
gp in the absence of gene copy number or mRNA levels, suggesting that
such mechanisms as protein stabilisation or increased translation may
occur.
Localisation of P-gp in normal human and rodent tissues has been
performed using specific DNA probes and antibodies. It has been found that
the P-gp genes are differentially expressed in a tissue-specific fashion.
Such studies demonstrate the consistently high expression of P-gp in
the adrenal cortex, liver, kidney, intesine, muscle fibres and gravid uterus
(Baas and Borst, 1988; Thiebaut et al, 1987; Croop et al, 1989). P-gp is
localised to the apical surface of the small and large intestine, renal proximal
tubules, bile and pancreatic ducts and the bile canilicular face of
hepatocytes. This distribution implies a secretory function for P-gp and a role
in clearing the cell of xenobiotics. P-gp is also found in the cells lining the
brain capillaries and may be involved in the blood/brain barrier (Cordon-
Cardo, 1989). In the adrenal cortex, P-gp may be responsible for the
transport of corticosteroids.
Recently Croop et al (1989) examined the distribution of P-gp in
mouse tissues by Northern blot analysis using gene specific probes. Class I
(mouse mdr 3) was found at highest levels in the intestine and at
intermediate levels in heart, brain and kidney. The highest level of class II
(mouse mdr I) were present in the gravid uterus and adrenal with medium
levels in kidney and heart. Medium levels of class III P-gp (mouse mdr 2)
were found in adrenal, liver, spleen, heart and muscle. The expression of
class III P-gp is also found in a subset of muscle fibres (Georges et al, 1989).
The class III P-gp is the only gene to date that has been shown to
undergo differential splicing. Three different class III transcripts have been
identified from a human liver library (Van der Bliek et al, 1988b). It is not
known whether the variants are expressed at the protein level and what
effect the changes would have on function.
P-gp increases dramatically in the uterus during pregnancy and is
localised to the luminal surface of the secretory epithelial cells of the
endometrium.lt was also demonstrated that female mice treated with
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oestradiol and progesterone demonstrated induced P-gp mRNA. This leads
to the conclusion that P-gp may be under steroidal control (Arceci et al,
1988).
P-gp expression also seems to be a specific response of cells to toxic
or metabolic stress. In carcinogen-induced preneoplastic and neoplastic
liver nodules and hepatocytes from regenerating rat liver, increased mRNA
levels have been observed (Thorgeirsson et al, 1987; Fairchild et al, 1987b).
The three classes of P-gp genes express different lengths of
transcripts. In mouse, class I (mdr 3) produces a 6 and 5 kb transcript, class II
(mdr 1) produces a 5 kb transcript and class III (mdr 2) is 4.5 kb in length
(Croop et al, 1989).
1.2.5 SIGNIFICANCE OF P-GLYCOPROTEIN IN CANCER
Increased levels of P-gp have been seen in human cancers, for
example leukaemias, lymphomas, sarcomas and carcinomas ( * ).
In many cases, an increased level of P-gp is detected in tumours
following relapse from chemotherapy compared to the biopsies before
treatment. However, in some tumours high levels of P-gp are found even
before therapy due to the cells expressing a phenotype which has
intrinsically high P-gp levels (Goldstein et al, 1989).
Chan et al (1989) reported an elegant study on soft tissue sarcoma in
childhood which indicated that the level of P-gp was a good prognostic
marker of relapse-free response. However, the answer does not appear so
straight-forward for other types of cancer, and the universal significance of P-
gp to clinical response has not yet been convincingly shown.
Reversing the mdr phenotype using chemosensitisers to aid cancer
treatment is being investigated. Ford and Hait (1990) recently reviewed the
pharmacology of drugs that alter mdr in cancer therapy. These compounds
were shown to fall into six broad categories.
Verapamil, a calcium channel blocker has been shown by many
investigators to reverse mdr in cell lines (Beck, 1984; Radel et al, 1988) by
altering drug accumulation (Tsuruo et al, 1981). Safa et al (1987, 1988)
demonstrated that verapamil binds to P-gp and can inhibit the binding of
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* Tsuruo etal, 1987; Goldstein et al, 1989; Gerlach et al, 1987; Kakehi et al,
1988.
many chemotherapeutic drugs. However, verapamil is extremely cardiotoxic
in the concentration range needed for antagonism of mdr. The use of less
toxic enantiomers of verapamil and it's analogs may provide a means of
utilising these compounds effectively at a clinically useful level (Pirker et al,
1990). Other calcium channel blockers have been studied and found to be
active.
Calmodulin antagonists, such as phenothiazines, are effective
chemosensitizers and can enhance drug accumulation in mdr cells (Ford et
al, 1990; Chafouleas etal, 1984).
Inaba's group (1984) investigated the chemosensitizing effects of
anthracycline analogs on mdr cells and found significant enhancement of
cytotoxicity. Similarly a number of relatively non-toxic Vinca alkaloid analogs
effectively antagonized cross-resistance of mdr cell lines (Inabe and
Nagashima, 1986).
Prompted by the high levels of mdr 1 mRNA found in the pregnant
murine uterus (Arceci et al, 1988), Yang et al (1989) studied the effects of
steroids on mdr. It was found that progesterone and deoxycorticosterone
increased vinblastine accumulation and caused an equivalent reversal of
vinblastine resistance in murine macrophages as verapamil. The results
suggested that progesterone may bind to a hydrophobic pocket present in
the P-gp molecule and that certain steroid hormones may be natural
substrates for P-gp. Anti-oestrogens, for example tamoxifen, can partially
overcome resistance (Ramu etal, 1984).
Cyclosporins are yet another group of chemosensitising agents.
Cyclosporin A (CsA) has immunosuppressive activity and can inhibit an
early stage of T lymphocyte activation (Handschumacher et al, 1984). CsA
has been found to reverse resistance in mdr cells (Twentyman et al, 1987,
1988). However cyclosporins also appear to increase the effect of
chemotherapeutics on certain sensitive cell lines (Chambers et al, 1989).
The mechanism by which the cyclosporins sensitise mdr cells remains
unclear, but it may be through an indirect effect of drug metabolism or
potentiation of drug toxicity.
CsA does not consistently alter drug accumulation. Silbermann et al
(1989) reported the increased accumulation of daunomycin in a multidrug
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resistant cell line but not it's sensitive counterpart due to CsA administration.
In contrast, Chambers et al (1989) showed that CsA had no effect on
doxorubicin accumulation in CHRC5 cells. Nooter et al (1989) reported
increased daunomycin accumulation and toxicity in P388/Dau cells.
The final group of sensitisers are the hydrophobic cationic
compounds such as quinidine (Tsuruo et al, 1984) and the antibiotic
erythromycin (Hofsli and Nissen-Meyer, 1989). Whether these compounds
act through a common mechanism is unclear, but their high degree of
hydrophobicity may cause non-specific perturbations in the cell membrane
leading to increased drug accumulation.
1.3 ALTERNATIVE MECHANISMS INVOLVED IN MUTIDRUG-
RESISTANCE
Apart from an increase in P-gp expression, an expanding number of
biochemical and molecular changes are observed in cell lines selected for
resistance to multiple cytotoxic drugs. These alterations have been
described for non-Pgp expressing cells and those that over-express P-gp.
Clinical drug resistance in human tumours probably comprises a
combination of cellular mechanisms of resistance. The two best
characterised additional resistance machanisms are firstly, changes in the
expression or activity of enzymes involved in the phase II glutathione
detoxification pathway and secondly, alterations in topoisomerase II.
Glutathione-S-transferases (GSTs) are enzymes that catalyse the
conjugation of electrophilic substances and endogenous xenobiotics to
glutathione (GSH), a tripeptide thiol, in order to form soluble stable
metabolites which can be more easily excreted (Jackoby, 1978; Chasseaud,
1979).
Many researchers have reported an alteration in GST and GSH-
related enzymes in cell lines resistant to alkylating agents (Lewis et al, 1988;
Saburi et al, 1989). Cowan et al{ 1986) also noted an increase in the activity
of the drug metabolising enzymes DT-diaphorase and glucuronyl
transferase when comparing the biochemical changes in mdr human breast
cells to those seen in carcinogen induced resistance to xenobiotics in rats. It
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is believed that these changes are not simply coincidental to the selection of
resistance but have a significant function or regulatory role in the process.
The role of GST in mdr involving non-alkylating agents is still under
debate. The role of GST n in mdr and correlation with P-gp is considered in
the following chapters. A fuller discussion of the GST multi-gene family will
therefore be given in section 1.4.
Topoisomerases are enzymes that catalyse the unwinding of DNA,
which is necessary for replication (Liu, 1983). Topoisomerase II (topo II) is
thought to be a target for DNA intercalating and non-intercalating drugs such
as doxorubicin, mitoxantrone and etoposide (Chen et al, 1984). Several mdr
cell lines display reduced Topo II activity in the absence of P-gp or changes
in drug accumulation (Pommier etal, 1986; deJong etal, 1990). Ganapathi
et al (1989) described a series of cells, selected for increased resistance to
doxorubicin, which exhibited increased levels of P-gp and reduced Topo II
mediated cleavage of DNA. This suggests that the alteration with this
enzyme can be multi-factorial.
Other changes described in cross-resistant cells appear only to occur
with over-expression of mdr 1 which suggests that this may be the result of
being passively transcribed along with amplification of mdr 1. Meyers et al
(1985, 1987) has shown that sorcin, a 22 kD anionic calcium binding
protein, is over-produced in vincristine resistant mouse and Chinese hamster
lung and ovary cells.
Ivy et al (1988) reported an alteration in the expression of cytochrome
P4501A1 in MCF 7 adriamycin resistant cells. Burt and Thorgeirsson (1988)
reported the co-induction of the mdr 1 gene with cytochrome P450 genes in
rat liver by exposure to xenobiotics. They concluded that P-gp was in fact
under the control of the Ah locus, as is P450 1A2 (Gonzalez etal, 1984). The
regulation of mdr genes by compounds known to operate through the Ah
locus will be discussed in the course of this thesis. A fuller description of
P450 genes and their regulation will therefore be given in section 1.5.
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1.4 GLUTATHIONE-S-TRANSFERASE DRUG METABOLISING
ENZYMES
GSTs are a multi-gene family of enzymes that catalyse the
conjugation of GSH to electrophilic reactive intermediates. The reaction
constitutes the first step in the mercapturic acid pathway which is involved in
the excretion of foreign compounds. The GSH conjugate may be excreted
directly into bile or further metabolised to mercapturic acid.
All the GSTs have in common a dimeric structure with subunits of
molecular weight between 23,000 and 26,000 kD. Eleven subunits have
been characterised for the rat as outlined in Table 1.4.
TABLE 1.4
GSH TRANSFERASE SUBUNITS IN THE RAT
NUMERICAL CLASS "Y" DESIGNATION MOL. MASS. REF
( D)
1 a Ya 25,000 1
2 a Yc 27,500 1
3 Ybi 27,500 1
4 Yb2 26,500 1
5
6 l^ -< cr co 26,000 2,3
7 K Yf or Yp 24,800 4,5
8 a Yk 25,500 1
9 Yn2 26,000 1
10 a Y1 25,500 1
11 Yo 26,500 6
1. Hayes (1988)
2. Abramovitz and Litowsky (1987)
3. Guthenberg efa/(1985)
4. Kitahara et al {1984)
5. Hayes and Mantle (1986)
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6. Kispert et a/(1989)
Complete sequences are known for subunits 1, 2, 3, 4 and 7. They fall into
three categories based on sequence homology. These have been named a
(1 and 2), p (3 and 4) and k (7) by Mannervick et al{ 1985 a, b). The genetic
relationship extends the a class to include 8 and 10 and p to include 6 and
9. Heterodimers exist within the multi-gene family (Ketterer et at, 1986). The
most commonly used substrate for most rat subunits is 1-chloro-2,4-
dinitrobenzene (CDNB). CDNB undergoes nucleophilic displacement of the
chloro substituent by GSH. Other substrates may be used to determine the
relative activity of a particular subunit.
A wide range of chemicals, both natural and synthetic, induce GST in
the rat. These include barbiturates, polyaromatic hydrocarbons (Igarashi et
al, 1987); certain antioxidants such as butylated hydroxyanisole (BHA) and
ethoxyquin (Benson, 1979; Rushmore and Pickett, 1990; Sato et al, 1984)
and natural products. Aflatoxin B-| (AFB-|) is a hepatocarcinogen in the rat.
FIGURE 1.2
GLUTATHIONE CONJUGATION OF AFLATOXIN B-,-8,9-OXIDE
Redrawn from Ketterer et al, 1988
The carcinogenic metabolite, AFB-|-8,9-oxide, is a substrate for subunits 1
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and 2 (Coles et al, 1985) (Figure 1.2). Induction of subunit 1 by ethoxyquin
results in a four- to five-fold induction in the biliary excretion of the AFB-|-
GSH conjugate and a decrease in genotoxicity (Kensler et al, 1986).
GSTs also have Selenium (Se)-independent GSFI peroxidase activity
for which lipid and nucleic acid hydroperoxides are good substrates. In vivo
it has been proposed that GSH peroxidases are part of a system for
repairing damage to membrane phospholipids by free radicals (van Kuijk et
al, 1987). Ketterer et al (1987) proposed that GSTs may be a part of the
repair system for thymidine hydroperoxides resulting from free radical
damage to DNA. The rat nucleus appears to contain a chromatin-associated
GST isozyme with high activity towards DNA hydroperoxide (Tan et al,
1988).
GSTs have been found in almost every rat tissue examined. Liver and
testis have very high CDNB-transferase activity, as reported by Meyer et al
(1983). In the rat liver, both a and p are abundant whereas k class GST is
*
present at very low levels. This isozyme is present in all bile duct cells and in
some hepatocytes (Tatematsu et al, 1985); a and p class isozymes are
present in all hepatocytes but are most abundant around the central vein
(Redick et al, 1982).
GST gene expression changes during development in the liver.
Before birth, levels are low and increase after birth until, at two weeks of age,
all adult subunits are expressed. The quantity continues to increase until at
maturity the female expresses higher levels of a class GST whereas the p
class is more abundant in male rats (Igarashi et al, 1987).
1.4.1 INDUCTION OF GLUTATHIONE-S-TRANSFERASE GENE
EXPRESSION
GSTs are inducible by various compounds. The dietary antioxidant
butylated hydroxysanisole (BHA) induces subunit 1 from the a class GST
(Rushmore and Pickett, 1990). Phenobarbitone and 3-methylcholanthrene
induce subunit 1 from the a class and subunits 3 and 4 from the p class in rat
liver (Hales and Neims, 1977; Pickett et al, 1982). In rat liver preneoplastic
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foci, a, p and k class GST are abundant (Kitahara et al, 1984). Many
develop into nodules which also have increased expression of epoxide
hydrolase, NAD(P)H-quinone oxido-reductase and UDP-glucuronyl
transferase (Eriksson et al, 1983). Some nodules persist and become
neoplastic primary hepatomas (Tatematsu et al, 1983). Progress to
malignancy is marked by the expression of the tc class (subunit 7) GST
making this isozyme a very useful marker for hepatocellular pre-neoplasia
and hepatocarcinomas (for reviews see Sato, 1988, 1989).
Four isozymes have been purified from mouse liver, as shown in
Table 1.5. These can be classed into the families a , p. and k (Warholm et
al, 1986). The rc-type enzyme, which can be resolved into three forms, is the
dominant form in the male mouse liver (McLellan and Hayes, 1987) but is
absent from many extrahepatic tissues (Hayes et al, 1987). The n class
isozyme expression is known to be male hormone-dependent (Hatayama
et al, 1986).
Benson et al (1978, 1979) reported up to ten-fold induction of GST
levels in the mouse by phenobarbitone, BHA and BHT administration.
Diethylnitrosamine (Agius and Gidari, 1985) and chronic ethanol
administration (David and Nerland, 1983) have been shown to induce GST
expression up to two-fold. However none of these studies identified the
TABLE 1.5
GSH TRANSFERASES IN THE MOUSE





Hayes et al{ 1987)
Warholm et al (1986)
McLellan and Hayes (1987)
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isozymes affected by the inducers.
More recently Pearson et al (1988) showed that BHA induced the
class p. and a GST mRNA levels in mouse liver 15- and 50-fold respectively
whereas class % mRNAs were much less responsive.
1.4.2 REGULATION OF GLUTATHIONE-S-TRANSFERASE GENES
Rushmore efa/(1990) and Paulson etal{ 1990) identified two regions
of the 5' flanking sequence of the GST Ya (alpha class) subunit gene that
have elements to control the regulation of gene expression by planar
aromatic compounds. One such element, spanning nucleotides -908 to -899,
contains the xenobiotic responsive element (XRE) sequence:
5'-T-GCGTG-3'
3'-A-CGCAC-5'
This consensus sequence is also found in the cytochrome P4501A1 gene
(Whitlock, 1987; Deninson et al, 1988, 1989).
The second region has no sequence identity to the XRE but responds
to the planar aromatic compunds (3-naphthoflavone (P-NF) and 3-
methylcholanthrene (3-MC). This element, known as the antioxidant
responsive element (ARE), can respond to phenolic antioxidants such a t-
butylhydroquinone in cells that lack afunctional^ receptor, but requires the
presence of the Ah receptor and a functional cytochrome P4501A1 protein
before responding to p-NF (Rushmore and Pickett, 1990). It spans
nucleotides -722 to -682 of the 5' flanking region of the rat Ya gene.
A particularly interesting example of endogenous regulation is the
induction of % class GST by interferons-a/p (Adams et al, 1987). Both
testosterone and interferon-a/p can induce the k family in female mice-
Many researchers have evidence indicating that the GSTs are an
important part of cellular protection against cytotoxic compounds.
Cowan (1986) reported similarities in the changes in GST expression
during preneoplasia and in drug resistant cell lines, indicating that similar
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mechanisms may be involved. Alteration in gene expression in
preneoplastic lesions may be due to an immortalisation of a transient stress
response (Adams et al, 1985; Hayes and Wolf, 1988). GSTs are found to be
over-expressed in cells undergoing cytotoxic insult, which is also indicative
of a stress response (Carmichael et al, 1986). The mechanism be which
these changes occur is not clear.
1.4.3 INVOLVEMENT OF GLUTATHIONE-S-TRANSFERASES IN DRUG
RESISTANCE
The 71 class isozyme is strikingly elevated in three rat models of broad
cross-resistance to multiple toxic agents. Firstly, in the Solt Farber model of
hepatocellular carcinogenesis, preneoplastic nodules develop resistance to
the toxic effects of the carcinogen that induce the transformation and also
become cross-resistant to other structurally unrelated carcinogens (Carr,
1987). The nodules have increased amounts of the rat 7c class GST, GST-P
(Kitahara et al, 1984.
Secondly, MCF-7 human breast cancer cell line selected for
resistance to doxorubicin (Cowan et al, 1986) show increased expression of
k class GST (Batist, 1986). Thirdly, v-H-ras transformed rat liver epithelial
cells demonstrate an mdr phenotype along with increased GST-P
expression (Burt et al, 1988).
Yf may play a role in the initiation of altered hepatocyte growth and it s
increase during preneoplasia is of great interest. Phorbol esters, such as 12-
0-tetradecanoylphorbol-3-acetate (TPA), are potent tumour promoters.
Alterations in gene expression following TPA has been suggested to involve
a PKC signal transduction mechanism. The promoter region of the human n
gene has a TPA response element (TRE) sequences (Cowell et al, 1988).
Burt et al (1988) transfected v-Ha-ras and v-raf into rat liver epithelial cells
and showed a marked induction of Yf GST and P-gp. The increase in Yf
during preneoplasia and in many tumours could therefore be explained by
linking it with the fact that Yf is induced by tumour promoters and genes
linked to cell growth and division. The role of Yf in the carcinogenic process
still requires further investigation.
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To determine whether GST 7c is directly involved in drug resistance
and because of the parallel over-expression of P-gp and GST n in models of
pleiotropic resistance, transfection experiments involving the expression of
the individual genes or the two genes expressed in the same cell line were
conducted (Moscow et al, 1989b). The study demonstrated that there was no
direct relationship between GST levels and mdr.
Mdr could be conferred by transfection of a full length mdr 1 cDNA but
transfection of GST rc alone could not impart resistance to doxorubicin. This
is in agreement with the observations of Tsuruo who examined paired
sensitive and resistant cell lines (Yusa et al, 1988). The apparent inability of
GST 71 to enhance cell resistance to anti-neoplastic compounds does not
rule out the involvement of this isozyme in drug-resistance. The
overexpression of GST tc and mdr 1 in several models of resistance
indicates that common factors may exist to coordinate the regulation of both
these genes and thus coordinate protection from toxic compunds. GST k is
found elevated in some tumours compared to normal tissues (Moscow et al,
1989) suggesting a possible role as a marker of drug resistance and
neoplasia.
1.5 CYTOCHROME P450 FAMILY OF DRUG METABOLISING
ENZYMES
The microsomal P450-dependent monooxygenase system has
evolved to cope with the plethora of toxic chemicals that organisms have to
deal with. The two main components of this system are NADPH-cytochrome
P450 oxidoreductase and cytochrome P450. Cooper et al (1965)
determined the role of P450 in the system as the terminal oxidase of the
microsomal electron transport chain. In this process, two electrons are
transferred from NADPH via NADPH cytochrome P450 reductase and P450
to mediate the incorporation of one atom from oxygen into a particular
substrate and the other oxygen atom is reduced to form water (Black and
Coon, 1987). The reductase is associated with the endoplasmic reticulum
membrane and contains one flavin mononucleotide (FMN) and one flavin
adenine dinucleotide (FAD) molecule per catalytic unit. Electrons pass from
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FAD to FMN within reductase and then to P450.
Multiple forms of P450 exist which exhibit overlapping substrate
specificities (Guengerich, 1987). P450 mediated reactions include oxidative
and reductive dehalogenation, N-hydroxylation, N-oxidation, S- , N- and O-
dealkylation and aliphatic and aromatic hydroxylation.
In general, the microsomal P450s, particularly those of the liver,
convert hydrophobic substances into more hydrophilic ones that can be
excreted from the body via the urine or bile.
Metabolism occurs in two phases. In Phase 1, a lipophilic compound
may be oxidised by the addition of a hydroxyl or epoxide group. In Phase 2,
the resulting electrophile is a substrate for transferase enzymes that attach
either GSFI sulphate or glucoronic acid, making it water soluble and hence
easily excretable (Nebert and Negishi, 1984). However, with certain
compounds, the high energy intermediate can attack DNA, RNA and protein
causing mutation, toxicity and carcinogenesis (Conney, 1982).
Some enzymes of steroid biogenesis are P450s found in the adrenal
gland, for example steroid 17 a-hydroxylase and steroid 11 (3-hydroxylase,
the latter being a mitochondrial P450 receiving electrons from adrenodoxin
and adrenodoxin reductase.
Many researchers have purified and characterised P450s which has
resulted in the confusing nature of P450 nomenclature. The classification
system is based on primary amino acid sequence alignment data. A recent
update of this classification has been made (Nebert etal, 1991).
The primary hepatic drug metabolising enzymes comprise four gene
families (1-4). Many P450 gene families contain multiple genes that have
arisen through the process of gene duplication.
Listed below is a brief synopsis of the gene families in rat and mouse
referred to later in this thesis.
CYP1
The CYP1A1 and CYP1A2 genes are ubiquitious in mammals and
have similar catalytic activities. CYP1A1 metabolises benzo(a)pyrene and
other substrates (Goldstein et al, 1982) and can be induced by 3-MC in
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many tissues (Kimura et al, 1986) and cigarette smoke in humans (Song et
al, 1985).
CYP1A2 metabolises arylamine compounds including 2-acetyl amino
fluorene (2-AAF) (Goldstein et al, 1984) and has AFB-j-4-hydroxylase activity
(Faletto, 1988).
CYP2A
CYP2A1 and CYP2A2 (Nagata et al, 1987; Matsunaga et al, 1988).
are 88% identical in rat but they are regulated differently during
development and have distinct substrate specificities. CYP2A1 hydroxylates
testosterone and other steroids at the 7a position whereas CYP2A2 has a
high testosterone 15a hydroxylase activity (Matsunaga et al, 1988; Wood et
al, 1983). Rat CYP2A3 is expressed only in lung and is induced by 3-MC
(Kimura et al, 1989).
Cyp2a-4 and Cyp2a-5 genes in the mouse are orthologous to the rat
CYP2A3 genes. The two mouse cDNAs are expressed in both liver and
kidney (Squires and Negishi, 1988).
CYP2B
Three cDNAs for CYP2B genes in the rat have been isolated;
CYP2B1, CYP2B2 and CYP2B3. Unlike CYP2B1 and CYP2B2, CYP2B3 is
consistently expressed as a minor form in male and female liver and is not
induced by phenobarbital (Labbe et al, 1988).
Southern blotting experiments suggest the possibility of multiple
genes in the mouse (Simmons and Kasper, 1983). Two female specific
mouse cDNAs, Cyp2b-9 and Cyp2b1-0, containing full amino acid coding
regions of P450s were isolated. They display 82% homology with rat
CYP2B1. Cyp2b-9 has been shown to have testosterone 16 a-hydroxylase
activity (Noshiro et al, 1988).
43
CYP2C
Members of this subfamily are mostly constitutively expressed, but
some are under developmental and sex-specific regulation. Several
constitutive P450s in the rat CYP2C subfamily have been isolated and
characterised. CYP2C6 and CYP2C7 are developmental^ regulated in
male and female (Gonzalez et al, 1986a). These have 75% amino acid
homology to each other. CYP2C11 is a male-specific P450 purified from rats
which metabolises testosterone at the 16 a, 2 a and 17 [3 positions (Ryan et
al, 1984).
CYP2D
The debrisoquine 4-hydroxlase P450, named CYP2D1, was purified
from rat (Gonzalez et al, 1987). CYP2D2 has 78% amino acid sequence
identity with CYP2D1. In total, 5 rat CYP2D genes have been isolated and
sequenced.
The mouse may also have up to five genes. Recently a mouse male
specific testosterone 16 a-hydroxylase (Cyp2d-9) was sequenced and
found to have between 70-82 % amino sequence identity with the rat
CYP2D genes (Wong et al, 1987).
CYP2E
Patten et al (1986) reported a form of ethanol inducible P450 in rats,
named CYP2E1. Only a single CYP2E gene has been identified in rats. This
subfamily can metabolise a range of substrates including ethanol, acetone,
acetol, benzene and N-nitrosodimethylamine (Koop et al, 1982; Johansson
and Sundberg, 1988; Hong and Yang, 1985). CYP2E1 is believed to be
involved in gluconeogenesis during the state of fasting (Casazza et al,
1984). CYP2E1 is also induced in rats with spontaneous and chemically
induced diabetes (Past and Cook, 1982). Circulating acetone as well as
hormonal factors have been implicated in the induction (Miller and Yang,
1984). A mouse Cyp2e1 gene has also recently been cloned (Freeman et al,
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1991), and has been shown to share 92%, 79%, 80% and 79% sequence
similarity over the coding region to rat, human, rabbit land rabbit 2 CYP2E1
cDNA sequences respectively. Cyp2e1 protein was found to be induced by
acetone treatment in all tissues studied in both male and female mice, but
this was accompanied by decreases in Cyp2e1 mRNA levels. This suggests
that acetone administration affects the stability of the protein or the efficiency
of mRNA translation.
CYP3
Enzymes in the CYP3 family, including CYP3A1 (Waxman, 1984),
have activities for erythromycin demethylation, triacetyloleandomycin
metabolism and testosterone 6 (3-hydroxylation (Wrighton et al, 1985;
Gonzalez et al, 1986b). Lu and West (1980) identified a cytochrome P450,
subsequently named CYP3A2, which could be induced by the synthetic
steroid pregnenolone 16acarbonitrile (PCN). CYP3A2 was isolated from an
adult male liver library, using CYP3A1 as a probe and was found to be 89%
amino acid sequence identical.
Humans have at least four CYP3A genes. CYP3A4 (Beaune et al,
1986) and CYP3A3 (Knodell, 1988) were found to be 98% similar at the
amino acid level. Human CYP3A5 was identified in 10 - 20% of human liver
samples examined using an anti-rat CYP3A1 antibody. CYP3A5 is the foetal
form.
There is evidence to suggest that a CYP3 enzyme can be induced in
humans by glucocorticoids (Molowa et al, 1986). Variability in CYP3
expression could have considerable clinical implications since CYP3
metabolises drugs including the calcium channel blocker nifedipine
(Gonzalez et al, 1988), progesterone (Waxman et al, 1988a), cyclosporin
(Kronbach et al, 1988) and the antibiotic erythromycin (Watkins et al, 1985).
These compounds are all well known substrates for P-gp.
CYP4
CYP4A1 is a clofibrate-inducible lauric acid co-hydroxylase isolated in
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rats by Tamburini et a/(1984). The enzyme is specific for fatty acid oxidations
and oxidises arachadonic acid (Bains et at, 1985). The main effect of the
hypolipidaemic peroxisome proliferator clofibrate is to lower triglycerides
and cholesterol concentrations in the plasma but also has been found to be
a rodent hepatocarcinogen. A peroxisome proliferator binding protein has
been found present in rat liver (Lalwani et al, 1983) and the cloning of a
novel member of the steroid hormone receptor superfamily activated by
peroxisome proliferators has been recently reported (Issemann and Green,
1990). The identification of the mouse peroxisome proliferator activated
receptor (PPAR) as a putative transcription factor activated specifically by
peroxisome proliferators suggests that the receptor directly mediates the
effects of this class of chemical.
Interestingly, the chemicals known to the most potent proliferators are
the same as the chemicals which are most potent in receptor mediated
activation of genes encoding P450 and other drug metabolising enzymes
(Nebert, 1990). It was proposed by Nebert (1990) that these enzymes control
the level of small organic oxygenated molecules that act as signals for
growth differentiation and tumour promotion and that PPAR mediates one
such pathway.
1.5.1 INDUCTION OF CYTOCHROME P450 GENE EXPRESSION
(a) 3-Methylcholanthrene/2,3,7,8-tetrachlorodibenzo-p-dioxin-
(TCDD) inducible
Rats fed 3-MC can metabolise certain amino azo dyes more efficiently
(Conney et al, 1956). Aryl hydrocarbon hydroxylase (AHH) activity is
induced by 3-MC, which is associated with the transcriptional activation of
CYP1A1 (Nebert and Gelboin, 1970).
A polymorphism for 3-MC induction was found in mice and was due to
a recessive mutation of a single gene (Thomas et al, 1972). Several other
enzymes are under the control of this locus, named the Ah locus. The locus
is controlled by a specific receptor. The potent inducer TCDD binds strongly
to the receptor in responsive mice whereas non-responsive mice have a
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receptor defect and hence possess a low affinity for the ligand and lack
inducibility by 3-methylcholanthrene (Poland and Glover, 1975). The
receptor probably has an endogenous ligand with a developmental or
physiological role. The TCDD receptor can mediate transcriptional activation
in hepatoma cells (Israel and Whitlock, 1984). To study the mechanism of
transcriptional activation, CYP1A1 promotor-chloramphenicol transferase
(CAT) expression plasmids have been constructed from cloned genes. The
regulatory elements that control induction of transcription by TCDD are at -
950 and -1100 from the ATG start site (Jones et al, 1986; Neuhold et al,
1986). Consensus sequences, named drug regulatory elements (DRE) and
xenobiotic regulatory elements (XRE) are found in many copies in this
region (Sogawa et al, 1986). The TCDD receptor and the glucocorticoid
receptor element (GRE) have various similar physicochemical properties
(Cuthill et al, 1987) and therefore the XRE may be evolutionarily related to
the GRE. The glucocorticoid, Ah and phenobarbital receptor are all thought
to be part of the steroid hormone receptor superfamily (Nebert, 1990).
The role of the TCDD receptor in gene activation is still not clearly
understood. However, Deninson et al (1988) reported an observation in
which the TCDD receptor plus ligand bound to the upstream control regions
of the mouse CYP1A1 gene. It was suggested that the receptor was
involved in binding the XRE.
CYP1A2 regulation has not been easily studied due to the lack of
detectable expression in established cell lines. However, CYP1A2 is
constitutively expressed in the liver and is inducible. It is not expressed
significantly in extra-hepatic tissues even under the influence of a potent
inducer (Kimura et al, 1986). CYP1A1 is readily inducible in all tissues but
constitutive expression is undetectable. Control of this gene is primarily
transcriptional, with a small contribution from mRNA stabilisation.
The control of mdr gene expression by the Ah locus will be a subject
for discussion in Chapter 5.
(b) Phenobarbital-inducible P450 genes
Phenobarbital (PB) causes proliferation of liver endoplasmic
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reticulum (ER) membrane (Remmer and Merker, 1963) and increases in the
levels of various cytochrome P450s (Orrenius et al, 1965). CYP2B1 and
CYP2B2 are coordinately regulated in liver by PB. CYP2B1 is
transcriptionally inactive in untreated rats while CYP2B2 is constitutively
expressed. Both mRNAs are induced in the presence of PB.
PB also induces two genes in the rat CYP3 family. CYP3A2, which is
male specific and constitutively expressed, and the CYP3A1 gene which is
not expressed are induced by PB. CYP3A1 is also induced by steroids.
These data suggest that the genes have common regulatory elements
for PB but distinct elements for steroid inducibility and constitutive
expression. Cis-acting regulatory elements have yet to be defined for
specific PB receptors. Extensive metabolism of the compound by liver
enzymes may account for difficulties encountered is such studies. Poland et
al (1980, 1981) reported the potent induction in mice caused by the PB-like
ligand 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP). This
compound is not extensively metabolised and hence will be valuble in the
study of such a receptor. The effect of TCPOBOP on mdr gene expression
will be discussed in Chaper 5.
(c) Steroid inducible P450 genes
The rat CYP3A1 gene is induced by glucocorticoids such as
dexamethasone and pregnenolone 16 a-carbonitrile. Regulation is distinct
from the control of classical glucocorticoid-regulated genes such as tyrosine
aminotransferase (Schuetz and Guzelian, 1984). Induction of CYP3A1
requires approximately ten-fold more steroid than is normally required.
Induction results from an activation of CYP3A1 transcription and increase in
mRNA (Simmons et al, 1987). The rat CYP3A1 and CYP3A2 are stabilised
by the macrolide antibiotic triacetyloleandomycin (TAO) (Watkins et al,
1986).
(d) Hypolipideamic drug-inducible P450 genes
Clofibrate induces CYP4A1, enoyl CoA hydratase and fatty acyl-CoA
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oxidase genes by rapid transcriptional activation (Hardwick et al, 1987;
Reddy et al, 1986). This leads to an increase in fatty acid (3-oxidation.
1.5.2 REGULATION OF CONSTITUTIVELY EXPRESSED P450 GENES
Four ways of constitutively-expressed P450 regulation have been
reported. These include activation of genes following birth, at the onset of
puberty, "sex imprinting" ( activation of expression in males or females) or
specific suppression of activity in either males or females at puberty.
CYP2D1 and CYP2D2 are elevated immediately after birth in rats due
to transcriptional activation correlating with changes in the methylation
states of the genes (Umeno et al, 1988). Levels peak at six days post partum.
Sex specific genes are present in the rat. Rat CYP2C6 and CYP2C7
are transcriptionally activated at the onset of puberty (Gonzalez et al,
1986a). CYP2C11 is expressed only in the adult male liver and is dependent
on testosterone exposure both in neonatal and adult life (Waxman et al,
1985).
CYP2C12 is expressed in a sex-specific manner in adult female rats,
but present in both sexes during adolescence. Suppression of this enzyme
occurs in males due to androgen exposure during the neonatal period
(Dannan et al, 1986).
The role of pituitary hormones in the regulation of sex specific
expression of P450s has been studied. Jansson et al (1985) reported that
adult male and female rats differ in their growth hormone secretion pattern in
that males have a pulsatile pattern, whereas females have a more constant
secretion. The patterns are set by neonatal androgen expression and adult
testosterone levels. CYP2C11 and CYP2C12 regulation both involve growth
hormone secretion patterns (Kato et al, 1986).
The sex specific expression of certain male and female genes
sometimes results from the suppression of gene expression. Expression of
CYP2A is decreased in males at puberty due to the loss of the CYP2A
protein associated testosterone 7 a-hydroxylase activity (Matsunaga et al,
1988). Growth hormone seems to play a role in suppressing P450
expression. Data suggests that the decrease in CYP3A2 in adult females is
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due to the continuously high levels of growth hormone found in female rats
(Kato et al, 1986).
Most P450s characterised to date are expressed in hepatocytes. In
the CYP2A family, both CYP2A1 and CYP2A2 are only present in the liver
(Matsunaga et al, 1988) but CYP2A3 is expressed only in the lung and is
undetectable in the liver (Kimura et al, 1989). Three different regulatory
mechanisms seem to exist for the CYP2A genes. First, CYP2A1 is inducible
by 3-MC, second CYP2A2 is induced in males at puberty, and finally tissue
specific expression of CYP2A1 and CYP2A2 (liver) and CYP2A3 (lung)
exists.
P450 genes can also be post-transcriptionally regulated. One of the
best examples of such regulation is the rapid induction of 2E1 protein in rats
following administration of ethanol, acetone or pyrazole. The levels of mRNA
for CYP2E1 do not appear to increase (Song etal, 1986). Song efa/(1989)
suggested that such an increase was due to protein stabilisation. An
increase in the efficiency of mRNA translation could also explain such a
finding. Fasting in rats causes an increase in CYP2E1 mRNA and protein in
addition to elevation of ketone bodies (Hong etal, 1987). CYP2E1 is thought
to be involved in the conversion of acetone to acetol and methylglyoxal
which is metabolised to D-lactate and pyruvate (Koop and Casazza, 1985).
1.6 CONCLUDING REMARKS AND AIMS OF THE THESIS
P-glycoprotein is widely accepted as being causative of mdr in many
cell lines and probably plays an important part in the failure of
chemotherapy. However, the physiological role and natural substrates for P-
gp remain largely unknown. How the expression of the mdr genes are
regulated in different tissues and in different species still awaits an answer.
The mechanism by which it transports drugs across the plama membrane is
still also unknown.
Studies indicate that P-gp has a major role in normal cell physiology,
probably to transport diverse molecules across the cell membrane. The
occurrence of an mdr-like protein in the drug-resistant parasite P. falcipirum
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suggests that active efflux by a protein such as P-gp may be a very common
defence mechanism against toxic compounds in many diverse species.
Other proteins belonging to a transport super family, each with unique
substrate specificity, probably await discovery.
Since little is known about the regulation of mdr gene expression,
various factors, known to effect the expression of P450 and GST drug
metabolising enzymes, were examined. In vivo regulation was studied in
mouse and rat liver. The rat genes have only recently been cloned and
sequenced (Silverman et al, 1991). However, much is already known about
the three mouse genes, which have been cloned, sequenced and studied to
some extent (Dhir, 1990; Buschman and Gros, 1991; Cohen et al, 1991;
Gros etal, 1988; Devault and Gros, 1990; Gros et al, 1986; Raymond etal,
1990) . The distribution of the genes in various tissues has been published
(Croop et al, 1989).
For our purposes, mouse liver was a good model to study for several
reasons. The tissue is known to express all three genes to some extent.The
expression and regulation of both cytochrome P450 and GST enzymes in
mouse liver has been widely studied. Correlations between the expression
of these drug metabolising enzyme systems and P-gp was evaluated.
Exogenous and endogenous regulation of the mdr genes was
examined. Exogenous regulation studies involved examining the effects of
P450 and GST inducing agents, carcinogens and anti-cancer drugs on the
expression of the mdr genes in liver.
The relative levels of expression of the P450 gene families, GST %
and P-gp appeared, from previous studies, to be particularly relevant to
study in an in vivo model. GST k is associated with multi-drug resistant cell
lines and is a marker for preneoplasia and hepatocarcinoma in rats. CYP1A
can be induced by carcinogens and it weakly induced by 2AAF and AFB-j
which have been reported to induce mdr in the rat (Burt and Thorgeirsson,
1988). CYP3A1 is inducible by steroids such as dexamethasone and can
metabolise progesterone.The mdr 1gene in the mouse is upregulated by
progesterone during pregnancy and it has been shown that progesterone
specifically binds to P-gp. Other compounds metabolised by CYP3A1 are
also substrates for P-gp, such as nifedipine and cyclosporin. A common
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mechanism of regulation by such compounds may be operative.
Endogenous regulation of mdrgene expression involved studying the
effects of pituitary hormones on mdr gene expression. Cytochrome P450s
have been shown to be under the regulation of growth hormone, which
determines the expression of sex specific enzyme forms (Mode et al, 1982,
1983; Skett, 1987; Zaphiropolous et al, 1988). Thyroid hormones are known
to have an effect on the expression of hepatic enzyme systems.
Hypothyroidism induced by propylthiouracil (PTU) in mice is accompanied
by an increase in hepatic GST and can be reversed by intraperitoneal
injection of 3,3',5-tri-iodothronine (T3) (Williams et al, 1986). It is of interest to
determine whether mdr genes were also under such types of hormonal
control.
To determine whether or not carcinogens act as sustrates for the P-gp
'pump', a tissue culture model was employed using a cell line known to
express P-gp to a high level.
As a first approach to study the expression of P-gp, it was aimed to
raise peptide antibodies against the protein and investigate their





2.1.1 COMMERCIAL MATERIAL SOURCES
Most chemicals were supplied by BDH Limited, Burnfield
Avenue,Thornliebank, Glasgow, G46 7TP and Sigma Chemical Company
Limited, Fancy Road, Poole, Dorset, BH17 7NH. A comprehensive list of
chemicals including tissue culture materials and suppliers is given in
Appendix 1.
2.1.2 NON-COMMERCIAL MATERIALS
(a) Antibodies and protein standards
Antisera against rat GST subunits and protein standards for use in
Western Blotting and SDS PAGE were obtained from Dr. J. D. Hayes,
Department of Clinical Chemistry, Royal Infirmary of Edinburgh. Use of these
antibodies to discriminate between GST subunits has been described
(Hayes and Mantle, 1986). Dr. L. I. McLellan of the same Department kindly
provided antisera against mouse GST subunits. The specificity of these
antibodies has also been tested (McLellan and Hayes, 1989).
Antisera to purified cytochrome P-450 isozymes were supplied by Dr.
C. R. Wolf and have been previously detailed (Wolf and Oesch, 1983, Wolf
et al, 1984). Monoclonal antibodies against the clofibrate-inducible CYP4
family were produced by Ciba Geigy, R-1066-4 -32, Basel, Switzerland and
have been characterised (Savoy et al, 1990).
Peptides corresponding to various regions of the human mdr 1
sequence (Chen et al, 1986) were synthesised and conjugated to
thyroglobulin and bovine serum albumin by Dr. J. Rothbard, Lincoln's Inn
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Fields, London. Peptide antibodies were raised against the thyroglobulin
conjugates in New Zealand White rabbits at Clare Hall Laboratories,
Imperial Cancer Research Fund, Blanche Lane, Potters Bar, Harts. EN6 3LR.
(b) cDNA clones
The Rat Yf cDNA clone was provided by Professor M. Muramatsu,
Department of Biochemistry, Tokyo. The rat Yb1 cDNA clone was gifted by
Dr. C. B. Pickett, Merck Frost Centre for Therapeutic Research, Quebec. The
rat Ya cDNA was obtained from Dr. J. B. Taylor, CRC Molecular Toxicology
Group, Middlesex Hospital, London. Dr. P. Gros, Department of Biochemistry,
McGill University, Montreal, Quebec, Canada kindly gifted the mouse mdr 1-,
2- and 3-specific clones. The human mdr 5A clone was obtained from Dr. R.
Brown, Wolfson Laboratory for Molecular Pathology, Beatson Laboratories,
Bearsden, Glasgow, G61 1BD.
Further details about these clones, and the P-450 clones used, are
outlined in Section 2.7.
(c) Chemicals
TCPOBOP (1,4-bis [2-(3,5 dichloropyridyloxy)] benzene) was a gift
from Dr. A. Poland, McArdle Laboratory for Cancer Research, Maddison,
Wisconsin, U.S.A.
Later aliquots were synthesised and kindly provided for use by Miss
G. Smith, Imperial Cancer Research Fund, Molecular Pharmacology Group,
University of Edinburgh.
(d) RNA
Hepatic RNA isolated from phenobarbital, dexamethasone and
TCPOBOP-treated mice as well as hypophysectomised and sham-operated
animals was generously donated by Dr. C. J. Henderson, Imperial Cancer
Research Fund, Molecular Pharmacology Group, Edinburgh.
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2.2 ANIMAL EXPERIMENTS
2.2.1 XENOBIOTIC EXPOSURE OF MICE
Mouse experiments were conducted at the Imperial Cancer Research
Clare Hall Laboratories, Blanche Lane, South Mimms, Potters Bar, Harts.
EN6 3LR.
Male C57BL/6 and DBA/2N mice were fed ad libutum on a standard
laboratory chow diet and acclimatised in a 12 hour light/dark cycle for at
least 4 days before treatments. The actual treatments administered are
outlined in Chapter 5. Either corn-oil or phosphate-buffered saline was used
as the treatment vehicle. On the final day of the experiment, the mice were
sacrificed by cervical dislocation. The organs were removed and snap-
frozen in card-ice or liquid nitrogen and stored at -70°C until required for
preparation of RNA or protein extraction. For measurement of corticosterone
levels, mice were sacrificed following treatment and cardiac puncture was
performed as described in Section 2.13.1. The assay was kindly conducted
by Dr. B. Williams, Western General Hospital, Edinburgh.
2.2.2 SURGICALLY TREATED MICE
Intra-auricular hypophysectomised male and female C57BL/6 mice
plus sham-operated control animals, were obtained from Charles Rivers
Laboratories, Willmington, Massachusetts. U.S.A.
2.2.3 MUTANT MICE
The mouse strain 'little' (lit/lit), deficient in pituitary growth hormone
releasing factor and wild type control animals were obtained from Charles
Rivers Laboratories.
Thyroid-deficient transgenic mice were obtained from Dr. R. Al-Shawi,
Department of Genetics, University of Edinburgh.
2.2.4 CONTROL MICE
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Male C57BL/6 (+/+) mice at 1, 2, 4, 6 and 10 weeks old, as well as 15
day embryo, were obtained from Clare Hall Laboratories, Imperial Cancer
Research Fund, Blanche Lane, Potters Bar, Harts, U.K.
The livers were removed, snap frozen following cervical dislocation
and stored at -70°C until required.
2.2.5 XENOBIOTIC INDUCTION OF RATS
Wistar and Fischer male rats (-150 gm) were obtained from Banton
and Kingman, UK. Animals were fed ad libitum and acclimatised, as
described for the mice, before treatments were administered.
2.2.6. PREPARATION OF MICROSOMAL AND CYTOSOLIC FRACTIONS
FROM MOUSE AND RAT TISSUES
Microsomal fractions from mouse liver, kidney and lung as well as rat
liver were prepared as described by Meehan et al (1988a). Tissue was
thawed at 37°C, scissor-minced and homogenised in 3 volumes of KCI-
phosphate buffer (10 mM potassium phosphate, pH 7.4, 1.15% (w/v)
potassium chloride, 0.1 mM EDTA). A Silverson Laboratory Mixer Emulsifier
was used to homogenise the tissue, whilst the samples were maintained at
4°C. The homogenate was then centrifuged in a Du Pont Sorvall RC-5B
Refrigerated Centrifuge (SS 34 rotor) at 11,000 g for 20 minutes to remove
nuclei and cell debris. The supernatant was retained and centrifuged at
45,000 rpm at 4°C for 80 minutes in a Du Pont Sorvall Ultracentrifuge OTD
65B (TFT 45.6 rotor). The supernatant (cytosolic fraction) was removed and
aliquoted in volumes of 1 ml before being frozen at -40°C until required. The
microsomal pellet was resuspended in KCI-phosphate buffer using a Teflon-
glass hand-homogeniser and re-centrifuged for 60 minutes at 4°C at 45,000
rpm. Finally, the pellet was resuspended in ice-cold sucrose buffer (0.25 M
sucrose, 10 mM potassium phosphate pH 7.4, 1% (w/v) KCI, 0.1 mM EDTA),
aliquoted and stored at -40°C until required.
56
2.3 HISTOLOGICAL EXAMINATION OF RAT TISSUES
Both tissue fixation and staining was dindly performed by Miss Linda
May and Dr D. Harrison, Department of Pathology, University of Edinburgh.
2.3.1 TISSUE FIXATION
Following treatment of Wistar rats with 2-acetylaminofluorene (2-AAF),
aflatoxin B-j (AFB-|) and diethylnitrosamine (DEN), as outlined in Chapter 5,
the liver and kidney were removed from the animal following sacrifice and
fixed for histological examination.
The fixative procedure used is designed to preserve both antigenicity
and ultrastructure (McLean and Nakane, 1974). The fixation used is a
periodate-lysine paraformaldehyde (PLPD) fixative (0.01 M periodate,
0.075M lysine HCI, 2% (w/v) paraformaldehyde and phosphate buffer, pH
7.4) which primarily stabilises carbohydrate moieties. The carbohydrates are
oxidised by periodate and cross-linked by lysine.
The tissues were sectioned into small pieces and fixed in the PLPD
solution for 3h before being further processed in the routine manner.
2.3.2 STAINING FOR MORPHOLOGY AND GLYCOGEN DISTRIBUTION
Haematoxylin and eosin (H/E) stain was used to demonstrate the
structure of the liver and kidney tissue following treatment of Wistar rats with
2-AAF, AFB-, and DEN.
The haemotoxylin component stains the cell nuclei blue-black, whilst
eosin stains cell cytoplasm and most connective tissue fibres red.
The sections were dewaxed in xylene and hydrated through graded
alcohols to water. The fixation pigments were removed and the section
stained in an alum haematoxylin for 30'. After washing the sections, they
were stained in 1% eosin Y for 10' and washed in water for 5'. The sections
were then dehydrated through alcohols, cleared in xylene and mounted in
DePex (BDH).
For glycogen staining, the periodic acid-Schiff (PAS) reaction was
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employed. The PAS reaction is a useful indicator of the presence of tissue
carbohydrates. The sections were dewaxed and placed in distilled water,
before being treated with periodic acid (0.5% (w/v), 5'). After washing in
distilled water they were immersed in Schiff's solution (0.5% (w/v) basic
fuchsin, 1% (w/v) potassium metabisulphite, 1% (v/v) hydrochloric acid) for
15' and washed in water for 5'. Nuclei were stained with haematoxylin. The
sections were finally washed in water, rinsed in alcohol, cleared in xylene
and mounted.
2.3.3 STAINING FOR P450 AND GST a
The tissue sections were deparaffinised and washed in water. They
were washed twice in TBS (0.01 M Tris, pH 7.6) for 5' and incubated in pre-
immune rabbit serum (1:5 dilution in TBS) for 10'. After draining off excess
serum, the sections were incubated in the cytochrome P450 or GST
polyclonal antibody (each at a 1:50 dilution in TBS) overnight at 4°C. After
washing in TBS, the sections were again blocked in pre-immune serum and
then incubated in biotinylated swine anti-rabbit (DAKO) (diluted 1:500 in
TBS, for 30'). The sections were washed in TBS and incubated for 30' in the
avidin biotin complex (ABC). The avidin is conjugated to horseradish
peroxidase (HRP) and extra sites on the avidin bind the second antibody.
After TBS washing, a diaminobenzidine substrate solution (0.05% (w/v)
diaminobenzidine, 0.068% (w/v) imidazole, 2% (v/v) hydrogen peroxide)
was applied to the tissue sections (10'). The sections were washed,
counterstained in Mayer's haematoxylin and blued-up in alkali. The sections
were then dehydrated, cleared and mounted in DePex (BDH).
2.4 CELL CULTURE
2.4.1 CELL LINES
Four human and four Chinese hamster cell lines were cultured during
the course of the project. Two of the human and two of the hamster cell lines,
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were drug resistant to varying extents and displayed the mdr phenotype. The
human line MES-SA was established from a uterine sarcoma
(Harker et al, 1983). The development and characterisation of the Dx-5
subline of MES-SA, selected by continous in vitro exposure to the
anthracycline antibiotic doxorubicin, has been reported (Harker and Sikic,
1985). The cross-resistance pattern of Dx-5 for various anti-tumour agents is
shown in Table 2.1. Both MES-SA and Dx-5 were kindly provided by Dr. B. I.
Sikic, Oncology Division, Department of Medicine, Stanford University
Medical Centre.
Dr. V. Ling, The Ontario Cancer Institute, Toronto, Canada kindly
provided both the human cell line SKOV 3 and the drug-resistant
counterpart SKVLB (1.0), and the Chinese hamster ovarian cell line Aux B1
and the drug-resistant derivative CHRC5. SKOV 3 is a human ovarian
carcinoma cell line (Fogh and Trempe, 1975) obtained originally from the
American Type Culture Collection. An SKVLB series of drug-resistant cell
lines were obtained by selection of SKOV 3 cells for growth in increasing
concentrations of vinblastine (Bradley et al, 1989). The levels of drug
resistance in SKVLB (1.0) cells are shown in Table 2.1.
The selection of mdr CHO cells from the parent line, Aux B1, has been
previously described (Ling and Thompson, 1974). The most sensitive cell
line, CHrC5 is 300 times relatively more resistant to colchicine and 42 times
more resistant to vinblastine than the wild-type Aux B1 cell line, as shown in
/resistant
Table 2.1 . The adriamycin CHO cell line, CHO-AdrR derived from wild-type
CHO cells was received from Dr. I. D. Hickson, I.C.R.F., University of Oxford,
The Institute of Molecular Medicine, John Radcliffe Hospital, Headington,
Oxford. 0X3 9DU.
2.4.2. CELL CULTURE TECHNIQUES AND CONDITIONS FOR CULTURE
The cell culture methods used were as described by Freshney (1987).
All culture was conducted in a Class 2 Biological Safety Cabinet, MDH Ltd.,
Walworth Road, Andover, Hampshire.The cabinet was U.V. sterilised when
not in use and cleaned at regular intervals.
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TABLE 2.1
CROSS-RESISTANCE PATTERNS OF THE MDR CELL LINES STUDIED
Dox-5, SKVLB and ChRcs were made resistant to doxorubicin, vinblastine
and colchicine respectively. CELL LINE
DRUG DOX-5 SKVLB CHRC5
Doxorubicin 100 260
Vincristine 240 10,000
Colchicine 25 510 300
Mitomycin C 1 0
Vinblastine 105 2,000 42
Colcemid - - 25
These values represent the fold resistance of the selected cell lines
compared to parental resistance levels.
not assayed
Harker and Sikic, 1985; Bradley et al, 1989; Ling and Thompson, 1974
(a) Freezing cells for storage and retrieving stocks
On reaching confluency, cells were harvested using 0.1% trypsin,
0.01% EDTA until the monolayer detached. The trypsin was then quickly
diluted out by adding growth medium (specific for each particular cell line)
and the cells spun down for 5 minutes at 2500 rpm in a MSE Microcentaur
centrifuge. The cell pellet was then resuspended at a density of 5-10 million
cells/ml in 90% new-born calf serum, 10% DMSO. Aliquots were frozen at -
70°C overnight before transfer to liquid nitrogen for long-term storage.
DMSO permeates cells rapidly and maintains long-term viability of cell lines.
To retrieve cells from storage, an aliquot was thawed at 37°C and carefully
resuspended in the appropriate growth medium (10 mis) pre-warmed to
37°C. The cells were then spun at 2500 rpm for 5 minutes and again
resuspended in growth medium before being seeded into a 25 cm2 tissue-
culture flat-bottomed flask. The cells were allowed to adhere overnight and
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refed the next morning to eliminate any dead cells or other debris from the
flask.
(b) Feeding cells
Cells were fed with their own specific media as required. Most ceil
lines required re-feeding every 2 days to maintain optimal pH and essential
growth requirements. MES-SA and Dx-5 were grown in RPMI 1640 medium
(Moore et al, 1967) plus 10% FCS. MES-SA had a generation time of 22 hr
whilst that of the Dx-5 cells was 30 hr. Dx-5 cells were routinely maintained
in 5 x 10"7 M adriamycin (adr) at which concentration the cells were selected
originally.
SKOV 3 and SKVLB (1.0) were routinely maintained in a-MEM
(Stanners et al, 1971). SKVLB (1.0) was also continously exposed to 1pg/ml
vinblastine whilst in culture. CHO and CHO-AdrR cells were maintained in
RPMI 1640 plus 1 pg/ml adriamycin for the drug-resistant variant. Aux B1
and CHrC5 cell cultures were grown in a-MEM with 10% FCS. These lines
are auxotrophic, requiring glycine, adenosine, thymidine and proline for
growth. CHRC5 did not require colchicine, the drug to which the cell line is
resistant, to passage it in culture in order to maintain resistance.
Glutamine (0.2 mM), penicillin (15 U/ml) and streptomycin (5 pg/ml)
were routinely added to the media of all cell lines.
(c) Sub-culture of cells
Just before reaching confluency, cells were sub-cultured by washing
them twice in PBS and harvesting them in 0.1% trypsin, 0.01% EDTA until
the cells detached. Fresh medium was then added to inhibit the trypsin and
the cell suspension spun at 2500 rpm for 5 minutes. The cell pellet was
disaggregated in fresh medium.
To ensure accurate seeding, when required, the cells were counted
using a Neubauer haemocytometer and seeded into fresh flasks. Their
viability could be assessed by nigrosin dye exclusion (Kaitenbach et al,
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1958).
Most parental cell lies were sub-cultured every 3-4 days at a dilution
of 1:10. The cell lines maintained in drug normally grew more slowly and
were passaged once a week at a dilution not exceeding 1:10. Drug was
routinely added 24 hr after the cells were sub-cultured in order to allow them
to re-adhere to the flask surface.
(d) Sterility
Culturing of cells was carried out in a sterile cabinet and aseptic
techniques were employed at all times. Solutions were either sterilised in a
Laboratory Thermal Equipment 225 EH autocalve or filter-sterilised (0.2 pm
pore size) before use. Testing the sterility of media and other solutions was
routinely done by inoculation of the test solution into sterile L-broth (2%
Bactotryptone, 1% Bactoyeast, 2% NaCI) and incubating for 4-7 days at
37°C. A turbid L-broth test was an indication of some form of contamination
and the solution could be discarded before use. Regular mycoplasma tests
were done by Mr. W. Christie, MRC Clinical and Population Cytogenetics
Unit, Western General Hospital, Crewe Road, Edinburgh. The mycoplasma
test involved staining with Hoescht 33258 flourescent dye and growth on
selective broth (Taylor-Robson,1978). Mycoplasma contamination can cause
such changes as chromosomal aberrations (Fogh and Fogh, 1965).
2.4.3. PREPARATION OF SOLUBLE PROTEIN LYSATES FOR P-
GLYCOPROTEIN ESTIMATION
Cells were grown in 25 cm2 flasks, seeded at a density of 1 x 106
cells per flask. The cells were grown overnight and re-fed with 5 ml of fresh
media until confluent. For the preparation of protein lysates, cells were
washed twice in ice-cold PBS to eliminate all traces of media. Cold lysis
buffer (0.1 M Tris, pH 8.0, 0.5 % NP 40, 10% glycerol, 0.5 ml and 2 mM
PMSF added from a 200 mM stock in ethanol just before use of the buffer)
was added to each flask and the cells rocked for 10 minutes at 4°C to
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detach the cells from the sub-stratum and solubilise the protein. The cells
were then harvested and disaggregated in the buffer using a fine-tipped
pastette. The lysate was then spun for 2 minutes at 13,000 rpm in a bench-
top microfuge at 4°C. The supernatant, containing the plasma membrane
fraction was retained, aliquoted and frozen at -40°C until required.
2.5 PROTEIN DETERMINATION OF SAMPLES
2.5.1 PROTEIN ESTIMATION
The method of Lowry et al (1951) was used to estimate the protein
content of both tissue and cell culture samples. A range of known bovine
serum albumin concentrations were used as the standards from which the
protein concentration of the unknown was calculated.
All samples were diluted, usually 1:40, in 0.1 M NaOH to within a
range of 0-200 pg/ml. The plot of protein concentration against ODggonm
the final complex was approximately linear over this range. A range of
standards were assayed each time samples were to be measured. A
Shimadzu UV 160 spectrophotometer was used to measure the optical
densities. Each standard was assayed in duplicate, whilst each sample was
determined in triplicate.
2.5.2 SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL
ELECTROPHORESIS (SDS PAGE)
Following the determination of protein concentration, all samples
were assessed using SDS-PAGE according to the method of Laemmli
(1970). This was performed to check the accuracy of the protein
concentration estimates and to ensure the integrity of the samples.
Using SDS-PAGE it is possible to estimate the relative intensities of
the proteins in the molecular weight range for P450s and GSTs, in the
mouse and rat microsomal and cytosolic samples respectively, by staining
the polyacrylamide gel in Coomassie Brilliant Blue R dye. P-glycoprotein is
difficult to detect using this method, but can be stained for by using the
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sensitive silver staining method of Switzer et a/(1979).
Samples for assessing P450 and GST proteins were prepared for
electrophoresis by diluting them to a protein concentration of 2 mg/ml with
water, adding an equal volume of sample preparation solution (0.05 M Tris-
HCI, pH 6.8, 2% (w/v)SDS, 5% (v/v) 2-mercaptoethanol, 10%(v/v) glycerol,
0.05% (w/v) bromophenol blue dye) and heating to 100°C for 5 minutes.
Samples could be loaded immediately or stored frozen at -40°C until
required.
Protein from tissue fractions (10pg) and cultured cell preparations
(30pg) was routinely separated by SDS-PAGE to assess loadings. For
immunoblotting, rat and mouse microsomes (15pg) and cytosols from liver
and other tissues were loaded for analysis. Rainbow molecular weight
protein markers (Amersham International pic., Bucks., U.K.) were used for
molecular weight calibration purposes. The marker proteins (5pl) were
diluted 1:1 in sample preparation solution and heated to 100°C for 5
minutes, prior to separation by SDS-PAGE. The marker proteins were
myosin (200,000 kD), phosphorylase b (92,500 kD), bovine serum albumin
(69,000 kD), ovalbumin (46,000 kD), carbonic anhydrase (30,000 kD),
trypsin inhibitor (21,500 kD) and lysozyme (14,300 kD). SDS PAGE gels
(0.15 cm thick) were cast using a BioRad Protean 2 Vertical Electrophoresis
kit.
For detection of P450 proteins, the separating gel consisted of 9%
(w/v) polyacrylamide (8.7% acrylamide, 0.3% N, N'-methylene-bis-
acrylamide) in 0.375 M Tris-HCI, 0.15% SDS. For separating GST proteins,
the gel was 12% (w/v) polyacrylamide. Ammonium persulphate (APS),
freshly prepared, and N, N, N',N'-tetra-methyl ethylenediamine (TEMED),
both 0.05%, were added to initiate polymerisation. A stacking gel (4.5% (w/v)
acrylamide, 0.125M Tris-HCI pH 6.8, 0.125% SDS, 0.05% APS, 0.05%
TEMED) was poured on top of the polymerised separating gel, and the
sample wells formed using a teflon comb of appropriate size.The gels were
run in Electrode buffer (0.05M Tris-HCI, pH 8.3, 0.05 M glycine, 0.1% SDS).
Proteins were run through the stacking gel at 50mA per gel, and thereafter at
30 mA per gel constant current until the dye front was 1 cm from the bottom
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of the gel (~4 hr). The apparatus was water-cooled. When separation was
complete, gels were fixed in 45.5 % methanol, 9% acetic acid for 1 hr,
stained in Coomassie Brilliant Blue R (0.25% (w/v) Coomassie Blue R in the
same solution) for 1 hr and destained in 10% methanol, 7% acetic acid, until
the background staining had disappeared and the protein bands were
clearly visible.
2.5.3 ELECTROPHORESIS OF PROTEINS FOR P-GLYCOPROTEIN
IMMUNOBLOTTING
Estimation of protein loading and integrity was done in the same
manner as for P450 and GST protein except that the separating gel
consisted of 7 % (w/v) polyacrylamide. Two methods were assessed for
separation of proteins to be immunoblotted.
The first method involved the use of the Laemmli system previously
described. The separating gel was 7% polyacrylamide and no stacking was
used.
Cells were harvested using trypsin/versene and hand-homogenised
using a teflon-glass homogeniser.The whole cell homogenate was then
spun at 4000g, 10 minutes to pellet the unbroken cells and nuclei. The
supernatant was retained and re-centrifuged (100,000g, 1 h, 4°C). The
resultant pellet was resuspended and retained.
The fractions examined were as follows:
(a) whole cell homogenate
(b) 4000g pellet
(c) 100,000g pellet.
All fractions were suspended in KCI-phosphate buffer previously
described in Section 2.2.6. Aux B1 and CH^C5 cell samples were prepared
under a variety of conditions, to assess the best method of maintaining
immunogenicity. All samples were diluted 1:1 in sample preparation
solution, as described in Section 2.5.2, and used directly, or after heating for
5 minutes at 100°C. Samples were also prepared with or without 2-
mercaptoethanol.
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Section 2.6.3 (a) describes the results obtained on these cell
preparations following immunoblotting.
The second method for SDS PAGE was more successful in resolving
the P-glycoprotein band and used a modification (Debenham etal, 1982) of
the procedure of Fairbanks et al (1971). The modifications were the
inclusion of 2% (w/v) SDS in the solubilising buffer and the addition of urea
to both the sample and the polyacrylamide gel (4.5 M and 9.0 M
respectively).
The cell lysate protein samples, prepared as described previously in
Section 2.4.3, were diluted 1:1 in a buffer consisting of 9.0 M urea, 2% (w/v)
SDS, 10% (w/v) sucrose, 50 mM dithiothreitol (DTT), 1mM EDTA, 10 mM
Tris-HCI pH 8.0. This buffer was prepared, aliquoted and kept frozen at -
40°C until required. Bromophenol blue was used as a tracking dye.
The sample volume was kept as small as possible to optimise the
resolution of the protein bands since the gel system of Fairbanks et al
(1971) does not employ a stacking gel.
Gels were prepared in electrophoresis buffer (1% (w/v) SDS, 2 mM
di-sodium EDTA, 20 mM sodium acetate, 40 mM Tris-HCI , adjusted to pH
7.4 with glacial acetic acid (Fairbanks et al, 1971). The gels contained 5.6%
(w/v) acyrlamide and 0.21% bis-acyrlamide polymerised by the addition of
0.025% (v/v) TEMED and 0.15% (w/v) APS and were routinely cast in a mini
Protean 2 BioRad kit with a 10-well comb. The sample wells were rinsed
with electrophoresis buffer immediately prior to loading to remove diffused
urea and the solubilised samples (50-100pg of protein) loaded by under¬
laying.
2.6 IMMUNOCHEMICAL DETECTION
2.6.1 ELISA ASSAY TO DETERMINE P-GLYCOPROTEIN ANTIBODY
TITRES
Rabbits were immunised with various peptide antigens, as described
in Section 3.2, and bled at specific time points throughout the immunisation
schedule. Serum was collected by allowing the blood to clot overnight at
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4°C and centrifuging (1500 rpm, 15 minutes) it to spin out the remaining red
blood cells. The serum was then aliquoted and stored at -40°C until the titre
was measured. Pre-immune serum from each rabbit was collected,
aliquoted and frozen at -40°C.
The protocol used to measure the serum titre was described by
Campbell (1984) and involves a chequerboard ELISA for soluble antigens.
The antigen of interest was initially diluted to 50pg/ml, and serially
diluted to a final concentration of 1: 64. The lowest dilution of the antigen
solution (100pl) was added to each well of row A of a 96-well plate. Row B
contained the next dilution and so on until row G. PBS (100pl) was added to
row H. The plate was incubated overnight at 4°C to allow the soluble protein
antigen to be passively adsorbed onto the plate surface. Since most solid
supports adsorb proteins non-specifically by hydrophobic interactions, they
will also adsorb the antibody if the plate is not fully saturated with antigen.
Therefore once the antigen was bound, the plate was then incubated for 1 h
at room temperature with 10 mg/ml BSA in PBS (1 OOpil). The plate was then
washed three times with PBS containing 0.05% (v/v) Tween 20, to reduce
the background and discourage the formation of further hydrophobic
interactions between the support and first and second antibodies. Dilutions
of the rabbit serum were made, starting with a 1:100 dilution (in PBS
containing 0.5 mg/ml BSA) up to 1:10,000 dilution. To all wells in column 1,
100 pi of 1:100 dilution of anti-serum was added; to each in column 2, 100
pi of 1:200 was added and so on. In column 12, a 1:100 dilution of control
serum was added and the plate incubated at room temperature for 2 h.
Washing was performed as before. Alkaline phosphatase anti-rabbit IgG
conjugate, diluted 1:500 in 0.5 mg/ml BSA, 0.05% Tween 20 (1 OOpI) was
then added to all wells and the plate incubated for 2 h at room temperature.
The wells were then washed three times in PBS containing 0.05 % Tween
20 and knocked dry.
A solution of 1 mg/ml p-nitrophenyl phosphate freshly dissolved in
9.7% (v/v) diethanolamine buffer, pH 9.8 (1 OOpI) was then added. The
reaction was stopped by the addition of 3N NaOH (50pl). Absorption was
read at 405 nm, in a BioRad Model 2550 EIA spectrophotometer adapted for
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96-well microtite plates. The ELISA plates were a strong colour in the top
left-hand corner fading to a weaker colour in the bottom left-hand corner.
Row H and column 12 had little colour and provided the background. The
titre of the serum was estimated by finding the highest dilution at which it
gave more colour that the pre-immune serum and the wells without antigen.
2.6.2 WESTERN BLOTTING ANALYSIS FOR CYTOCHROME P450
AND GLUTATHIONE S-TRANFERASE PROTEINS
Western blot analysis was performed by a modification of the method
of Towbin et al (1979). For analysis of both the microsomal and cytosolic
fractions from rat and mouse liver, kidney and lung the same basic
procedure was adopted. Where polyclonal antibodies were employed, dual
labelling with horseradish peroxidase (HRP)-conjugated donkey anti-serum
against rabbit IgG was used. Where the first antibody was monoclonal, the
second antibody was HRP-conjugated rabbit anti-seum against mouse IgG.
SDS-PAGE was performed as described in Section 2.5.2.
For liver, kidney and lung microsomes, 15 pg, 30 pg and 50 pg of
protein were loaded respectively. For liver cytosols, 20 pg (for Ya-|, Ya2 and
Ya0 subunits) and 5 pg (for Yf and Yb subunits) of protein was required. For
kidney and lung cytosols, 30 pg and 50 pg were loaded respectively.
Following electrophoresis, the gel was marked to identify it and
placed on top of a 0.45 pm nitrocellulose filter, cut to a slightly larger size
than the gel. This was sandwiched between 2 sheets of Whatman 3 mm
paper and "Scotch-brite" pads to keep the gel in place. The sandwich was
placed in a BioRad transblotting cassette and this was transblotted overnight
at 250 mA, with the nitrocellulose sheet nearest the anode, in a BioRad
transblotting tank. The transblotting buffer (20mM disodium ortho-phosphate,
20% methanol) was gently agitated throughout this procedure. After transfer,
the nitrocellulose was trimmed to the exact size of the gel and washed for
two 10 minute periods in 50 mM Tris-HCI, pH 7.9, 0.15 M NaCI, 0.05 %
Tween 20 (TBST buffer) then blocked in 3% low fat powdered milk (Marvel -
Cadbury's) in TBST for 1 h. To check protein transfer from the gel, it was
fixed and stained in Coomassie Brilliant Blue R and destained as described
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in Section 2.5.2.Transfer was complete if no protein bands were visible.
After blocking the nitrocellulose, the filter was washed twice in TBST
and incubated for 60 minutes with the anti-serum against the P450 or GST
protein of interest (1:500 or 1:1000 dilution of antirabbit or antimouse
antibody respectively). The nitrocellulose was then washed 4 times (10
minutes each wash) and incubated with HRP- conjugated anti-rabbit IgG or
anti-mouse IgG (both 1:1000 dilution in TBST). A further four 10 minute
washes in TBST followed before the immuno-reactive proteins were
visualised. This was done by exposing the filter to the HRP substrate(120 mg
of 4-chloro-1-naphthol in 40 ml methanol, 200 ml of TBS (50 mM Tris-HCI
pH 7.9. 0.5M NaCI) and 80 pi of 30% H2O2). The filter was shaken gently in
this mixture until the immuno-reactive proteins were visible and then washed
for 10 minutes in distilled water to stop the reaction. It was then labelled with
0.19 MBq 1 ^-conjugated protein A (Amersham International pic.,
Amersham, Bucks, U.K.) in 50 mis of TBST for 45 minutes and repeatedly
washed with TBST to remove unbound radioactivity, until the wash solution
recorded background levels. Filters were air-dried, covered in Saran wrap
and exposed to Kodak X-Omat AR-5 X-ray film at -70°C in a lead cassette
with intensifying screens. The film was developed at an appropriate time
interval using a Gevamatic 60 (Agfa-Gevaert) automatic developer.
2.6.3 WESTERN BLOTTING OF P-GLYCOPROTEIN
Various methods were assessed for immunoblotting P-glycoprotein
using cultured cells. Aux B1 sensitive and CH^C5 mdr chinese-hamster
ovary cells were used to develop the best method. Initially, a system using
standard 7% Laemmli SDS-PAGE followed by wet-blotting transfer to
nitrocellose was used. Later a more successful system, using SDS-PAGE
urea gels followed by semi-dry blotting, was employed.
(a) Laemmli SDS-PAGE/wet blotting method
Polyacrylamide gels (7%) were prepared as described in Section
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2.5.3. The wet transfer of the proteins from the gel to the nitrocellulose and
subsequent blocking was as described in Section 2.6.2. After blocking the
filter was incubated in C219 P-glycocheck monoclonal antibody (1:100 in
TBST) overnight at 4°C. The monoclonal recognises the lgG2a class of
immunoglobulin. The filter was then given two 10 minute washes in TBST
before being incubated in either 0.19 MBq 125 | conjugated anti-mouse IgG
or1 25l conjugated protein A for 45 minutes. The filter was then repeatedly
washed in TBST to remove unbound radioactivity. Filters were air-dried ,
covered in Saran wrap and exposed to Kodak X-Omat AR-5 film at -70°C.
The film was developed between 4-14 days using an automatic developer.
The results of this immunoblotting method for Aux B1 and CH^C5 cell line
samples, prepared in various ways, described in Section 2.5.3, is shown in
Figure 2.1.
Using the Laemmli SDS PAGE system, the detection of the P-gp was
best when using a 100,000g fraction of the solubilised, non-heated mdr
cells. Exposure of the blot to antimouse IgG-l125 gave a more specific
reaction than Protein A-l12^. Protein A is characterised by it's ability to
interact to some degree with the IgG of almost all mammals but gives only a
weak reaction with IgG-j. However, the isotype of C219 is lgG2a (Kartner et
al, 1985) and thus a reaction between the Protein A and C219 was
expected. The time required for autoradiograph exposure to detect P-gp
using this Laemmli system was considerable. Even using antimouse IgG-
l^2^ as the second antibody still required a considerable lenghth of time for
exposure of the autoradiograph. It was decided later therefore to adopt the
urea gel system and ECL detection to improve the integrity of the signal and
the speed of detection. The procedure for this technique is outlined in below.
Greenberger et al (1988) reported a comparative study using a
polyclonal antibody against P-gp electrophoresed using the Laemmli and
modified Fairbanks gel system. He found that the electrophoretic mobility
and the amount of P-gp detected were remarkably dependent on the
conditions of analysis. He observed that boiling P-gp containing samples
before Laemmli gel electrophoresis decreased it's mobility by ~15kD and
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reduced the apparent amount of the protein. Figure 2.1 shows similar results
obtained in this study using such a system.
(b) Modified Fairbanks urea gel SDS-PAGE/semi-dry blotting method
Western blot analysis was performed using a semi-dry
electrophoresis blotter which allowed for fast, efficient electro-transfer of P-
gp from polyacrylamide gels onto nitrocellulose. The Milli-blot SDE
(Millipore) transfer system provided an even, uniform pressure across the
entire surface of the gel, ensuring consistent transfer from the entire gel. It
was found that this was a superior method for transfer of high molecular
weight proteins such as P-gp, than the BioRad buffer tank transfer system.
SDS-PAGE was performed using the modified urea gel system of
Fairbanks et al (1971), as described in Section 2.5.3, loading 50-100 |ig of
solubilised protein per track.
Following electrophoresis, the gel was marked for orientation and
briefly soaked in cathode buffer (25 mM Tris-HCI, 20% methanol, 0.1% SDS,
40 mM 6 amino-n-hexanoic acid, pH 9.4). Six pieces of Whatman 3 mm
paper were cut to the same size as the gel along with one piece of
nitrocellulose. Two pieces of 3 mm paper were soaked in anode buffer no.1
(0.3 M Tris-HCI, 20 % methanol, 0.1% SDS, pH 10.4), 1 piece in anode
buffer no. 2 (25 mM Tris-HCI, 20% methanol, 0.1% SDS, pH 10.4) and 3
pieces in cathode buffer. The nitrocellulose was placed briefly in distilled
water to wet it. The anode and cathode of the transfer apparatus consisted of
2 graphite plates which were first washed in distilled water. The 2 anode
buffer no. 1 papers were carefully placed on the anodic plate, excluding air
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FIGURE 2.1 IMMUNOBLOTTING AUX B1 AND CHRC5 CELL
LINES
























bubbles, upon which the no. 2 anode buffer filter paper was placed. The
nitrocellulose, gel and cathode buffer soaked papers were then assembled
in order, with the cathodic plate placed on top. Transfer was routinely carried
out for 90 minutes at 1 mA/cm2.
The assembly was taken apart carefully and the nitrocellulose filter
washed, blocked and incubated in C219 monoclonal antibody, as described
in Section 2.6.3 (a). The filter was washed in TBST for two 10 minute
periods before being incubated in HRP conjugated-rabbit anti-serum raised
against mouse IgG (diluted 1:5000 in TBST) for 20 minutes at room
temperature. The filter was then washed 4 times in TBST for a total time of
20 minutes. The immunoreactive proteins were visualised using the ECL
detection system (Amersham International pic., Amersham, Bucks., U.K.)
2.6.4 ECL DETECTION OF PROTEINS
The Enhanced Chemiluminescence (ECL) Immuno-blotting detection
system is a light-emitting method for detection of immobilised specific
antigens conjugated indirectly with HRP-labelled antibodies.
The principle of the detection is shown in Figure 2.2. The
chemiluminescent reaction of cyclic diacyl hydrazines such as luminol has
been extensively studied (Roswell et al, 1978). HRP is used to catalyse the
oxidation of luminol in the presence of H2O2. Following oxidation, luminol
decays to a ground state via the emission of light. This system is more
sensitive than radioactive detection systems and was used for the detection
of P-glycoprotein in cell line samples. Following washing in TBST,
nitrocellulose filters were covered in a 1:1 mixture of the solutions provided
in the kit to a final volume of 0.125 ml/cm2 of membrane and incubated for 1
minute, drained, wrapped in Saran wrap and exposed to Kodak X-Omat AR-
5 film for between 10 seconds to 30 minutes depending on the level of the
protein present.
2.7 cDNA CLONES
Hepatic GST, P450 and mdr mRNA levels in mouse and rat were
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investigated by Northern blot analysis.Two cytosolic gene families were
examined. The alpha class GST mRNA was measured using pGSTr155,
which contained a partial cDNA insert coding for the N-terminal 129 amino
acids of the rat Ya subunit. A clone containing the complete amino acid
sequence for the human acidic GST cloned into pUC 19 was used to probe
for homologous sequences in the mouse.







(b) Oxidation of luminol
in presence of H202
Hybond-ECL Hyperlilm-ECL
N, ♦ light
Mouse and rat liver were also probed with various P450 clones. A
full-length human clone of 1.75 kb was used to probe the cytochrome P450
sub-family CYP2A6. This clone encodes a protein with coumarin 7 -
hydroxylase (COH) activity (Miles et al ,1990). Yamano et al {1989) also
described a full length human CYP2A cDNA which differed from the pMP 81
sequence by only 3 nucleotides in the coding region. The human CYP2A6
cDNA deduced protein displayed 85% and 82% homologies with rat
CYP2A3 (Kimura et al, 1989) and mouse Cyp 2a-4 (Squires and Negishi,
1988) proteins. A full-length clone encoding the rat CYP2B1 (Friedberg et
al, 1986) was provided by Dr. M. Adesnik, Department of Cell Biology, New
York University School of Medicine, New York, U.S.A. A partial length (1.4
kb) mouse othologue of the rat CYP2C clone ( Meehan et al, 1988) was
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also used. Dr. K. Stevenson, Imperial Cancer Research Fund, Molecular
Pharmacology Group, Edinburgh kindly provided a 727 bp fragment of
human CYP3A4 cloned into an EcoR1 site of pUC 9. The isolation and
characterisation of the full-length cDNA clone has been previously
described (Stevenson et al, 1988). Dr. G. Gibson, Department of
Biochemistry, University of Surrey, Guildford, Surrey kindly provided the full-
length rat CYP 4A1 clone (Earnshaw et al, 1988).



















The cONA 5A (EcoRI-EcoRI, 1 383 bp) was subcloned into EcoRI site of
pGEM4 (Promega Biotec).
r i T7 promoter; EH, SP6 promoter;
A, Acc I; B, BamHI; E. EcoRI; H, HindiII; P.Pvull;
5, Stu I; X, Xmn I.
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TABLE 2.2 INFORMATION ON CLONES
PLASMID VECTOR cDNA CLONED INSERT REFERENCE
pGSTr155 pAT153 153 amino acids 452 bp Taylor et al,
of rat Ya 1984
pGP5 pUC8 complete rat Yf 734 bp Sugoaka et al,
1985
pMP81 pUC19 human CYP2A3 1.75 kb Miles et al, 1989
pMP23 pUC19 rat CYP2B1 1.7 kb Friedberg
et al, 1986
pMP63 pl)C9 mouse Cyp2c 1.4 kb Meehan et al,
1988




pMP112 pUC9 full length rat
CYP4A1
2.1 kb Earnshaw et al,
1988
pMP90 pUC19 mouse actin 1.2 kb Leader et al,
1985
pMDR5A pGEM-4 partial human 1.38 kb
mdr 1
Ueda etal, 1987
BBpG4 pGEM-4 mouse mdr 1 180 bp Raymond et al,
1990
H1pG3 pGEM-3 mouse mdr 2 408 bp as above
H3pG3 pGEM-3 mouse mdr 3 140 bp as above
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A mouse actin cDNA probe was given by Dr. J. McNab, Institute of Virology,
Glasgow. Dr. R. Brown provided the mdr 5A clone for the 1383 bp EcoR1
insert of the human mdr 1 gene (Figure 2.3) cloned into pGEM.
All 3 mouse gene specific mdr clones were gifted by Dr. R Gros, Department
of Biochemistry, McGill University, Quebec, Canada, H3G 1Y6. The plasmids
all have a pGEM backbone and their isolation is described by Raymond
(1990). The specificity of these probes was examined before use, as shown
in Section 5.3 and Figure 5.12.
The information regarding these clones is summarised in Table 2.2.
2.8 PLASMIDS
2.8.1 PLASMID CULTURE
Bacterial cells were transformed using the calcium chloride method of
Mandel and Higa (1970). Transformed Escherichia Coli K12 strain HB101
were selected and maintained on L-agar plates with appropriate antibiotic
selection. Tetracycline (10 pg/ml ) or ampicillin (100 pg/ml) was used
depending on the plasmid construct.
2.8.2 STORAGE OF PLASMIDS
Transformed bacteria were grown in L-broth overnight with
appropriate antibiotic selection. Glycerol was added to a final concentration
of 40% (v/v) and 1 ml aliquots were frozen at -70°C. Plasmid DNA from
transformed cells was also prepared as described in Section 2.8.4 and
stored at -70°C.
2.8.3 MEDIA USED FOR BACTERIAL CULTURE
L-broth and L-agar were used for the culture of HB101 in liquid and
solid phase respectively. L-agar plates with streaked out colonies were
stored at 4°C for up to 4 weeks and then sub-cultured by selecting a single
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colony and incubating it in L-broth plus antibiotic at 37°C overnight followed








As for L-broth but including 15g/l Difco agar.
2.8.4 PREPARATION OF PLASMID DNA
Initially the procedure used for large-scale preparation of plasmid
DNA was a modification of the method of Birnboim and Doly (1979). Latterly,
Qiagen kits were employed.
(a) Plasmid DNA preparation (Birmboin and Doly, 1979)
A single colony from an L-agar plate was inoculated into 10 ml of L-
broth plus appropriate antibiotic and incubated for 6-8 hr at 37°C with
shaking. This culture was seeded into a 1 litre conical flask containing 500
ml of pre-warmed L-broth plus appropriate antibiotic and shaken at 37°C
overnight. The cell suspension was spun at 8,000g at 4°C for 10 minutes in
a Sorvall RC 5B, SS34 rotor. The bacterial pellet was then resuspended in
20 ml of solution A (2 mg/ml lysozyme, 50 mM glucose, 25 mM Tris-HCI pH
8.0, 10 mM di-sodium EDTA) and kept on ice for 30 minutes to lyse the
bacterial cell wall. Solution B (1% SDS, 0.2 M NaOH, 40 ml) was then
added and the mixture left on ice for 5 minutes to further disrupt the bacterial
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cell membrane. To precipitate the proteins, Solution C (3M sodium acetate,
pH 4.8, 20 mi) was added and the mixture left on ice for a further 1 h. The
heavy white precipitate which had formed was pelleted by centrifugation at
10,000 g , 4°C, 15 minutes. The supernatant, which contained the plasmid,
was retained and ice-cold isopropanol (0.7 volumes) added. The DNA was
precipitated by chilling the solution for 30 minutes at -20°C, followed by a 10
minute spin (10,000 g, 4°C). The pellet was resuspended in Solution D (100
mM sodium acetate, 50 mM Tris-HCI, pH 8.0, 10 ml). Cold ethanol (2
volumes) was added and the solution kept at -20°C for 1 h until re-
centrifuged for 10 minutes at 10,000 g , 4°C. The pellet from this spin was
resuspended in TE (10 mM Tris-HCi, pH 8.0, 0.1 mM EDTA, 6.7 ml) to which
caesium chloride (74g) and ethidium bromide (10 mg/ml,1.4 ml ) was added.
After the suspension was centrifuged (200,000g, 16 hr ,20°C) the nucleic
acid bands were visualised using a short-wave transilluminator. Using a
hypodermic needle inserted into the side of the ultracentrifuge tube, the
band of closed, circular plasmid DNA was collected as described by
Maniatis (1982). Ethidium bromide was then extracted using water-saturated
butanol and the solution dialysed against three changes of 1000 volumes of
TE at 4°C for 16 hr with stirring. The DNA was precipated at -70°C for 30
minutes by adding cold ethanol (2 volumes) and 3M sodium acetate, pH 4.8
(0.1 volume) and spinning at 10,000g, 4°C for 10 minutes. The plasmid was
finally resuspended in an appropriate volume of TE buffer and stored at -
20°C.
(b) Plasmid DNA Preparation (Qiagen Column Method)
The initial steps of the protocol were essentially the same as for part
(a). Following addition of 0.2M NaOH and 1%(w/v) SDS, 2.55M potassium
acetate, pH 4.8 was added to precipitate proteins. The mixture was then
centrifuged at 4°C for 30 minutes, 20,000g. The supernatant was carefully
but promptly removed to obtain a particle-free clear lysate. A Qiagen column
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was equilibrated with 10 ml of buffer QBT (750 mM NaCI, 50mM MOPS, 15%
(v/v) ethanol, pH 7.0, 0.15% (v/v) Triton X-100) and allowed to empty by
gravity flow. The supernatant, containing plasmid DNA was then applied to
the column and allowed to enter the resin by gravity flow. The column was
then washed with 3 x 10ml buffer QC (1.0 M NaCI, 50 mM MOPS, 15% (v/v)
ethanol, pH 7.0). At pH 7.0, the solubility of DNA is reduced and it will stick to
the column. The DNA was then eluted with 15 ml of buffer QF (1.25M NaCI,
50 mM MOPS, 15%(v/v) ethanol, pH 8.2). Normally plasmid DNA is highly
soluble at slightly alkaline pH. The DNA was then precipated with iso-
propanol ( 0.7 volumes) and centrifuged at 4°C for 30 minutes, 10,000g. The
DNA pellet was finally washed in 70% ethanol, dried briefly by dessication
and redissolved in a suitable volume of buffer and kept frozen at -20°C.
2.9 RNA PREPARATION
To prevent degradation of RNA by contaminating nucleases, all items
used in the extraction procedure were thoroughly soaked in 0.1% DEPC-
treated water for 2h, rinsed and autoclaved. DEPC is a strong but not
absolute inhibitor of RNAases. Rinsing and autoclaving removes traces of
DEPC that might otherwise modify purine residues in RNA by
carboxymethylation. All tissues were snap-frozen in liquid nitrogen
immediately following sacrifice and dissection. Extractions were carried out
on ice and gloves were worn at all times.
2.9.1 PREPARATION OF TOTAL CELLULAR RNA FROM CULTURED
CELLS
Total cellular RNA was prepared from 75cm^ flasks of confluent cells
in culture using the method described by Birnboim (1988) which utilises
differential precipitation to separate high molecular weight RNA from other
types of nucleic acid.
To detach the cells from the sub-stratum, the culture medium was
poured off and the cells washed in PBS followed by the addition of RES
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buffer (2 ml of 0.5M LiCI, 1M urea, 0.25% SDS, 0.02M sodium citrate, 2.5
mM CDTA, pH 6.8) with gentle shaking. The mixture was then poured into an
ice-cold universal tube and the culture flask washed with a further 1 ml of
RES buffer. This was pooled with the first wash and the cell suspension was
sonicated for 5-10 seconds at low power to disrupt the cells before adding
proteinase K (150pl of 1mg/ml) and incubating the mixture for 30 minutes at
50°C. Proteinase K is a non-specific serine protease that is prepared free
from nuclease activity. The sample was then cooled to room temperature
and sodium acetate, pH 5.2 (200|il) and ice-cold ethanol ( 7ml) were added.
The mixture was cooled at -20°C for 20 minutes and centrifuged at 10,000
rpm for 10 minutes. The pellet from this spin was dissolved in RES buffer
(1ml) and extracted with chloroform/isoamyl alcohol (24:1, 100pl) vortexed
for 2-3 minutes and centrifuged at 13,000g for 5 minutes.
The aqueous phase was precipated in 2M acetic acid, pH 5.2 (7.5pl )
and 5M LiCI/ethanol, 3:2 (1ml). RNA was precipated overnight at 4°C and
centrifuged at 13,000g for 2 minutes. The pellet was dissolved in 1mM
sodium citrate, 1mM CDTA, 0.1% SDS, pH 6.8 (1 OOpil) and frozen at -70°C
until required. The quality and quantity of the RNA was assessed as outlined
in Section 2.10.
2.9.2 PREPARATION OF TOTAL RNA FROM WHOLE TISSUES
Total RNA was extracted using approximately 1g of tissue from
pooled samples of snap-frozen tissue using the method of Cox (1968).
Proteins dissolve readily in solutions of potent denaturing agents such as
guanidium hydrochloride. Cellular structures disintegrate and
nucleoproteins dissociate from nucleic acids as protein secondary structure
is lost.
Tissue was removed from storage at -70°C and kept on dry-ice until
8M guanidine HCI (20ml) was added. The tissue was then quickly scissor-
minced and homogenised using a Silverson Laboratory Mixer Emulsifier, for
1 min. The homogenate was spun at 4°C for 5 minutes at 9000 g (Sorvall
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RC 5B centrifuge, SS-34 rotor) after which the fatty layer was removed. Cold
absolute alcohol (0.5 volumes ) was then added to the supernatant which
was left at -20°C for 45 minutes. The solution was spun at 9000g, 4°C, 10
minutes to pellet the nucleic acids. The pellet was then resuspended in a
small volume of 6M guanidine HCI using a teflon-glass hand-homogeniser.
The volume was made up to 20 ml and ice-cold absolute alcohol (10 ml )
added. The solution was mixed immediately and stored at -20°C for 45'. The
nucleic acids were recovered by centrifugation at 9000 g, 4°C, 10 minutes
and the ethanol precipitation step in 6 M guanidine HCI repeated once
more. Following this, the recovered pellet was dissolved in DEPC-treated
water ( 1 ml ) andprecipitated in 7.5 M ammonium acetate (0.5volume) and
cold absolute alcohol (2.5 volumes) at -20°C for at least 2 h. Under these
conditions, cellular DNA remains soluble whilst the RNA is precipitated-The
solution was centrifuged at 9000 g, 10 minutes, 4°C and the pellet
redissolved in DEPC-treated water (1 ml). The nucleic acids were
reprecipitated2-3 times with 2M sodium acetate, pH 4.8 (0.1 volume), and
cold absolute alcohol (2.5 volumes) at -70°C for 1 h.The final pellet was
spun out at 9000 g, 10 minutes, 4°C and resuspended in DEPC-water. After
assessing the concentration of the RNA samples, as outlined in Section
2.10.1, they were aliquoted and frozen at -70°C until required.
2.10 QUANTITATION OF DNA AND RNA
2.10.1 SPECTROPHOTOMETRIC QUANTITATION
DNA or RNA concentrations were estimated by UV absorption
spectrophotometry. DNA or RNA samples were diluted 200 or 250 fold
respectively, mixed and transferred to a spectrophotometric quartz cuvette.
The spectrophotometer was blanked against DEPC- water and the
absorbance of the sample was read at 260 nm. The concentration of DNA or
RNA, in 1 pg/ml of sample, was calculated as 10 times the O.D. reading.
To assess the purity of the samples, the absorbance at 280 nm was
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also measured and the ratio of absorbance at 260 nm to 280 nm calculated.
For DNA and RNA the ratio should be 1.8 and 2.0 respectively. If the ratio
was below 1.6 the sample was re-extracted with phenol/chloroform and
ethanol precipated to eliminate contaminating protein.
2.10.2 ETHIDIUM BROMIDE FLUORESCENCE QUANTITATION
(a) DNA estimation
DNA concentrations were estimated by electrophoresing samples in
0.8% (w/v) agarose in TBE (130 mM Tris-HOI, 45 mM boric acid, 2.5 mM
EDTA). Mini-gels (50mm x 75mm x 5mm) were cast, transferred to a BRL
horizontal electrophoresis kit H6 (BRL, Uxbridge, U.K.) and run in TBE with
ethidium bromide (0.5 pg/ml) at 20 V for 2-3 hr. A series of DNA standards
were also run to estimate the size of linear DNA. A 1 kb ladder (BRL, Paisley,
U.K.) with a range of fragment sizes from 75 - 12,216 bp was used. A DNA
sample of known concentration was run to check the concentration of
unknown samples, as calculated from spectrophotometric analysis.
DNA fragments were visualised using a short wavelength
trasilluminator (Model TM-40, Ultraviolet Products Incorp.). The amount of
UV induced-fluorescence emitted by ethidium bromide molecules,
intercalated with DNA, is proportional to the total mass of DNA.
(b) RNA estimation
RNA loadings were assessed by electrophoretic size fractionation
under denaturing conditions using a method developed by Lehrach et al
(1977). Horizontal 1% (w/v) agarose gels were prepared by melting 1gm of
agarose, cooling it to 60°C and adding 5 x GRB (0.1 M MOPS, pH 7.0, 40
mM sodium acetate, 5 mM EDTA, pH 8.0, 20 mis)) and 37% (12.3 M)
formaldehyde to give final concentrations of 1x and 2.2 M respectively.
The RNA samples were prepared by mixing the following solutions in










and heating for 15 minutes at 55°C. Loading dye (0.4% bromophenol blue,
0.4% xylene cyanol, 50% glycerol, 1mM EDTA, pH 8.0, 2 pi)) was
immediately added to the samples. Electrophoresis was carried out at 40 V
for 2-3 hr. After electrophoresis, the gel was stained in ethidium bromide (0.5
pg/ml) for 30 minutes, to visualise the abundant 28 S (6333 nucleotides) and
18 S (2366 nucleotides) ribosomal RNA species. This allowed for an
approximate estimation of loading equality between the samples and
assessed the integrity of the RNA.
2.11 NORTHERN BLOTTING
The attachment of denatured RNA to nitrocellulose is presumed to be
non-covalent but essentially irreversible. It is possible to hybridise RNA
immobilised on nitrocellulose to several radioactive probes without
significant loss of bound nucleic acid. Unfortunately, nitrocellulose is not
durable enough to withstand more than 2 rounds of hybridisation and
washing. This difficulty can be solved by transferring the RNA to positively
charged nylon membranes. Hybond is a nylon membrane which is
inherently hydrophobic and thus requires no pre-wetting. It is possible to
easily and quickly cross-link nucleic acids to the nylon using UV light.
Combined with the physical strength of the membrane it is ideal for multiple
rounds of hybridisation. Reed and Mann (1985) have reviewed the practical
information regarding membranes.
2.11.1 SEPARATION, TRANSFER AND HYBRIDISATION OF RNA
RNA was size-fractionated under conditions described in Section
2.10.2 (b). 15 pg samples of RNA along with 3 pi of an RNA ladder (0.24 -
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9.5 kb derived from bacteriophage 17, yeast 2p circle and bacteriophage
lamda DNA. BRL, Paisley, U.K.), were run routinely using a BRL horizontal
electorphoresis unit (BRL, Uxbridge, U.K.) at 20 V for -16 hr until the dye
front was -5 cm from the edge of the gel. The gel was then washed for 10
minutes in 10 x SSC (1 x SSC is 0.15 M NaCI, 0.015 M Na citrate) and
transferred to Amersham Hybond N membrane by capillary transfer in 2 x
SSC. Following a 16-18 hr transfer, the RNA was fixed to the nylon
membrane by exposing the filter to ultra-violet irradiation (254 nm) for 30
seconds using a Stratalinker 2400. This method enhances the hybridisation
signal obtained with charged nylon membranes compared to convential
oven-baking (Khandjian, 1987). The aim of the procedure is to form cross¬
links between a small fraction of the bases in the RNA and the positively
charged amino acids on the surface of the membrane (Church and Gilbert,
1984). To check the efficiency of transfer the gel was stained for 45 minutes
in a solution of ethidium bromide and examined under ultra-violet
illumination. The part of the membrane containing the RNA ladder was
stained with methylene blue (0.04% methylene blue. 0.5M sodium acetate)
for 5-10 minutes at room temperature. The details of this method are
described by Herrin and Schmidt (1988). After washing in distilled water, the
RNA standards were clearly visible as a series of blue bands which were
used to estimate the size of the RNA transcript hybridising to the probe used.
The filter was placed in hybridisation mix (5 x SSC, 4 x Denhardt's
solution, 10% (w/v) dextran sulphate, 0.1% (w/v) SDS, 0.1% (w/v) sodium
pyrophosphate) for at least 4 hr at 65°C in a glass tube in a preheated
oven. To maximise the rate of annealing of the probe to target DNA,
hybridisation was carried out at high ionic strength (5 x SSC). The rate of
hybridisation is accelerated 10 fold in the presence of 10% (w/v) dextran
sulphate according to Wahl et at (1979). Denhardt's reagent (0.02% (w/v)
polyvinylpyrrolidine, bovine serum albumin and Ficoll 400) is used to block
non-specific attachment of the probe to the filter surface.
Probes, prepared and radiolabeled as described in the following
sections, were added directly to the hybridisation solution following
denaturation and allowed to hybridise to the RNA for 16-18 hr at 65°C. The
filter was washed 3 times in 2 x SSC, 0.1% (w/v) SDS, 0.1% (w/v) sodium
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pyrophosphate (NaPPi). Higher stringency washes of 0.2 x SSC, 0.1% (w/v)
SDS, 0.1% (w/v) NaPPi were carried out for certain probes, to eliminate
cross-reactivity to similar gene sequences. The filter was wrapped in Saran
wrap and exposed to Kodak X-Omat AR-5 film at -70°C in a cassette with
intensifying screens.
In order to reprobe the RNA, the filters were washed in stripping
solution (5mM Tris HCI, pH 8.0, 2mM EDTA, 0.1 x Denhardt's) for 1 h at
65°C, according to the manufacturer's instructions.
Autoradiographs were sometimes quantitated by scanning with a
Joyce Loebl chromoscan. Non-saturated blots were scanned in order to
ensure linearity across the samples.
2.11.2 PREPARATION OF cDNA PROBES FOR USE IN
HYBRIDISATION
To isolate the cDNA clones referred to in Section 2.7, the plasmids
were cut with the appropriate restriction enzyme. Usually this involved only a
single enzyme digest at 37°C which was left for 6 hr, in a buffer as supplied
by the manufacturer of the restriction enzyme.
Loading dye (50% glycerol, 1 x TAE, 1% bromophenol blue, 1%
xylene cyanol, 2pl) was added to the digests and samples were
electrophoresed in TAE buffer (40 mM Tris acetate, 1 mM EDTA) in a mini-
gel containing 0.8% (w/v) low melting point agarose and 0.5 pg/ml EthBr.
Aliquots of both cut and uncut plasmid DNA were run to assess the digestion
procedure and a 1 kb DNA ladder was also run to estimate the insert size.
Segments of the gel containing the inserts were excised and sterile water
added at 1.5 ml per 1 gm of gel. This solution was then heated to 100°C for
7 minutes and frozen at -20°C until required.
2.11.3 RADIOLABELLING OF cDNA CLONES
Small amounts of DNA (50-200 ng) were labelled to high specificity
using the method of Feinberg and Vogelstein (1983). This method is used to
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generate probes from denatured double-stranded DNA. The purified DNA,
mixed with a molar excess of primers, is denatured and synthesis carried out
using the Klenow fragment of polymerase I. This enzyme lacks 5'-3'
exonuclease activity so that the product is synthesised exclusively by primer
extension. The reaction is carried out at pH 6.6, thus reducing the 3'-5'
exonuclease activity of the enzyme (Lehman and Richardson, 1964). These
conditions favour random initiation of synthesis.
DNA was denatured by heating at 100°C for 3 minutes and kept at
37°C until the radio-labelling reaction was initiated. The following
constituents were mixed and the radiolabelling reaction was allowed to
proceed for 3h or 16h according to convenience.
BSA (Fraction 5, Sigma) 10 mg/ml 2pl
Oligonucleotide-labelling buffer (OLB) 5jil
water 18pl
DNA 20|il
Klenow fragment of EColi DNA pol 1 2pl
[a-32P]dCTP] sp. act. >3000 Ci/mmole; 10 (iCi/ml 3pl
OLB consists of a mixture of solutions A, B and C mixed in a ratio of 2:5:1
and was routinely stored at -20°C.
Solution A




10 mM dATP, dGTP, dTTP 50pl (of each)
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Solution B
2M Hepes titrated to pH 6.6 with NaOH and stored at 4°C.
Solution C
Hexadeoxyribonucleotides suspended in 3 mM Tris-HCI 0.2 mM EDTA, pH
7.0 at a concentration of 90 O.D. units/ml and stored at -20°C.
Following incorporation, the DNA was denatured for 5 minutes at
100°C and added to the hybridisation solution as quickly as possible. To
estimate the percentage of radioactivity incorporated into the DNA, a 1pl
aliquot was removed from the reaction mixture and spotted onto DE 18
Whatman filter paper. A chromatograph was run in 0.3 M ammonium
formate, pH 8.0 for 15 minutes and exposed to Kodak X-Omat AR-5 film for
10 minutes. Radioactivity incorporated into the DNA appeared as a spot at
the origin whereas unincorporated nucleotides eluted up the paper with the
solvent front. Incorporation was routinely between 70-90%.
2.12 CYTOTOXICITY TESTING
2.12.1 MTT ASSAY
The MTT assay relies on the cleavage of the ring structure of the
tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) to a blue crystalline formazan product by the mitochondrial enzyme
succinate dehydrogenase of viable cells. The assay can be used for both
chemosensitivity and radiosensitivity testing (Carmichael et at, 1987 a,b)
and was chosen because it is rapid, simple and can also be used to
measure the toxicity of hydrophobic compounds. The assay appears to give
results comparable to the clonogenic assay which is widely used to assess
the chemosensitivity of tumour cells in vitro although it cannot distinguish
between cytostasis and cytotoxicity.
The assay was performed according to the method of Carmichael et
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al (1987a). Cells (2500) were seeded in a volume of 180jo.l in medium
and continuously exposed to the compound
of interest in Costar 96-well micro-titration plates. The outer wells were filled
with water to prevent evaporation from other wells and also since growth of
cells in these wells differed from the rest of the plate. The plate was blanked
against 6 wells (1 column) which had medium in them. To allow the cells to
adhere, plates were incubated overnight at 37°C, 5% CO2 in a humid
atmosphere. The following day, the compound of interest was dissolved in
serum-free medium from a stock prepared in DMSO, sterile water or ethanol.
Serial dilutions were made from the compound dissolved in medium. The
diluted compound ( 20jil ) was then added to the wells. Each dilution was
assayed in triplicate.
Plates were left 4 days at 37°C followed by the addition of MTT (50 pi
of 2 mg/ml in distilled water). Following a further 4 hr incubation, the medium
was aspirated off and DMSO (50pl) added to the formazan crystals which
had formed at the bottom of the wells. The plate was then read at 504 nm in
a Biorad Model 2550 EIA plate reader. The absorbance of each well,
containing cells in the presence of the compound of interest, was calculated
as a percentage of the absorbance of the wells containing cells in the
absence of the compound of interest (% control absorbance). The blank
column (media only) reading was automatically subtracted from the rest of
the plate. Each assay was carried out in triplicate and the results combined.
Hydrophobic compounds were dissolved in DMSO for use in this assay. The
toxicity of DMSO was tested on the CH^CS and Aux B1 cell lines and it was
found to be non-toxic at 0.5% (v/v) and this concentration was never
exceeded in the assay. When compounds dissolved in DMSO were tested,
the seeding medium was aspirated from the cells before the test compound
(dissolved in DMSO and diluted further in medium) was added. The rest of
the assay was as described before. A control with cells exposed to 0.5%(v/v)




In order to assay corticosterone levels in mice treated with
dexamethsone and TCPOBOP, C57BL/6 male adult mice (2 per group) were
treated with dexamethsone (100 mg/kg, 3 dy) or TCPOBOP (3 mg/kg, 1 dy).
Controls (10 mice) were treated with corn-oil (0.2 ml, 3 dy). Mice were
sacrificed by cervical dislocation following treatment. Cardiac puncture was
performed on each animal and the blood collected into tubes
(Brunswick, England). The blood was spun ( 12,000 g, 2', 4°C) and the
supernatant (serum) removed and stored at -20°C until assayed for
corticosterone. Serum was pooled for dexamethasone and TCPOBOP
treated mice as well as controls.
2.13.2 CORTICOSTERONE ASSAY
A simple and highly specific radioimmunoassay for corticosterone
was developed (Al-Dujaili et al, 1981) and used in this study. The assay
utilises a specific antibody raised against corticosterone-3-(o-
carboxymethyl)-oxime-BSA and y-labelled corticosterone of high specific
activity. The production and assessment of antisera used in the assay has
been previously described (Al-Dujaili et al, 1981). Dilutions of corticosterone
standards in steroid-free medium ranging from 0-1152 nmol/l were used to
construct the standard curve. Corticosterone free medium was prepared by
the charcoal stripping method which involves adding 10% charcoal to the
plasma to be stripped and agitation for at least 5h. The solution was then
spun (30', 12K) and the plasma removed and filtered.
Triplicate standard or sample aliquots (25pl, 1:10 dilution) were
assayed;-5000 cpm of [125l] corticosterone (100jil) and corticosterone
antibody (1 OOpil, 1:5000 dilution), each dissolved in assay buffer (0.05 M
phosphate/citrate buffer, pH 3.0) were added. The assay buffer at pH 3.0 was
found to be the optimum pH which produces maximum inhibition of
90
corticosteroid-binding globulin (CBG) with minimum effect on the antibody-
antigen binding. Therefore at pH 3.0, most of the steriod is in the unbound
form and the assay can measure approximately total steroid concentration.
The tubes were mixed and incubated at 4°C for 4h. The antibody-
bound and free fractions were separated by adding dextran-coated charcoal
suspension (0.5 ml of 0.1 M phosphate buffer, pH 7.4, 0.05% (w/v) gelatin,
0.6% (w/v) activated charcoal, 0.06% dextran T70) and spinning the tubes at
4°C, 30', 2000g. The supernatant was then aspirated and the antibody-free
fraction (spun down in the charcoal pellet) counted in an automatic gamma
counter.
Total unbound counts were estimated by adding only the label
solution to the incubation without antibody.
To calculate bound counts:
Total counts - unbound counts = Bound counts
(without antibody) (standard or sample
with antibody)
% Binding = (bound counts/total counts without antibody) %
From the percentage binding values, a standard curve can be plotted
against known amounts of corticosterone. From the standard curve, an
estimation of corticosterone (nmol/l) for the unknowns can be determined.
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CHAPTER 3
DEVELOPMENT OF PEPTIDE ANTIBODIES TO P-
GLYCOPROTEIN
3.1 INTRODUCTION AND AIMS
The precise role of P-gp in acquired drug resistance is uncertain,
however evidence suggests that it may directly bind drugs and act as an
efflux pump (Safa et al, 1986). An alternative mechanism is that drugs bind a
carrier protein and the drug-protein complex is actively transported from the
cell. In either case, P-gp should be in high concentrations in the plasma
membrane if it is involved in the transport of drugs out of the cell.
The first monoclonal antibody with a high affinity to P-gp which was
useful for detecting this transmembrane protein was developed by Ling's
group (Kartner et al, 1985). Several others have also described the
development of monoclonal antibodies that appear useful in the detection of
P-gp (Scheper et al, 1988; Hamada and Tsuruo, 1986; Danks et al,
1985).The monoclonal antibody MRK16, reactive with an epitope present in
P-gp which is expressed on the external face of the plasma membrane of
human mdr cells was isolated (Hamada and Tsuruo, 1986). This antibody
reacts only with human P-gp and has been used to localise the protein in
normal human tissues by means of peroxidase immunohistochemisrty
(Thiebaut et al, 1987) and in cultured mdr cells by use of electron
microscopic immunocytochemisty (Pastan et al, 1988; Willingham et al,
1987). Using MRK16 to probe normal human tissues, the protein was found
concentrated in a small number of specific sites. Most tissues contained very
little P-gp. In liver, P-gp is found exclusively on the biliary canalicular front of
hepatocytes and on the apical surface of epithelial cells in small biliary
ductules. In kidney, P-gp was found concentrated on the apical surface of
epithelial cells of the proximal tubules. Colon and jejenum both showed high
levels of expression on the apical surfaces of superficial columnal epithelial
cells. It was also diffusely distrubuted on the surface of cells in the adrenal
cortex and medulla (Fojo et al, 1987; Thiebaut et al, 1987).
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The localisation of P-gp in human tissues on the apical surface of
certain cell types facing an excretory compartment suggests that the protein
may have a role in the excretion of drugs and physiological metabolites
produced by cells. Liver, kidney and bowel are the sites from which cytotoxic
natural products in the diet or introduced are removed from the body. The
mdr 1 gene transporter may be protecting animals from a variety of cytotoxic
compounds. In the mouse, mdr 1 is expressed at high levels in the secretory
epithelial cells of the gravid uterus (Arceci et al, 1988). In the adrenal gland
or pregnant uterus, the mdr 1 gene product may be involved in the transport
of endogenous metabolites.
In mdr vinblastine-selected KB-V1 and colchicine-selected KB-C4
cells, MRK16 was used to detect P-gp in high concentrations in the plasma
membranes compared to the drug sensitive parental KB-3-1 cells
(Willingham et al, 1987).
Monoclonal antibody C219 (Kartner et al, 1985) has been shown to
react with P-gp in many mammalian species and detects an epitope located
on the cytoplasmic face of the plasma membrane, near the C-terminal end,
close to one of the putative ATP binding sites. The presence of these sites in
the primary sequence of the mdr 1 gene and the requirement for ATP in the
efflux activity of P-gp in intact cells (Willingham et al, 1986) and in isolated
transporting vesicles (Horio et al, 1988) suggested that P-gp could be an
ATPase. Myosin possess strong ATPase activity and contains ATP binding
sites (Strehler et al, 1986). C219 shows strong localisation patterns in
human skeletal and cardiac muscle using immunohistochemical labelling
and immunoblotting of the tissue (Wishart et al, 1990).
In rat liver extracts, a band of slightly faster mobility (-165 kD)
compared to cultured human mdr cells (170 kD) was seen (Thiebaut et al,
1989). C219 localisation showed a bile canalicular pattern in rat liver as
seen with MRK16 in human liver.
Sensitive immunocytochemical techniques have been developed to
detect P-gp in cell lines with varying degrees of resistance using the C219
monoclonal antibody.
Immunocytochemical detection, with either alkaline phosphatase or
peroxidase-antiperoxidase with silver gold intensification, gave a good
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correlation with results obtained using immunoblot analysis (Friedlander et
al, 1989). Such a technique detects P-gp in small numbers of cells that
immunoblot analysis could miss, making it more suitable for clinical
application. Epitope mapping of monoclonal antibodies to P-gp was
performed by Georges et al (1990). He demonstrated that C219 recognises
a highly conserved amino acid sequence found in all P-gp isoforms
characterised to date. Other monoclonals such as C494 are gene specific
and bind to a sequence present only in the class 1 isoform of hamster (pgp
1) and human (mdr 1). The monoclonal antibody C32 recognises a
sequence conserved in hamster class 1 (pgp 1) and class 2 (pgp 2) isoforms
but not in class 3 (pgp 3). These monoclonals were used to reveal
differential expression and specific localisation of the three P-gp isoforms in
hamster tissues by immunohistochemical staining and competition with
epitope-specific peptides (Georges et al, 1990). Each P-gp isoform was
found in a small, distinct group of differentiated cell types, and supports the
notion that each P-gp isoform may have a different physiological role in
normal cells. This approach may be particularly useful for the class 3 isoform
(hamster pgp 3, human mdr 3 and mouse mdr 2) because it has not been
possible to select in vitro for cells expressing high levels of this isoform. The
expression of the class 1 isoform in brain capillary endothelium may reflect
the involvement of P-gp in the function of the blood-brain barrier (Cordon-
Cardo et al, 1989). This P-gp is also detected in the endothelium of small
blood vessels in the testis, ovary, oviduct, uterus and vagina. This pattern of
endothelial cell expression may indicate a physiological role for P-gp in
regulating the entry of certain molecules into the central nervous system and
other anatomic compartments, such as the testes. Bradley et al (1990) gave
an alternative suggestion when pointing out that endothelial cells,
hepatocytes and intestinal lining epithelial cells are all thought to secrete
hormones and metabolites. Thus the P-gp class 1 isoform may function in
specific secretory pathways that operate in these differentiated cells but not
in similar cells in other sites. The pattern of expression of class 2 and 3 P-gp
isoforms in specialised cells of the adrenal cortex, uterus and muscle
suggests a normal function of these isoforms in the transport of normal
metabolites. P-gp has been suggested to be involved in steroid transport in
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the adrenal gland (Thiebaut et al, 1987). In hamster, as well as mouse, the
class 2 isoform has been detected on the luminal surface of the lining
epithelium of the gravid uterus (Bradley et al, 1990; Arceci et al, 1988). It is
speculated that the expression of the class 2 isoform in uterine epithelium
during pregnancy is also associated with specific aspects of steroid
metabolism. The class 3 isoform (hamster pgp 3, human mdr 3 and mouse
mdr 2) was the predominant form found in cardiac muscle fibres and a
subset of striated muscle fibres (Bradley et al, 1990). Structural features of
this isoform imply that it is a membrane transport protein.
Sugawara et al {1988) used MRK 16 to detect P-gp in human tissues
and found strong staining in adult adrenal kidney and placental tissue. No P-
gp was found in the immature adrenal and hence the expression may be
developmental^ regulated. Sugawara et al (1989) also reported that MRK
16 reacted with cortical adenomas of human adrenals secreting
testosterone, aldosterone and corticosteroid, suggesting that these
adenomas possess P-gp. MRK 16 did not react however with
pheochromocytoma, non-functioning corticol adenoma (adrenal derived
hormones in the serum were unchanged). Therefore it was speculated that
P-pg transports hormones or hormone metabolites through plasma
membranes of adrenal corticol cells.
Expression of P-gp has been examined in numerous clinical studies
to determine whether or not it can be used as a useful marker for screening
the mdr phenotype in tumours. In a study of childhood sarcoma, Chan et al
(1989) elegantly demonstrated that the overexpression of P-gp influences
the outcome of therapy. The probability of relapse-free survival was
significantly different in patients with P-gp-positive versus negative tumours.
Schlaifer et al {1990) warned that P-gp expression by macrophages may be
responsible for overestimation of mdr content of tumour cells with Northern
blot or immunoblot techniques of fresh tissue homogenates. Since mdr 1
expression in clinically refactory tumours untreated with chemotherapeutic
drugs is difficult to detect using conventional assays, Noonan et al (1990)
devised a sensitive, specific and quantitative protocol for measuring mdr 1
mRNA in clinical samples based on the polymerase chain reaction (PCR).
Such a system requires much less tissue and ensures reliable detection of
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mdr 1 gene expression in samples from cells with a low level of drug
resistance.
AIMS
At the outset of the project only C219 and MRK 16 were widely
available as antibodies useful for the study of P-glycoprotein.
The initial aims of the project were to raise a useful polyclonal
antibody (PA) or antibodies against the sequence of human mdr 1 in order to
study the expression of the protein in cell lines and whole tissue and
examine the physiological role of mdr.
3.2 CHOICE OF PEPTIDE SEQUENCES, IMMUNISATION AND
RAISING THE ANTIBODIES
In this study, performed previous to the Marquadt et al (1990) study
using synthetic peptides to examine vincristine resistant HL/60 cells, five
different peptide sequences were chosen. The sequence of the peptides
and the regions to which these sequences correspond are given in Table
3.1. Peptides were synthesised, according to the deduced sequence of
human P-gp (Chen et al, 1986), using the Marglin and Merrifield solid state
method (Marglin and Merrifield, 1970) by Jonathan Rothbard, Imperial
Cancer Research Fund, 44 Lincoln's Inn Field, London WC 2A 3PX.
The sequence of the human mdr 1 gene product is shown in Figure
3.1. Figure 3.2 shows the location of the peptide sequences in the
postulated model of human mdr 1. Peptide 1-9 is the sequence of nine
amino acids at the N-terminus of the mdr 1 gene product, which is predicted,
from hydropathy plots, to be cytoplasmic. Peptide 73-87 is upstream from
three potential N-glycosylation sites, predicted to be in an extracytoplasmic
domain. Potential transmembrane domains were determined for P-gp using
the algorithm of Eisenberg efa/(1984) and reported by Chen et al (1986)
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FIGURE 3.1
PRIMARY STRUCTURE OF THE MDR 1 GENE PRODUCT AND
ALIGNMENT OF THE N-TERMINAL AND C-TERMINAL HALVES
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The standard single-letter amino acid code is used Colons indicate identical residues Potential N-gtycosylation sr.es (Asn-X Ser/Thr) are underlined,
the sites localized in the predicted exlracytoplasmic region (see Figure 7) are underlined twice Potential transmembrane segments (1-6 and 1a-6a).
predicted by the algorithm of Eisenberg et al. (1984). are enclosed in thin boxes Potential nucleotide-bindmg sites (N6-1 and N8-2) are enclosed
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PEPTIDES SYNTHESISED FROM HUMAN MDR 1
SEQUENCE
AMINO ACID







One such domain includes residues 52-72. From such predictions, the
peptide sequence of 73-87 should be extracytoplasmic and precede an N-
glycosylation cluster. Peptide 543-552 spans ten amino acid residues in the
predicted potential nucleotide-binding site, NB-2, as shown in Figure 3.2.
Peptide 741-751 spans a region in the first extracytoplasmic loop in the
second half of the protein. Peptide 1273-1280 represents the C-terminal end
of the protein which is predicted to be located on the cytoplasmic side.
Kartner et al (1985) have used antibodies against the C-terminal region of
hamster P-gp to show that the C-terminus is located inside the cell.
The peptides chosen were aligned with mouse and hamster
sequences to determine the extent of the homology between these and the
human sequence. This is shown in Table 3.2. The sequence of human mdr
1 was reported by Chen et at (1986). Mouse mdr 1 and mdr 3 sequences
were aligned by Devault and Gros (1990). The hamster gene family has
been partially sequenced. Endicott et al (1987) reported the partial
sequences of pgp 1 and pgp 2. Ng et al (1989) reported the partial
sequence of pgp 3.
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TABLE 3.2
HOMOLOGY BETWEEN HUMAN, MOUSE AND HAMSTER
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HUM mdr 1 RALVRNPKIL
MS mdr 1 RALVRNPKIL
MS mdr 2 RALVRNPKIL










HUM mdr 1 R I DDPETKRQN
MS mdr 1 RDDDHETKRQN 82
MS mdr 2 PGDD - AVKQQK 36
MS mdr 3 NGGPP ETQRQN 55
HAM pgp 1 RNTDDETKRHD 55
HAM pgp 2 RDDDPKTKQQN 73
PEPTIDE 1273-1280 (20/21)
HUM mdr 1 VSVQAGTKRQ
MS mdr 1 V - QAGAKRS 70
MS mdr 2 VN I QAGAKRS 50
MS mdr 3 VSVQAGTQNL 80
HAM pgp 1 VSVQAGAKR 80




Synthetic peptides containing cysteine at the amino terminus were
conjugated to thyroglobulin and also to bovine serum albumin (BSA) by
Jonathon Rothbard, Imperial Cancer Research Fund, Lincolns Inn Fields.
The thyroglobulin conjugates were used to immunise New Zealand White
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rabbits (two rabbits per conjugate). The conjugated material (200pg) was
emulsified with Freund's complete adjuvant and thereafter injected
subcutaneously (so) into the rabbits. Prior to this initial injection, pre-immune
serum was obtained from each rabbit, stored at -20°C. This pre-immune
serum was subsequently used as the negative control in ELISA assays to
measure the antibody titres of the immunised animals. After three weeks, a
second injection of conjugated material (100 pg) in incomplete adjuvant
was made. At weeks six and eight, further boosts were given and the
animals bled nine days after the last boost. Blood was removed from the
animals one week following each boost to estimate the titre of the antibody.
Antisera were tested for reactivity against synthetic peptides by using an
ELISA assay procedure, as described in Section 2.6.1. The sera from all
bleeds were collected and stored at -20°C until assayed.
3.3 MEASURING ANTIBODY TITRES USING THE ELISA
ASSAY
To estimate the titre of the antibodies and to assess the increase in
titre following each boost, ELISA assays were performed. BSA-conjugated
peptides were used in the assay and were adsorbed onto the microtitre
plates overnight. Wells in the plate were also coated with the pre-immunune
serum as a negative control. By screening with the BSA- conjugate it was
intended that the assay would measure the antibodies raised against the
peptide sequences only. Table 3.3 shows the results obtained following
each boost and the final titre of the antibody for each peptide and each
rabbit immunised. The final antibody titres ranged from 1:6,400 to 1:102,400.
Such titres were considered sufficient for using these antibodies to
immunoblot for P-gp in mdr cell lines.
3.4 IMMUNOBLOTTING USING THE C219 MONOCLONAL
ANTIBODY
In order to assess whether the peptide antibodies raised against P-gp
were valuble for use in immunoblotting, techniques for immunoblotting P-gp
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in mdr cell lines and tissues were developed using the commercially
available monoclonal antibody C219. The immunoblotting procedures for P-




PEPTIDE RABBIT 1ST 2ND 3RD 4TH
(FINAL)
1-9 18 1:3,200 1:6,400 1:25,600 1:25,600
19 1:3,200 1:12,800 1:12,800 1:12,800
73-87 59 1:3,200 1:6,400 1:6,400 1:6,400
60 1:6,400 1:6,400 1:12,800 1:25,600
543-552 61 1:12,800 1:12,800 1:25,600 1:51,200
62 1:12,800 1:51,200 1:51,200 1:51,200
741-751 16 1:12,800 1:25,600 1:25,600 1:102,400
17 1:3,22 1:12,800 1:12,800 1:12,800
1273-1280 20 ND 1:51,200 1:51,200 1:102,400
21 ND 1:51,200 1:51,200 1:102,400
ND not determined
Several cell lines were immunoblotted for P-gp using the Laemmli
system without heating. Two of these cell lines were of human and two were
of hamster origin. Wild type (sensitive) and derived (resistant) lines were
matched. In the case of Messa, Dx-5, CHO-K1 and CHO-AdrR, a whole cell
sonicate was electrophoresed and for the other cell lines a 100,000g fraction
was examined. All mdr cell lines, except CHRC5, were grown continuously
in the presence of the drug to which they were originally selected. The
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immunoblot of the various cell lines probed with C219 is shown in Figure
3.3. To compare the levels of P-gp detected in the sensitive cell line Aux B1
and it's drug resistant counterpart CHRC5, the exposure time of the
immunoblot was 30 days following Protein A-l125 labelling. SKVLB
(human), CHRC5 (hamster) and CHO-AdR (hamster) cell lines demonstrated
immunoreactivity with C219. Both fractions from the CHRC5 cell line cross-
reacted strongly with C219 to give a band of 155 kD. This same protein was
detected in both fractions of AuxB1 but at a greatly reduced level. This cell
line pair has been widely used in the literature as a control for P-gp
expression. Riordan and Ling (1979) reported the purification of P-gp from
the colchicine resistant Chinese hamster ovary cell line, CHRC5.The drug
sensitive SKOV3 human cell line also displayed negligible levels of P-gp in
the 100,000g fraction. SKVLB resistant cells show a greatly increased level
of a 150 kD protein in the 100,000g fraction. CHO-K1 cells displayed a low
level of the 155 kD P-gp and the CHO-AdrR cells showed a smeared lower
band of -150 - 155 kD. Both the 150 kD and the 155 kD proteins represent
P-gp in different glycosylation states. In the case of SKVLB, P-gp has lost ~5
kD of carbohydrate residues. Greenberger et al (1988) reported the effect of
heating P-gp samples; in CHRC5 cells, P-gp shifted from 155 kD to a broad
smeared band of -170 kD. He proposed that since both the Fairbank's
system (SDS + urea) and the Laemmli system (SDS + boiling) should
completely denature P-gp, in the absence of heat or urea the protein is
probably incompletely unfolded and therefore migrates aberrantly.
Dox-5 failed to show P-gp protein expression using this system.
However, the cell line was shown to be resistant to adriamycin, as shown in
Chapter 4. The lack of a detectable protein using this immunoblotting
technique is therefore probably due to the low level of P-gp expression in
the mdr Dx-5 cell line.
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FIGURE 3.3
EXPRESSION OF P-GP IN CELL LINES IMMUNOBLOTTED WITH
C21 9















































To assess the usefulness of the blotting technique on whole tissues,
microsomes from mouse, human and Wistar rat liver were prepared and
immunoblotted using the modified Fairbank's urea gel system.
Using the urea gel system, C219 was also shown to cross-react with
normal mouse and rat liver. The MW of the P-gp detected in these tissues
was smaller than the one detected in the CHRC5 cell line. The results are
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shown in Figure 3.4. Silverman efa/(1991) reported the sequencing of the
first rat mdr gene. A full length rat cDNA clone was identified and the
predicted protein was 1276 amino acids with a calculated Mr of 141 kD. The
sequence was found to have high homology to mouse mdr 1. Mouse liver
also contained a protein at -60 kD that cross-reacted strongly with the C219
monoclonal antibody. This protein must contain the epitope VQAALD
recognised by the C219 monoclonal antibody. Human liver showed very
weak expression of P-gp although Fojo et al {1987) indicated that normal
human liver contained substantial expression of P-gp. The low P-gp level
may be due to sample degradation or variations in the expression of P-gp in
different human liver samples.
Rat liver treated with dexamethasone, araclor, 2-acetylaminoflourene
and untreated control were electrophoresed along with CHRC5 and AuxB1
to determine whether these treatments induced P-gp expression. Figure 3.5
shows the results and illustrates the effects of a range of xenobiotic
treatments on rat P-gp expression. The treated rat liver showed increased
levels of P-gp compared to control.
Having established the usefulness of the C219 monoclonal antibody
in immunoblotting both cell lines and whole tissues, the reactivity of the
polyclonal antibodies raised against peptide sequences of human mdr 1
was assessed.
3.5 IMMUNOBLOTTING USING PEPTIDE ANTIBODIES
All the antibodies were assessed by immunoblotting. Both the
Laemmli and urea gel system were employed. Antibodies were diluted from
1:50 to 1:1000 and C219 was used as the positive control antibody against
the CHRC5 mdr cell line. From such immunoblotting studies, polyclonal
antibody (PA) 21 and PA61 were considered to be useful. Polyclonal
antibodies 21 and 61 had titres of 1:100,000 and 1:51,200 respectively. PA61
had 100% and 80% homology with mouse and hamster sequences
respectively over the peptide region to which it was raised. PA21 had 70%,
50% and 80% homology with the mouse mdr 1, mdr 2 and mdr 3 primary
amino acid sequences over the region to which it was raised. It also had
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FIGURE 3.4
EXPRESSION OF P-GP IN MOUSE, RAT AND HUMAN LIVER
Male C57BI/6 mice, Wistar rat and human liver were prepared, as described in Section 2.5.3,
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EXPRESSION OF P-GP IN DEXAMETHASONE, ARACLOR AND
2-ACETYLAMINOFLUORENE-TREATED RATS
Wistar rats were treated with dexamethasone (100 mg/kg, 3 dy), Araclor (500 mg/kg, 1 dy) and
2-acetylaminofluorene (50 mg/kg, 4 dy). Control animals were treated with phosphate
buffered saline.
Livers were removed following treatment, snap frozen and solubilised protein prepared from
them, as described in Section 2.5.3 (Fairbank's method). 100 pg of each liver sample was






This represents the results of one experiment. Tissue was pooled from 4 rats in each
treatment group.
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80% and 60% homology to hamster pgp 1 and pgp 2 respectively over this
region.
3.5.1 IMMUNOBLOTTING USING POLYCLONAL ANTIBODY 21
PA21 was raised against a ten amino acid peptide sequence which is
highly conserved between human, mouse and hamster. The sequence is
found at the C-terminal of all P-gp proteins thus far described. This region in
the protein is cytoplasmic according to hydropathy plots (Chen et al, 1986)
since it is near a long, relatively hydrophobic region.
Immunoblots were run using this antibody against cell lines and
bovine adrenal microsomes. Figure 3.6 shows two immunoblots from an
SDS PAGE gel that was run with two sets of identical samples and then cut
in half. The samples were microsomal cell preparations from Messa, Dox-5,
CHO-K1 and CHO-AdrR and adrenal microsomes from whole tissue,
medulla and cortex.
The immunoblots were blotted with the C219 monoclonal antibody
and PA21. The serum from the final bleed-out was used for immunoblotting
to ensure a high titre. The antibody was used at a dilution of 1:100. A
separate gel was run on the identical samples and blotted with the pre-
immune serum from rabbit 21. C219 recognised P-gp in the hamster cell line
CHO-AdR more strongly than the low level of expression in CHO-K1. It also
detected P-gp expression in all three adrenal microsome fractions. No
obvious difference was apparent between the expression of P-gp in the
cortex or medulla. The size of the P-gp detected using this electrophoresis
and blotting system was 150 kD. A lower smeared band of 130-140 kD was
also detected in the adrenal microsomes and CHOAdR cell line. No P-gp
was detected in the cytosolic fractions of the adrenal cortex or medulla as
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FIGURE 3.6
IMMUNOBLOTTING CELL LINES AND ADRENAL MICROSOMES
USING POLYCLONAL ANTISERUM 21 AND C219
Cell lines and adrenal fractions were prepared, as described in Section 2.5.3, and Western
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expected. PA21 also recognised a protein of 150 kD in the adrenal
microsomes but no such protein was detected as being present in the
cytosolic fractions. CHO-AdrR cells showed a slightly higher level of
expression of the protein than CHO-K1. Although both sets of samples had
been treated identically, PA21 did not detect the lower smeared protein of
between 130-140 kD. The antibody did however detect a protein of 110 kD
represented at equivalent levels in both Messa and Dox-5 cell lines.
The autoradiograph of the immunoblot with the C219 monoclonal
antibody required an exposure time of eleven days whereas the polyclonal
antibody autoradiograph required only a 16 h exposure to achieve a
reasonable level of detection. The consistent failure of antibodies raised
against P-gp to detect P-gp expression in the mdr Dox-5 cell line suggests
that very low levels of expression were present in the cell line.
The difference in the sensitivity of PA21 and C219 may be explained
in two ways. Firstly, the difference may be due to one antibody being
monoclonal and the other being polyclonal. Monoclonal antibodies
recognise only one epitope in constrast to polyclonals which normally
recognise several different epitopes represented in the protein sequence.
Monoclonal antibody C219 recognises a six amino acid sequence which
occurs both in the N-terminal and C-terminal half of the protein as shown in
Figure 3.2. PA21 recognises a ten amino acid sequence which only occurs
at the C-terminal end of the protein. From these facts it would be difficult to
explain the difference in sensitivity of C219 and PA21 in terms of the number
of epitopes recognised. A second explanation involves the antigenicity of
the epitope and the ease with which it is recognised by the antibody. Since
the C-terminal region is not masked by sugar residues, which may be true
for external epitopes, the epitope site is exposed and easily recognised by
an antibody raised against it.
The protein of 110 kD recognised by PA21 in the human cell line is
unlikely to be involved in mdr since it is expressed to equivalent levels in
both cell lines. The epitope recognised by PA21 must be present in these
human cell lines.
Figure 3.6 also shows the same samples blotted with pre-immune
serum from rabbit 21. The immunoblot with this serum was exposed for nine
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days. A faint band of 165 kD was detected in all the samples except the
Messa sensitive cell line. Such a protein size or pattern of expression is not
represented in the PA21 immunoblot. Therefore the protein recognised by
PA21 is not recognised by the antibodies normally present in the rabbit
before immunisation.
Using the Laemmli system, PA21 was found to cross-react well with
bovine adrenal microsomes but failed to detect P-gp expression in normal
rat liver or kidney even when 100pg of protein was immunoblotted as seen
in Figure 3.7.
FIGURE 3.7
DETECTION OF P-GP IN BOVINE ADRENAL, RAT LIVER AND
KIDNEY USING POLYCLONAL ANTIBODY 21
Bovine adrenal, rat liver and kidney solubilised protein was prepared, as described in Section
2.5.3, and Western blotted (100 pg, 50 pg and 20 pg of each) using the polyclonal antibody
21.
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The detection of a protein in tissue fractions compared to ceil fractions is
always more difficult since the number of different cell types represented in
the tissue microsomal fraction is much greater. Immunohistochemical
methods are therefore usually employed to circumvent this problem.
A high level of P-gp was detected in bovine adrenal microsomes on
loading between 100-20 pg of protein. The strong detection of P-gp in this
tissue indicates very high levels of expression compared to other tissues.
Such a finding is in agreement with Croop et al (1989) who reported very
high levels of expression of the mdr 1 gene in mouse adrenal. The level of
expression was 20 to 40 fold the level in the non mdr cell line NIH 3T3.
Georges et al {1990) reported that pgp 2 is predominantly expressed in the
hamster adrenal gland. This expression may be involved in the transport of
corticosteroids. The elevated levels of expression detected by PA21 in the
bovine adrenal is therefore not surprising. The specificity of the polyclonal
antibody for the protein recognised in bovine adrenal microsomes was
tested for.
Figure 3.8 shows the results of an experiment in which 50 pg and
20pg of bovine microsomal protein were run side by side and
immunoblotted using PA21 at 1:500 dilution. The lower half of the figure
shows an immunoblot with the same samples using PA21 at 1:500 dilution
preincubated with an excess of BSA-conjugated peptide, to which peptide
the antibody was raised. The incubation was at 37°C for 1 h with gentle
agitation. The antibody solution was then spun down and the serum used as
the 'competed-out antibody'. Peptide competition from the conjugate
resulted in an antibody that recognised the protein in bovine adrenal
microsomes at much reduced levels. This demonstrates the specificity of the
peptide sequence in the antibody for the protein detected by PA21 in
adrenal microsomes. Even at dilutions of 1:1000 and a protein loading of
20pg, PA21 still strongly detected P-gp.
3.5.2 IMMUNOBLOTTING USING POLYCLONAL ANTIBODY 61
PA61 was raised against amino acid residues 543-552 which are
situated near the ATP-binding site in the N-terminal half of the protein. This
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FIGURE 3.8
SPECIFICITY OF P-GP DETECTION IN BOVINE ADRENAL
TISSUE BY POLYCLONAL ANTIBODY 21
Adrenal fractions (100 p.g and 50 jag of protein) were Western blotted using polyclonal
antibody 21 and the 'competed out' polyclonal antibody 21, as described in Section 3.5.1. 1











region is highly conserved and located in the cytoplasm. The highest level
of homology is observed in the nucleotide binding regions (Chen et at,
1986) with each region corresponding to two parts of the nucleotide-binding
fold (Walker et al, 1982). These folds have been detected previously in
bacterial transport proteins (Higgins et al, 1982).
PA61 recognised a protein in the CHRC5 cell line which was present
at much lower levels in the Aux B1 drug sensitive parental line. This protein
was exactly equivalent in size to P-gp, as shown in Figure 3.9. This figure
shows the results of immunoblotting these cell lines with PA61 at a dilution of
1:2000 and 1:10,000. C219 recognises P-gp in the CHRC5 cell line at a
dilution of 1:1000. The additional proteins recognised by PA61 are non¬
specific and are detected at equivalent levels in both the resistant and
sensitive cells.
To assess whether or not PA61 recognises P-gp in other mdr cell
lines, membrane preparations from CHO-AdrR, CHO-K1,SKVLB and SKOV
were also prepared and immunoblotted. To determine the detectability of P-
gp in mouse and rat liver, membrane fractions from these rodent tissues
were extracted and immunoblotted alongside the cell lines. Figure 3.10
shows the immunoblot results obtained after probing the above samples
with PA 61 and C219. P-gp (155kD) is detected most strongly in the CHRC5
cell line. The level of expression in AuxB1 is very low in comparison. SKVLB
also had a raised level of P-gp (155kD) compared to it's sensitive parent
SKOV. The cell lines CHO-AdrRand CHO-K1 showed very little difference in
*
the expression of P-gp. Both mouse and rat liver expressed P-gp of a lower
molecular weight of 150 kD. The C219 antibody detected P-gp in CHRC5
and SKVLB at the same molecular weight as PA61. A lower molecular
weight form of P-gp was also detected in rat and mouse liver. A protein of 60
kD was also strongly detected in mouse liver by C219. Since the protein
cross-reacts strongly with C219 but not PA 61, the protein must contain the




DETECTION OF P-GP IN MDR AND SENSITIVE CELLS BY C219
AND POLYCLONAL ANTIBODY 61
Cell lines were prepared, as described in Section 2.5.3, and Western blotted (100 pg each)
using polyclonal antibody 61 and the monoclonal antibody C219.
Track no. Sample






Tracks 2 /3 and 4/5 were blotted against polyclonal antibody 61 at a dilution of 1:2000 and
1:10,00 respectively.





These results are representative of several experiments in which repeated cell line
preparations were made and different antibody dilutions were used.
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FIGURE 3.10
DETECTION OF P-GP IN CELL LINES AND RODENT TISSUES
USING C219 AND POLYCLONAL ANTIBODY 61
Cell lines, rat and mouse liver solubilised protein was prepared, as described in Section 2.5.3,
and Western blotted (100 pg each) using the polyclonal antibody 61 and the monoclonal
antibody C219.
STD standard
mouse con mouse control (untreated)
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3.6 IMMUNOHISTOCHEMISTRY USING THE PEPTIDE
ANTIBODIES
For testing the usefulness of the peptide antibodies the cell line
CHRC5 and it's sensitive parental cell line AuxB1 were used. P-gp in the
CHRC5 cell line was shown to be recognised by PA61 following
immunoblotting. All the peptide antibodies were tested including those that
did not detect P-gp in the immunoblotting procedure. With
immunohistochemistry the epitope recognised by the antibody is in a
conformation which is normally adopts whereas the epitope is linearised to a
great extent following immunoblotting. Epitope presentation can alter the
extent to which the antibody recognises the antigen.
Cells were prepared from both cultured cell lines and spun onto
glass slides to achieve an equal proportion of cells on each slide (50,000).
The cells were fixed in acetone for four minutes and stored at -20°C until
required. The cells were quickly thawed in acetone for one minute when
immunohistochemistry was performed on them. The cells were washed
twice in TBS for five minutes and incubated in normal rabbit serum (1:5) for
ten minutes. The cells were then incubated in a 1:50 dilution of each
polyclonal peptide antibody for 30 minutes at room temperature. Following
this step the cells were washed in TBS and treated as outlined in Section
2.3.3 with biotinylated swine anti-rabbit second antibody. The rest of the
procedure is also shown in this section.
3.6.1 RESULTS OF PEPTIDE IMMUNOHISTOCHEMISTRY
Table 3.4 shows the results of the immunohistochemisty on the
CHrC5 and AuxB1 cells.
None of the peptide antibodies stained CHRC5 more strongly than
AuxB1. Both nuclear and cytoplasmic staining was evident. PA21 and PA61
did not specifically recognise P-gp in the plasma membrane of the CHRC5
cells but cross-reacted with other proteins present.
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TABLE 3.4
PEPTIDE ANTIBODY IMMUNOHISTOCHEMISTRY RESULTS ON
C HRC5 AND AUXB1 CELLS
ANTIBODY AUX C HrC 5 COMMENTS
16 + + staining is cytoplasmic
17 ++ +
18 +++
19 ++ + nuclear staining in
AuxB1
20 + + both nuclear staining
21 +/- +
59 ++ ++






Using the same method to detect P-gp in the cells with the C219 monoclonal
antibody resulted in both CH^C5 and AuxB1 being stained. The difference
in intensity between the two cell lines was not apparent. The staining was
however more plasma membrane specific.
3.7 SUMMARY OF RESULTS
Using hamster and human mdr cell lines and C219 as the positive
control antibody, the peptide antibodies PA21 and PA61 were shown to
cross-react with P-gp using the Laemmli and urea gel system for
immunoblotting. The remaining peptide antibodies did not cross-react with
P-gp following immunoblotting. Both PA21 and C219 detected P-gp in
bovine adrenal microsomes at -145 kD. PA61 and C219 detected P-gp in rat
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and mouse liver.
The ability of PA61 to recognise P-gp in the Chinese hamster mdr cell
lines and both mouse and rat liver indicates that the peptide sequence
against which the antibody was raised is highly conserved and the epitope
is available for recognition by the antibody following immunoblotting. PA21
did not detect P-gp in either rat or mouse liver and this indicates that the
homology between the peptide sequence in human, rat and mouse is not
sufficient for antibody recognition or that mdr 1 is not expressed at sufficient
levels for detection. However, the detection of P-gp in the Chinese hamster
ovary cell line CHO-AdrR infers that this may not fully explain the lack of
detection since the hamster sequences have a similar level of homology to
human mdr 1 as the mouse sequences. The difference in expression of P-gp
between CHRC5 and AuxB1 is considerable. However, using
immunohistochemistry no difference could be detected between these cell
lines. Unlike C219 however, the polyclonal antibodies also cross-reacted
with other proteins in the cell lines and whole tissue to varying extents. Such
cross-reactivity would have to be eliminated by increasing the dilution of the
antibody or pre-adsorbing it with pre-immune serum.
The specificty of C219 was considered to be much greater than either
of the polyclonal antibodies raised. Polyclonal 61 has 100% homology with
the mouse mdr 1, 2 and 3 gene sequences and therefore would not
distinguish between them. Antibodies to detect specific mdr 1, 2 or 3 gene
products will enable examination of their location and function. Since the
antibodies raised were not specific enough to dfferentiate individual mdr 1,
mdr 1, 2 and 3 gene products, it was decided to use Northern blotting to
examine the levels of expression of each isoform in various models. Chapter
5 describes the use of such gene specific probes.
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CHAPTER 4
P-GLYCOPROTEIN - AN EFFLUX PUMP FOR
CARCINOGENS?
4.1 INTRODUCTION
The physiological function of P-gp in normal tissues is unknown
although it's role as an efflux pump has been widely studied. Early work
demonstrated that mdr cells were associated with a decrease in intracellular
cytotoxic drug accumulation when compared to sensitive cells (Riehm and
Biedler, 1971; Ling and Thompson, 1974). Such decreased accumulation
has been generally ascribed to enhanced outward, rather than diminished
inward, transport (Inaba et at, 1979). A number of investigators have found
an energy-dependent mechanism responsible for the outward transport of
all drugs to which cells display resistance. Depletion of ATP by removal of
glucose or addition of metabolic inhibitors results in a reversal of the
accumulation defect, whereas replacing glucose restores mdr (Dano, 1973).
A number of radiolabeled drugs and photoactivatable drug analogs bind in
a specific, saturable and energy-dependent manner to mdr plasma
membranes but not to sensitive cell membranes (Cornwell et al, 1986a).
Purified P-gp has been shown to posses ATPase activity (Hamada and
Tsuruo, 1988). The deduced amino acid sequence of P-gp reveals that it
bears striking homology to the ATP-binding domains of periplasmic transport
proteins of bacteria such as the hyl B oc-hemolysin export pump (Higgins et
al, 1982) as well as the yeast Saccharomyces cerevisiae STE6 gene
product which exports hydophobic lipopeptide pheremones (McGrath and
Varshowsky, 1989). Unlike well-defined carrier molecules such as the Ca2+
Mg2+ ATPase or Na+K+ exchange pump, P-gp is less selective with regard
to substrate.
Most experimentally induced mdr cell lines have been selected for at
least 100-fold drug-resistance, although it has been argued that clinically
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relevant drug resistance is in the order of two to ten fold (Yang, 1989). To
understand the clinical importance of mdr, the normal levels of P-gp in a
variety of human tissues have been studied.
Immunoblots have demonstrated the presence of P-gp in liver
(Hitchins et al, 1987) and it has been localised to the apical biliary surface of
hepatocytes (Thiebaut et al, 1987). The polarised expression of P-gp
suggests a secretory role for the membrane glycoprotein. Endothelial cells of
human capillary blood vessels also express P-gp, but cells from larger blood
vessels and other tissue capillaries do not. This suggests that P-gp may
exclude toxic compounds from the central nervous system and other sites
(Cordon-Cardo et al, 1989; Thiebaut et al, 1989). P-gp almost certainly has a
normal physiological function in human tissues related to secretion and
protection of tissues from various naturally occurring toxins or commonly
encountered xenobiotics.
The first report of pharmacological reversal of mdr came form Tsuruo
et al (1981). He showed that verapamil, a calcium channel blocker, and the
calmodulin (CaM) antagonist, trifluoperazine, potentiated the
antiproliferative effect of vincristine in vivo and in vitro. Investigators have
determined the magnitude of the effect of chemosensitisers by comparing
IC50 (the concentration of a compound which causes 50% reduction in
viable cells) values for a cytotoxic drug in the absence and presence of a
relatively non-toxic fixed concentration of reversing agent. A large amount of
interest has been focused on devising clinical protocols incorporating
chemosensitisers to circumvent resistance in humans (Skovsgaard et al,
1984;Ozols et al, 1987; Miller et al, 1988; Dalton etal, 1989; Gottesman and
Pastan, 1989). The chemosensitisers can be grouped into various broad
categories.
Calcium channel blockers, such as verapamil, have been studied for
their effects on reversing mdr.Tsuruo etal (1981) showed that 2.2 - 6.6 pM
verapamil reversed the -30 fold resistance to vincristine and seven fold
resistance to vinblastine displayed by P388/VCR, a mdr murine leukemia
cell line. Verapamil did not alter vincristine binding to tubulin, the cytotoxic
target of vinca alkaloids (Owellen et al, 1974) but altered drug accumulation
(Tsuruo et al, 1981). In certain studies, verapamil was found to be more
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effective in reversing resistance to the selecting agents than the cross-
resistant drugs (Beck et al, 1986; Ford et al, 1990). Bellamy et al (1988) used
DNA alkaline elution to determine the number of DNA strand breaks in
sensitive and resistant cell lines alter exposure to doxorubicin. He found a
decrease in the number of lesions in mdr cells which was elevated in the
presence of verapamil. Since anthracycline cytotoxity is through
topoisomerase ll-mediated DNA strand breaks (Ross et al, 1978) verapamil
is believed to inhibit P-gp transport of doxorubicin, leading to increased
intracellular doxorubicin concentrations and increased cellular toxicity. From
studies using photoactivated verapamil analogues, it has been shown that
verapamil inhibits the binding of many chemotherapeutic drugs and other
chemosensitisers to P-gp (Safa et al, 1987). Although verapamil is an
effective P-gp antagonist, it has toxic cardiovascular effects in humans at
concentrations needed for such antagonism (Candell et al, 1979). Other less
toxic compounds have therefore been examined. Structurally dissimilar
calcium channel blockers, such as nicardipine, have been shown to be
potent antagonists of mdr (Tsuruo et al, 1983).
Another group of anti-mdr agents are drugs which inhibit calmodulin-
mediated processes. Tsuruo et al (1982) studied several drugs known to
alter calcium homeostasis.Trifluoperazine, for example, was found to cause
a 5-10 fold increase in vincristine and doxorubicin sensitivity in 20-40 fold
resistant P388/VCR and P388/Adr cells respectively. Several studies have
shown that CaM antagoists such as trifluoperazine modulate cell sensitivity
to bleomycin through increased DNA damage and inhibition of repair
(Chafouleas et al, 1984; Lazo et al, 1985). Skovsgaard (1980) tested the
hypothesis that the drug transport pump would be competitively inhibited by
an excess of a non-toxic analog of a chemotherapeutic drug. He examined
the anthracycline analog N-acetyl-daunorubicin which lacks the ability to
intercalate with DNA, is less cytotoxic than daunorubicin and can achieve
higher cytoplasmic concentrations (Zunino et al, 1972). The compound was
found to inhibit active daunomycin transport from mdr but not sensitive cells.
Steroids and hormonal analogues have also been examined for their
effects on mdr reversal. Yang et al (1989) found that progesterone and
deoxycorticosterone caused an increase in vinblastine accumulation and
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some reversal of vinblastine resistance in mdr murine macrophages.
Progesterone was the most potent steroid for inhibiting labelling of
endometrial P-gp, suggesting that it may be a natural substrate for P-gp. The
anti-oestrogens, for example tamoxifen, can partially overcome resistance in
P388/Dox cells independent of their effect on oestrogen receptors (Foster et
al, 1988).
Many compounds which circumvent mdr fall into a large group of
compounds which share a broad structural similarity. They are amphipathic
and lipophilic and have a heterocyclic ring separated from a cationic, amino
group. These include quinidine (Tsuruo et al, 1984), the antibiotic
erythromycin (Hofsli and Nissen-Meyer, 1989) and the anti-malarial
quinacrine (Inaba and Maruyama, 1988).
Cyclosporins, as well as being immunosuppressants, have
sensitising activity in mdr cells (Twentyman, 1988). However, cyclosporin A
(CsA) has been shown to potentiate drug action in vitro and in vivo in both
tumour and normal cells (Twentyman, 1988).
Cationic, amphipathic drugs, including most chemosensitisers,
interact with polar lipids such as phosphatidylserine in the plasma
membrane (Lullmann and Wehling, 1979). It has been suggested that
membrane differences may alter drug accumulation in mdr cell lines.
Chemosensitisers may perturb the mdr cell membrane fluidity and change
cellular accumulation. Investigators have found increased membrane fluidity
in mdr cells (Bhushan et al, 1989; Ramu et al, 1983). Evidence indicates that
altered calcium physiology is not involved in mdr. Lee et al (1988)
demonstrated that both drug sensitive and mdr cells lack voltage-gated
calcium channels, unlike excitable tissues. Treatment of mdr cells to reduce
or increase calcium levels had no influence on doxorubicin accumulation or
cytotoxicity in mdr cells (Huet and Robert, 1988). The role of CaM in mdr is
unknown. CaM regulates a variey of critical cellular functions including
activation of plasma membrane calcium ATPase to stimulate protein kinases
and phosphatases (Schulman and Greengard, 1978). Whether CaM-
mediated phosphorylation may activate or regulate P-gp function in mdr is
not known. Some evidence exists for the regulatory role of the calcium-
dependent protein kinase C (PKC) in mdr. PKC has been found to enhance
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cellular secretion in many tissues (Katakami et al, 1984). Weiss et al (1982)
found that anthracyclines inhibit PKC and Fine et al (1988) showed that PKC
activity was increased in MCF-7 mdr cells. Treatment of sensitive human KB
cells with a phorbol ester activator of PKC caused a two-fold protection
against the cytotoxity of VP16, vincristine and mitoxantrone which could not
be reversed with verapamil (Ferguson and Cheng, 1987). Flowever, results
of additional studies have been conflicting. Hait and DeRosa (1990) were
unable to show significant changes in doxorubicin accumulation in HL-60
cells with low, normal or overexpressed activity of PKC. Specific inhibitors of
PKC and cell lines resistant to these inhibitors will allow the hypothesis to be
more rigourously tested.
Phorbol esters have been reported to increase P-gp phosphorylation
(Flamada et al, 1987) which indicates that PKC may modulate the function of
P-gp. However, insufficient data is available at present to draw any firm
conclusions regarding the regulatory or modulatory role of PKC in P-gp
associated mdr. The strongest body of evidence available is that body which
suggests that chemosensitisers directly affect the function of P-gp. Cornwell
et al (1986b) reported the irreversible binding of the photoactive analogs of
vinblastine ([2H] NABV and [l12^] NASV) to mdr membranes. P-gp was
specifically photoaffinity labelled in mdr cell lines. Verapamil has been found
to inhibit [l12^] NASV labelling of P-gp from KB-V1 cells (Cornwell et al,
1987). Chemosensitisers may compete for a common drug-binding site, for
overlapping sites or for sites that cause allosteric changes which prevent the
binding of other drugs. They may also inhibit P-gp by interacting with sites
such as the ATPase or phosphorylation domains or act by altering the
membrane environment to cause functional changes in P-gp.
AIMS
The aim of this chapter was to determine whether P-gp functions as
an efflux pump for xenobiotic substances and in particular carcinogens. It
was proposed that P-gp may function as such in normal tissues. To test this
hypothesis, the mdr cell line CH^C5 and it's drug sensitive counterpart
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AuxB1 were used, which provided a model for P-gp expression and non-
expression, respectively. The MTT assay system was employed to determine
the extent to which carcinogens can reverse the mdr phenotype in CHRC5
cells when used at non-toxic levels. Inhibition of drug binding to the CHRC5
cells was measured to determine whether carcinogens act as substrates for
the P-gp transport pump or whether these compounds must first be
metabolised by the P450 drug metabolising system.
4.2 RESISTANCE PROFILES OF MULTIDRUG RESISTANT
CELLS USING THE MTT ASSAY
Carmichael et al (1987a) reported the use of the MTT assay in
screening cell lines for drug sensitivity. Good correlation was observed using
the CHO-AuxB1 cell line and the pleiotropic drug-resistant mutant CHRC5
with similar degrees of relative resistance observed with both the MTT and
clonogenic assays.
The MTT assay is dependent on the cellular reduction of 3,(4,5-
dimethylthiazol-2-yl-2,5-diphenyl) tetrazolium bromide (MTT) by the
mitochondrial dehydrogenase of viable cells to a blue formazan product
which can be determined spectrophotometrically (Mosmann, 1985). The
procedure for the assay is described in Section 2.12.1.
(a) DETERMINING THE RELATIONSHIP BETWEEN CELL NUMBER
AND MTT FORMAZAN CRYSTAL FORMATION (I.E. ABSORBANCE)
In order to determine the relationship between cell number and
absorbance, increasing numbers of both CHRC5 and AuxB1 cells, ranging
from 100 to 200,000 cells per well, were plated. MTT was added after four
days and the plates incubated for a further four hours. A time period of four
days was chosen since this incubation time allowed sufficient time for cell
death to occur, but was short enough to obviate the need to re-feed the cells.
The growth curves for both the AuxB1 and CHRC5 cell lines are shown in
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FIGURE 4.1
GROWTH CURVE OF AUXB1 AND CHRC5 CELLS




Plates were set up with 100-200,000 AuxB or CHRC5 cells per well (6 wells per cell density) in
a volume of 200 pi. The cells were grown for a total time of 5 days followed by the addition of
MTT (50 pi of 2 mg/ml) and incubated for 4 hours until the crystals formed, the colour
developed and plates read.
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Figure 4.1. The relationship between cell number and absorbance was
found to be linear between 100 to 5000 cells per well for CHRC5. However,
at a seeding density of 5000 cells per well, the AuxB1 cells had reached
confluency before the end of the assay period and the absorbance had
almost reached a plateau. The absorbance values for CHRC5 are lower
than AuxB1 for each time point, which is a reflection of the difference in
doubling time for each cell line; reported to be 13-15h for AuxB1 and 22h for
CHrC5 (Carmichael et al, 1987). In order to ensure that both cell lines were
growing exponentially after 5 days in culture, all subsequent experiments
employed a seeding density of 2500 cells per well for both CHRC5 and
AuxB1.
(b) ASSESSMENT OF DRUG RESISTANCE IN THE CHRC5 CELL LINE
COMPARED TO THE DRUG SENSITIVE AUXB1 CELL LINE
Chemosensitivity was assessed by continuous exposure of the cell
lines to colchicine and doxorubicin. CHRC5 was made resistant to
colchicine and has been shown to exhibit a cross-resistance pattern to
several other drugs including adriamycin (Ling et al, 1983).
Equal numbers of AuxB1 and CHRC5 cells (2500 cells per well) were
plated into each well in 180pl of culture medium to which 20jil of 10 x
concentrated drug or serum free medium was added 24h later. Following
incubation for 4 days, MTT solution (50)il of 2mg/ml) was added to each well
and incubation continued for a further four hours. Following this incubation,
DMSO (50pl) was added to each well to dissolve the formazan crystals
which had formed. Absorbance values were read at 540nm. The results
obtained with the two cell lines following colchicine and doxorubicin
exposure are shown in Figures 4.2 and 4.3 and summarised in Table 4.1.
These results show that CHRC5 is more resistant to colchicine and
doxorubicin than the wild type AuxB1 sensitive cell line as expected.
Colchicine is a drug which causes cytostatic effects on the cell lines which
accounts for the lack of cell kill at high concentrations in both cell lines.
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FIGURE 4.2
TOXICITY OF COLCHICINE TOWARDS CHRC5 AND AUXB1
CELLS
(a) Toxicity towards AuxB1 cells
[colchicine] M
(b) Toxicity towards CHRC5 cells
[colchicine] M
Plates were set up with 2500 CH^CS or AuxB1 cells per well in a volume of 180 pi. The cells
were allowed to adhere overnight and then 20 pi of 10 x stock colchicine in serum-free
medium was added to give final concentrations in the range 0-100 pM. The plates were then
incubated for 4 more days followed by the addition of MTT (50 pi of 2 mg/ml) and colour
developed as described previously.




TOXICITY OF DOXORUBICIN TOWARDS CHRC5 AND AUXB1
CELLS
(a) Toxicity towards AuxB1 ceils
Each individual point represents the mean of 3 experiments (6 wells were read in each
experiment).
(b) Toxicity towards CHRC5 cells
Plates were set up with 2500 AuxB1 or CHRC5 cells per well in a volume of 180 pi. The cells
were allowed to adhere overnight and then 20 pi of 10 x stock of doxorubicin in serum-free
medium was added to give final concentrations in the range 0-50 pM. The plates were then
incubated for 4 days followed by the addition of MTT (50 pi of 2 mg/ml) and colour developed
as described previously.
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doxorubicin, rapid changes in cell viability were With doxorubicin, rapid
changes in cell viability were observed even at high concentrations of the
compound.
These results established that the cell lines demonstrated differential
sensitivity to chemotherapeutic compounds and are suitable for use in the
MTT assay.
TABLE 4.1
TOXICITY OF DOXORUBICIN AND COLCHICINE TOWARDS
C HRC5 AND AUXB1 CELLS
IC50
DRUG CHRC5 AUXB1 FOLD RESISTANCE
Doxorubicin 2 pM 0.015 (iM 133
Colchicine 15 pM 0.8 pM 21
4.3 REVERSAL OF RESISTANCE WITH VERAPAMIL
As discussed in the introduction to this chapter, verapamil can reverse
the mdr phenotype in various cell lines. Eliason et al (1990) used the MTT
assay to quantitate the modification by verapamil on P-gp in the mdr cell line
KB5-5 and the parental line KB-3-1. Since l-(-)-verapamil was shown to be
approximately four times more active the d-(+)-verapamil in modifying mdr
(Eliason et al, 1990), l-(-)-verapamil was used in this study.
In order to assess the cytotoxity of verapamil itself, several
concentrations of the compound, ranging from 60 to 0.6pM, were tested on
both resistant and sensitive cell lines. Both cell lines gave the same results.
No difference in sensitivity to verapamil was observed throughout the range
of verapamil concentrations used. The experiment was repeated, but
incorporating 10"^M colchicine. CHRC5 cells were normally resistant to
such a concentration of colchicine (Figure 4.2). The result is depicted in
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FIGURE 4.4
REVERSAL OF RESISTANCE TO COLCHICINE IN CHRC5 CELLS
BY VERAPAMIL
Each individual point represents the mean of 3 experiments (6 wells were read in each
experiment).
[VERAPAMIL] pM
Plates were set up with 2500 CHRC5 cells per well in a volume of 160 pi. The cells were
allowed to adhere overnight and then 20 pi of 10 x stock colchicine in serum-free medium was
added to give a final, non-toxic concentration of 0.1 pM. Verapamil (20 pi of 10 x) was also
added to give final concentrations in the range 0-60 pM. The plates were then incubated for a
further 4 days followed by the addition of MTT (50 pi of 2 mg/ml) and colour developed as
described previously.
Figure 4.4. It was shown using this experiment that the calcium channel
blocker verapamil can reverse the mdr phenotype in CHRC5 cells, which are
normally resistant to colchicine. Since reversal was demonstrated using
verapamil, a similar experiment was used with carcinogens to assess their
ability to reverse the mdr phenotype and act as substrates for P-gp.
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4.4 CYTOTOXICITY OF CARCINOGENS ON DRUG RESISTANT
C HrC5 AND DRUG SENSITIVE AUXB1 CELLS
In order to ensure that the four carcinogens used in this study were
not cytotoxic over the range of concentrations chosen for assessing their
potential to compete for P-gp, the MTT assay was used to test their
cytotoxicity. In each case, the control used was the solvent treatment alone
i.e. serum free medium (20 pi) or DMSO (20 pi). Since DMSO was used as
the solvent for some of the compounds, it was assessed for cytotoxicity
towards CHRC5 and AuxB1 cells in order to ensure that it did not interfere
with the assay in any way. The toxicity of DMSO towards CHRC5 and
AuxB1 cells is shown in Figure 4.5. 0.25% DMSO was considered to be non¬
toxic to either cell line being used and this value was considered to be
highest concentration of DMSO to which the cells could be exposed without
altering the results of the assay. Compounds dissolved in DMSO were
therefore diluted in serum-free medium to achieve such dilutions of DMSO
before being added to the assay. The results are shown in Figures 4.6-4.8
and summarised in Table 4.2.
(a) 2-acetvlaminofluorene: 2-AAF was slightly less cytotoxic to the
CHRC5 cell line than the parental, drug sensitive AuxB1 cell line
(Figure 4.6) with 50% reduction in the control O.D. at -140 pM for
CHRC5 and -125 pM for AuxB1 cells (Figure 4.6).
(b) Benzofafpvrene: B(a)p was cytotoxic to both cell lines and caused
50% reduction in O.D. at a concentration of -100 pM for CHRC5 and
140 pM for AuxB1 (Figure 4.7).
(c) Aflatoxin B-]: AFB-) was slightly cytotoxic to CHRC5 cells and
AuxB1 cells. The IC50 value for the CHRC5 cell line was -60 pM and
50 pM for the AuxB1 cell line (Figure 4.8).
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FIGURE 4.5
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Plates were set up with 2500 AuxB1 arid CHRC5 cells in a final volume of 180 pi. The cells
were allowed to adhere overnight and then 20 pi of 10 x stock of DMSO in serum-free medium
was added to give the final concentrations in the range 0-10%. The plates were then
incubated for a further 4 days followed by the addition of MTT (50 pi of 2 mg/ml) and colour
developed.




TOXICITY OF 2-ACETYLAMINOFLUORENE TOWARDS CHRC5
AND AUXB1 CELLS
(a) Toxicity towards AuxB1 cells
[2-acetylaminofluorene] M
(b) Toxicity towards CHRC5 cells
[2-acetylaminofluorene] M
Plates were set up with 2500 AuxB1 or CH^CS cells per well in a volume of 180 pi. The cells
were allowed to adhere overnight and then 20 pi of 10 x stock 2-AAF in DMSO was added to
give final concentrations in the range 0-1.1 mM. The plates were then incubated for 4 days
followed by the addition of MTT (50 pi of 2 mg/ml) and colour developed as described
previously.
Each individual point represents the mean of 3 experiments (6 wells were read in each
experiment). 1QC-
FIGURE 4.7
TOXICITY OF BENZO(A)PYRENE TOWARDS CHRC5 AND AUXB1
CELLS
(a) Toxicity towards AuxB1 cells
[benzo(a)pyrene] M
(b) Toxicity towards CHRC5 cells
120 -i
10"7 1 0~ 6 10"5 1 0~ 4 1 0" 3
[benzo(a)pyrene] M
Plates were set up with 2500 AuxB1 or CHRC5 cells per well in a volume of 180 pi. The cells
were allowed to adhere overnight and then 20 pi of 10 x stock of B(a)p dissolved in DMSO
added to give final concentrations in the range 0-40 mM. The plates were incubated for a
further 4 days and then MTT (50 pi of 2 mg/ml) was added and the colour developed.




TOXICITY OF AFLATOXIN B-, TOWARDS CHRC5 AND AUXB1
CELLS
(a) Toxicity towards AuxB1 cells
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[Aflatoxin B1]
Plates were set up with 2500 AuxB1 or CHRC5 cells per well in a volume of 180 pi. The cells
were allowed to adhere overnight and then 20 pi of 10 x stock AFB1 in DMSO added to give
final concentrations in the range 0-25 mM. The plates were incubated for a further 4 days and
MTT (50 pi of 2 mg/ml) added and the colour developed as described previously.
Each individual point represents the mean of 3 experiments (6 wells were read in each
experiment). 137
TABLE 4.2







140 pM 125 pM
99 pM 141 pM
63 pM 50 pM
4.5 EFFECT OF CARCINOGENS ON THE RESISTANCE
PROFILE OF CHrC5 CELLS
(a) EFFECT OF 2-ACETYLAMINOFLUORENE ON COLCHICINE
TOXICITY TOWARDS CHRC5 AND AUXB1 CELLS
CHrC5 and AuxB1 cells were plated at 2500 cells per well in 160pl of
medium and allowed to adhere overnight. 2-AAF (20pl) was then added to
48 wells of the 96-well assay plate to a final non-toxic concentration of 17.5
pM. Serum-free medium was added to the remaining wells.Colchicine (20
pi) was then added to all 96 wells of the plate in a concentration range from
0-0.1 mM. The final volume was therefore 200 pi. Triplicate plates were
assayed for each cell line.
Figure 4.9 shows the results of the study. Co-incubation of the CHRC5
and AuxB1 cells with 2-AAF did not alter the cytotoxicity of colchicine toward
the cells. As expected, colchicine was less toxic to the drug resistant cell line
than the drug sensitive one. However, the presence of a non-toxic dose of
the carcinogen 2-AAF did not alter the result. This indicates that 2-AAF does
not compete for the plasma membrane protein, P-pg, of the drug resistant
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CHRC5 cell line, at the concentration at which the carcinogen was tested.
(b) EFFECT OF BENZO(A)PYRENE ON COLCHICINE TOXICITY
TOWARD CHRC5 AND AUXB1 CELLS
An experiment, such as described in Section 4.5.(a), was performed
using benzo(a)pyrene (B(a)p), at a non-toxic dose in the presence of a
range of cytotoxic colchicine concentrations. As before, both CHRC5 and
AuxB1 cells were assessed to re-affirm the difference in cytotoxicity to
colchicine between the two cell lines and the functionality of the P-gp pump.
Figure 4.10 shows the results of the experiment. As with 2-AAF, B(a)p
did not alter the cytotoxicty of colchicine towards the cells. As expected,
CHrC5 displayed greater resistance to colchicine than AuxB1 cells. B(a)p
does not appear to compete for the binding of colchicine to the P-gp pump at
the non-toxic concentrations at which it was used.
(c) EFFECT OF AFLATOXIN B-| ON COLCHICINE CYTOTOXICITY
TOWARD CHrC5 AND AUXB1 CELLS
An experiment, such as described in Section 4.5.(a), was conducted
using AFB-) at a non-toxic dose in the presence of colchicine at a variety of
cytotoxic concentrations. Both CHRC5 and AuxB1 cells were assessed
under these conditions.
Figure 4.11 shows the results of the experiment. AFB-| failed to alter
the cytotoxicity caused by colchicine toward the CHRC5 cell line and hence
does not appear to compete for the binding of P-gp. Table 4.3 summarises
the results of Section 4.5.
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FIGURE 4.9 EFFECT OF TREATMENT WITH A NON-TOXIC DOSE
OF 2-ACETYLAMINOFLUORENE ON THE CYTOTOXICITY OF
COLCHICINE TOWARDS CHRC5 AND AUX B1 CELLS
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Plates were set up with 2500 AuxB1 or CFI^CS cells per well in a volume of 160 pi. Cells
adhered overnight and 20pl of 10 x stock colchicine added to give final concentrations in the
range 0 - 0.1 mM. 2-AAF (20 pi) was added to half the wells to give a final non-toxic
concentration of 17.5 pM. Serum free medium was added to the remaining wells. Plates were
incubated for 4 days, MTT added and the colour developed and read.
Each individual point represents the mean of 3 experiments (6 wells were read in each
140experiment).
FIGURE 4.10 EFFECT OF TREATMENT WITH A NON-TOXIC
DOSE OF B(a)P ON THE CYTOTOXICTY OF COLCHICINE
TOWARDS CHRC5 AND AUXB1 CELLS
(a) Toxicity towards AuxB1 cells
Each individual point represents the mean of 3 experiments (6 wells were read in each
experiment).
[colchicine] M
(b) Toxicity towards CHRC5 cells
Plates were set up with 2500 AuxB1 or CH^CS cells per well in a volume of 160 pi. Cells
adhered overnight and then 20 pi of 10 x stock colchicine was added to give final
concentrations in the range 0-0.1 mM. B(a)p (20 pi) in DMSO was added to half the wells of
the plate give a final, non-toxic concentration of ~4 pM. Serum free medium (20pl) was added
to the remaining wells. Plates were incubated MTT added and colour read.
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FIGURE 4.11 EFFECT OF TREATMENT WITH A NON-TOXIC
DOSE OF AFLATOXIN B1 ON THE CYTOTOXICTY OF
COLCHICINE TOWARDS CHRC5 AND AUXB1 CELLS
(a) Toxicity towards AuxB1 cells
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Plates were set up with 2500 AuxB1 or CHRC5 cells per well in a volume of 160 pi. The cells
were allowed to adhere overnight and then 20 pi of 10 x stock of colchicine was added to give
final concentrations in the range from 0-0.1 pM. AFB1 (20 pi) was also added to half the wells
to a final, non-toxic concentration of 10 pM. Serum free media was added to the remaining
wells. Plates were incubated for a further 4 days, MTT added and the colour read.
142
TABLE 4.3
TOXICITY OF COLCHICINE TOWARDS CHRC5 AND AUXB-,
CELLS IN THE PRESENCE OR ABSENCE OF CARCINOGENS
IC50 (|iM)
CARCINOGEN CHRC5(+) CHRC5(-) AUXB1(+) AUXB1(-)
2-AAF 30 30 0.95 0.95
B(a)p 50 20 0.85 0.9
AFB1 35 35 3.5 3.5
(+) plus carcinogen
(-) minus carcinogen
4.6 SUMMARY OF RESULTS AND DISCUSSION
In this section of the project, the MTT assay was characterised and
used to assess the toxicity of chemotherapeutic agents and carcinogens on
the CHrC5 and AuxB1 cell line. The mdr-reversing agent verapamil was
also used in the assay to determine the reversibility of the mdr phenotype in
CHrC5 cells. The assay was relatively quick and simple to perform
compared to other clonogenic and dye exclusion techniques. Several
compounds were assayed and their relative toxicity evaluated as IC50
values. However, the assay does not distinguish between cytostatic and
cytotoxic effects.
Experiments conducted in the absence of drug were designed to
determine whether the cell number chosen for the assay meant that the cells
were still in logarithmic growth at the end point of the assay. The O.D.
obtained at the end of the assay also had to be high enough to give
reproducible measurements of cytotoxicity.
The carcinogens tested caused little toxicity to either of the cell lines. It
was aimed to establish whether carcinogens can act as substrates for P-gp
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in CHRC5 cells and as such compete for the binding site on the protein and
increase the cytotoxicity of the drug to which the cell line was made resistant.
From the experiments conducted, it was found that this was not the case.
The cytotoxic chemotherapeutic agents colchicine and doxorubicin did show
differential toxicity toward AuxB1 and CHRC5 cells, with the drug sensitive
line AuxB1 being much more sensitive to the effects of the drugs. Verapamil
reversed the mdr phenotype of the CHRC5 cell line to some extent and thus
demonstrated that known chemosensitising agents can be shown to cause
such an effect using the MTT assay. Ford et al (1990) also reported a very
small (4-fold) change in the resistance (400 fold) of MCF-7 AdrR cells to
colchicine using verapamil. A 13-fold reversal of doxorubicin resistance
(200-fold) and 33-fold reversal of vinblastine resistance (100-fold) in the
same cell line was demonstrated. Fojo et al (1985) demonstrated that 20 pM
verapamil completely reversed the 20- to 70-fold cross-resistance to
doxorubicin, vinblastine and vincristine in colchicine selected KB human
carcinoma cells but caused only a 60-fold reduction in the 220-fold
resistance to colchicine.
The most likely reason for the lack of cytotoxicity of the carcinogens
used in this study is the requirement for metabolic activation of drugs and
carcinogens, by specific P450s, to cause toxicity. Such activation often
results in the formation of highly reactive intermediates such as epoxides
(Jollow and Smith, 1977). Various compounds undergo P450-dependent
metabolic activation including the aromatic amine 2-AAF (McManus et al,
1984) and acetaminophen (Potter et al, 1973). The structures of the
compounds used in this study are shown in Figure 4.1 2.
In the present study, the ovarian cell line employed is not known to
express P450 enzymes and would not be capable therefore of metabolising
the carcinogens examined to more toxic compounds.
Several reasons can be postulated for the lack of competition for P-gp
between colchicine and the test carcinogens, apart from the explanations
that P-gp may not function as an efflux pump for carcinogens and other
xenobiotics or that the concentration of carcinogen employed in each case
was insufficient to demonstrate a difference in toxicity levels.
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FIGURE 4.12













Firstly, the carcinogens may have to be metabolically activated before acting
as substrates for P-gp. To examine such a possibility would involve
employing a drug resistant cell line known to express P450 enzymes
capable of metabolising the carcinogen of interest. Such a cell line would
probably be a hepatoma since liver tissue is known to express P450s at high
levels in vivo. Alternatively an mdr cell line transfected in order to express
P450 enzymes could be employed to metabolise the carcinogen of interest.
The metabolites of the carcinogens could also be used directly in the assay
to overcome the problem.
Secondly, colchicine may be a greatly preferred substrate for P-gp
and would not allow the binding of other weaker substrates. By using
several other chemotherapeutic drugs such as colcemid or vincristine this
hypothesis could be tested.
Thirdly, the assay may lack the sensitivity required to detect small
changes in the binding of colchicine to the P-gp transport pump. To improve
the sensitivity of detection, azidopine photoaffinity labelling of P-gp could be
utilised. The arylaside, 1,4 dihydropyridine, azidopine, is a calcium channel
antagonist which photolabels calcium channels (Glossmann et al, 1987).
[3|-l] azidopine can specifically photolabel P-gp. It has been demonstrated
that binding is influenced by other calcium antagonists and drugs used to
select resistant cells, for example vinblastine, colchicine and taxol (Yang et
al, 1988). Such a system may demonstrate that carcinogens compete for P-
gp labelling.
Since the study conducted does not conclusively prove the role of P-
gp in xenobiotic efflux, further analysis will need to be undertaken to answer
this question. Such a study would merit further consideration since the
physiological role for P-gp in normal tissues remains unknown. By using the
natural substrates for the P-gp pump, its activity in tumour cells could be




EXOGENOUS REGULATION OF MDR GENES IN RAT AND
MOUSE
5.1 INTRODUCTION
The hypothesis that exposure to chemical carcinogens led to the
development of a cell population resistant to the cytotoxic effects of those
carcinogens was first proposed by Haddow (1938) more than 50 years ago.
Haddow showed that although polycyclic aromatic hydrocarbon (PAH)
carcinogens were toxic and inhibited growth in vivo, the tumours induced by
exposure to them were resistant to these effects (Haddow and Robinson,
1937). The inhibition of normal cell growth and stimulation of tumour cell
growth has been reveiwed (Vasilier and Guelstein, 1963; Melzer, 1980).
Novicki et al {1985) noted that one acute effect of many hepatocarcinogens
is inhibition of hepatocyte proliferation. Chronic administration results in
altered hepatocytes which continue to grow despite the presence of the
carcinogen.
Carcinogen-induced resistance to toxicity has been most extensively
studied in rodent liver. The classical Solt-Farber model of chemical
carcinogenesis in rat liver (Solt and Farber, 1976) involves treatment of rats
with an initiating agent, for example diethylnitrosamine (DEN), followed by
administration of 2-acetylaminofluorene (2-AAF) and partial hepatectomy.
Hyperplastic nodules (preneoplastic lesions) may be isolated six to eight
weeks after initiation with DEN, whereas neoplastic nodules (neoplastic
lesions) representing primary hepatocellular carcinomas may be isolated six
to eight months after initiation. Cells derived from the nodules appear cross-
resistant to a wide variety of toxins (Carr, 1987).
Hepatocellular carcinoma (HCC) is a very common cancer and has a
high rate of frequency in South East Asia and sub-Saharan Africa (Hutt,
1981). The resistance of HCC to ionizing radiation and chemotherapeutic
agents has been studied (Falkson, 1975) and appears to have some
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common similarities with the resistance of carcinogen altered rat
hepatocytes to cytotoxicity, as discussed below.
Carr and Laishes (1981) showed that hepatocytes from rats treated
with the hepatocarcinogen 2-AAF in vivo were resistant in vitro to the
cytocidal effects of many compounds, including chemotherapeutic agents
such as adriamycin, compared to normal hepatocytes.
Batist et a\ (1986) isolated a doxorubicin resistant human breast
cancer cell line (DoxR MCF7) that had developed the phenotype of mdr, and
also displayed an increase in an anionic GST isozyme with high peroxidase
activity. The induction of a similar anionic GST is also noted in rat
hyperplastic liver nodules (Kitahara et at, 1984). Rat hyperplastic nodules
(HNs) also contain lower levels of cytochrome P450 dependent enzymes,
including aryl hydrocarbon hydroxylase (AHHase), aminopyrene N-
demethylase and NADPH cytochrome c reductase relative to normal
hepatocytes (Astrom, 1983; Cameron et al, 1976). DoxR MCF7 cells also
displayed a marked decrease in 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCCD)-induced AHHase activity and CYP1 gene transcription. Since
AHHase is involved in the intracellular metabolism of the carcinogen
benzo(a)pyrene, this change alters the sensitivity of the DoxR cells to the
cytotoxic effects of this carcinogen (Cowan etal, 1986).
Thorgeirsson et al (1987) measured the expression of the mdr gene
in normal rat liver cells, preneoplastic and neoplastic nodules and
regenerating liver, since all these altered tissues had been shown to be
resistant to a broad range of carcinogens. Levels of mdr mRNA were
increased in both preneoplastic and neoplastic lesions. Expression of mdr
was also dramatically increased 24-72 hours after partial hepatectomy in
regenerating rat liver. This suggests that the expression of the mdr gene is
regulated in liver and represents a component of the hepatic response to
toxic insults.
More recently, Marino et al (1990) reported a study to determine
whether the increased levels of mdr mRNA observed in regenerating rat liver
was due to an increased rate of transcription or a post-translational event.
Nuclear run-on assays were performed on nuclei from regenerating rat liver,
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isolated 4 -72 h, after partial hepatectomy. Northern blot analysis showed
that a greater than 20-fold increase in mdr mRNA levels had occurred but no
increase was found in mdr gene transcription rates. This suggests that the
observed increase in mdr mRNA levels may be due to a post-transcriptional
event, for example message stabilisation.
It is unlikely that an increased expression of the mdr gene can totally
explain the resistance to chemical carcinogens in early initiated cells since
many of these carcinogens are compounds not usually effected by the mdr
phenotype. These compounds do not appear to be transported by P-
glycoprotein, for example mdr cells with high levels of P-gp are not more
resistant to 2-AAF than their drug resistant counterpart (see chapter 4). Also
if increased mdr following partial hepatectomy made liver cells resistant to 2-
AAF then the Solt-Farber protocol would not result in liver nodules.
Therefore other factors such as over-expression of GST may be contributing
significantly to the development of the resistant phenotype, as suggested by
Cowan efa/(1986).
In this chapter, the effects of xenobiotics on mdr genes in mouse liver
will be investigated. All three mouse mdr genes are expressed in the liver
(Croop et at, 1989) but the changes in the expression levels of these
particular genes following toxic insult have not been studied. The use of
gene specific cDNA probes has allowed such a study of mouse mdr gene
expression.
Burt and Thorgeirsson (1988) speculated that as a detoxification
transport system, mdr 1 might be coordinately regulated in the liver, and
other tissues, with such enzymes as UDP-glucuronyltransferase and
cytochrome P450 isoforms. They demonstrated that treatment of rats in vivo
with certain chemical carcinogens namely 2-AAF, isosafrole, phenothiazine
and TCCD increases mRNA levels for mdr 1 and the CYP1 family.
Therefore, interaction of these compounds within the cell may
generate an intracellular signal which results in alterations in RNA levels for
several different detoxification systems.
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AIMS
The aims of this part of the study were to investigate the acute effects
of a range of xenobiotic compounds, including both P450 and GST enzyme
inducers, on hepatic mdr levels in both rat and mouse. The expression of
mdr genes compared to P450 and GST genes were compared to determine
whether or not similar regulatory mechanisms are operating following
exposure to xenobiotics. Since the induction of gene expression is different
in the rat and mouse, both rodent groups were examined.
In rats both mRNA and protein levels were studied, whereas in mice
only mRNA levels were measured. Western blotting on mouse liver tissue
resulted in cross-reactivity between a 60 kd protein and the C219
monoclonal antibody. Northern blotting was conducted using gene-specific
cDNA probes in mouse but using a non-specific human cDNA clone in the
rat. Therefore the expression of specific rat genes could not be determined.
5.2 XENOBIOTIC REGULATION OF MDR GENES IN RAT
5.2.1 TREATMENT OF WISTAR AND FISCHER RATS
Adult (~250g) male Wistar rats (2 per group) and Fischer 344 rats (4
per group) were treated with various xenobiotics.
The protocol for treating the Wistar rats is shown in Table 5.1. Figure
5.1 shows the structures of these compounds. The Fischer rats were treated
with 3-MC and AFB-| as for the Wistar rats except that two of the 3-MC
treated rats were also treated for an extra day and then sacrificed 24 hours
later. Two Fischer rats were dosed with 20 mg/kg of 2-AAF for 3 days and two
rats for 4 days and then sacrificed 24 hours later respectively. The
appropriate controls were included for all rat treatments. Both corn-oil and
PBS were used to dissolve the compounds and therefore both corn-oil and
PBS controls were done.
Most compounds were administered intraperitoneal^. The exceptions
were ethanol which was given in the drinking water, carbon tetrachloride,
which was given sub-cutaneously, and 2-AAF which was administered
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intragastrically by means of a 100 mm plastic cannula, size 8 FG
(International Market Supply, Cheshire) after grinding the compound with a
mortar and pestle and resuspending it in corn-oil.
Both liver and kidney from Wistar rats were removed following
treatment. Some was retained for histological examination and the
remainder was washed briefly in PBS and frozen at -70°C until RNA was
prepared and cytosolic and microsomal protein fractionated. Only liver was
removed from Fischer rats. No histological examination was performed on it.
5.2.2 HISTOLOGICAL EXAMINATION OF 2-ACETYLAMINOFLUORENE-,
AFLATOXIN B1- AND DIETHYLNITROSAMINE-TREATED WISTAR
RAT LIVER AND KIDNEY
Liver and kidney were removed from Wistar rats following treatment
with the compounds 2-AAF, AFB-) and DEN. Pieces of these organs were
washed briefly in PBS and prepared for histological examination as
described in Section 2.3.
Both the liver and kidney tissues from all three treatments and the
control were stained with hematoxylin and eosin (H/E). Such staining shows
the morphology of the tissue. Glycogen distribution was also examined
using the PAS method as described in Section 2.3.2.
The results of the H/E staining is shown in Figure 5.2 and 5.3.
Necrotic areas are clearly visible around the central vein and in zone 3 of
the DEN treated liver but the 2-AAF and AFB-) treated livers appear
apparently normal in comparison. Such a result for a potent hepatotoxin
such as DEN is expected. Figure 5.3 depicts the results of the treatments on
the rat kidney. Some renal tissue damage is occuring for all three treatments
but is much more readily apparent in the DEN treated kidney. Glycogen
distribution in the treated livers is shown in Figure 5.4. Widespread glycogen
storage, which is found in normal liver, is absent in the DEN treated liver.
Following DEN treatment, glycogen storage is greatly diminished compared




H/E STAINING OF CONTROL AND TREATED WISTAR RAT LIVER
Wistar rats were treated with 2-acetylaminofluorene, aflatoxin B1 and diethylnitrosamine, as
described in Table 5.1, and the livers removed following treatment and sectioned.















H/E STAINING OF CONTROL AND TREATED WISTAR RAT
KIDNEY
Wistar rats were treated with 2-acetylaminofluorene, aflatoxin B1 and diethylnitrosamine, as
described in Table 5.1, and the kidneys removed following treatment and sectioned.










GLYCOGEN DISTRIBUTION IN CONTROL AND TREATED
WISTAR RAT LIVER
Wistar rats were treated with 2-acetylaminofluorene, aflatoxin B1 and diethylnitrosamine, as
described in Table 5.1, and the livers removed following treatment and sectioned. Glycogen












5.2.3 ANALYSIS OF RAT MDR EXPRESSION FOLLOWING XENOBIOTIC
TREATMENT
From each of the Wistar and Fischer rat treatment groups described,
total RNA was extracted and microsomes prepared from pooled livers.
Cytosolic fractions were also extracted from the Wistar rats. Actin controls
were run on the RNA samples as well as comparing intensities of ethidium
bromide staining to check for equal loading on Northern blots.
SDS PAGE gels were run on the cytosolic and microsomal fractions
to check for equal loading. Immunoblotting was then performed using
antibodies raised against P450 and GST proteins (Section 2.5.2). The
monoclonal C219 was used to immunoblot P-glycoprotein (Section 2.5.3).
(a) NORTHERN BLOT ANALYSIS
Northern blots were performed on 15pg of each RNA sample. The
human mdr 1 gene cDNA probe, MDR5A, was used to detect the mdr
transcript in treated rat livers.This clone encompasses the middle third of the
human cDNA (Fojo et at, 1987) and has been previously used in Northern
blot analysis against cultured rat cells treated with different
chemotherapeutic drugs (Chin et at, 1990) and in rats following partial
hepatectomy (Marino et at, 1990). Other cDNA probes such as the human
cDNA probe pADR-1, isolated from AdrRMCF7 cells,havealso been used to
probe rat liver treated in various ways (Fairchild et al, 1987; Burt and
Thorgeirsson, 1988).
The use of such probes was necessary since no rat probes were
available at that time. Recently, clones have been identified which encode
the rat homologue of the mouse mdr 2 gene and a full length gene of 4253
bp which is 90% homologous to the mouse mdr 1 gene.
The MDR5A probe (hybridised at a final stringency of 2xSSC)
detected two transcripts in the Wistar rat liver treated wtih 2-AAF, AFB-j and
DEN as shown in Figure 5.5. The transcript sizes were calculated to be
approximately 5.3 and 4.3 kb. However, the 4.3 kb transcript was expressed
at a much greater level than the 5.3 kb transcript. No other treatment induced
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mdr mRNA levels above control, which was in fact undetectable using this
system. Since it is known that a high degree of homology exists between
the rodent mdr genes, as shown in Table 5.2, it could be speculated that
these rat gene transcripts have equivalent mouse homologs which are
also induced by similar compounds.
FIGURE 5.5 EXPRESSION OF MDR 1 IN TREATED WISTAR
RAT LIVER
Wistar rats were treated, as described in Table 5.1, and the liver RNA (15 pg of each treated
liver) probed with the mdr 1 human probe MDR5A, as described in Section 2.11.
DEX dexamethasone CF clofibrate
ARA arachlor DEN diethylnitrosamine
2-AAF 2-acetylaminofluorene carbon tet carbon tetrachloride
3-MC 3-methylcholanthrene lead nit lead nitrate
AFB1 aflatoxin B1 4-NQO 4-nitroquinoleneoxide
PYZ pyrazole 4-AAP 4-acetaminophen
|3-NF P-naphthaflavone stave o/n starve overnight
Liver from each rat was kept separate and Northern blots were done using the livers from each
individual treated rat. This blot represents the results obtained from one of the two rats from
each treatment group. The results from the duplicates in each group were identical.
In all three cases where the induction of mdr in rat occurs, both transcripts
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are induced together above control levels. This suggests a co-induction of
both genes by a common regulatory element activated by such compounds.
TABLE 5.2 PERCENTAGE IDENTITY OF RAT, HAMSTER,
MOUSE AND HUMAN MDR SEQUENCES
HUM HUM MS MS MS HAM HAM
MDR MDR MDR MDR MDR MDR MDR
1 2 3 1 2 1a 1b
RAT 79.1 71.5 82.5 90.4 69.6 78.1 80.4
MDR 1b
HAM 75.7 47.7 76.8 83.4 77.9 82.0
MDR 1b
HAM 83.5 64.2 89.3 77.9 65.0
MDR 1a
MS 71.1 86.1 71.1 69.4
MDR 2






Adapted from Silverman eta! (1991b)
Chin et at (1990) employed the same probe and conditions of
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stringency as used in this study. He also detected two different transcript
sizes in the rat PC12 pheochromocytoma cell line treated with adriamycin,
daunomycin, m-AMSA and mitoxantrone but did not elude to this fact in the
discussion of his findings. Subsequent slot blots used in his study failed to
distinguish between the two different transcripts and therefore it cannot be
determined which of the genes were being regulated. The use of slot blotting
in examining mdr gene expression is only completely valid when the
FIGURE 5.6 EXPRESSION OF MDR 1 mRNA IN TREATED
FISCHER RAT LIVER
Fischer rats were treated with 3-methylcholanthrene, aflatoxin B1 and 2-acetylaminofluorene,
as described in Section 5.2.1, and the liver RNA (15 pg of each treated liver) was probed with
the mdr 1 human probe MDR5A, as described in Section 2.11.
CON control AFB1 aflatoxin B1


















































Livers from each treatment group (2 rats per group) were combined. This blot represents the
results obtained from one experiment.
163
specificity of the probe for a particular gene has been proven.
Fischer rats treated with AFB-| and 2-AAF also demonstrated raised
hepatic mdr levels, as shown in Figure 5.6.
Again, two transcripts of 5.2 and 4.3 kb were co-induced, but the 4.3 kb
transcript was induced to a much greater extent. 3-MC failed to cause any
change to mdr levels in these rats. AFB-) had a greater effect (~2-fold) in
these Fischer rats than the Wistar rats. Induction of mdr by 2-AAF was
maximal after 3 days of treatment as opposed to 4 days .
(b) IMMUNOBLOTTING ANALYSIS
Microsomal fractions for immunoblotting were prepared from both
Wistar and Fischer rat liver. C219 monoclonal antibody was used to detect
P-glycoprotein in these samples. This antibody has been used in both
immunoblotting of rat cannalicular membrane vesicles (Thiebaut et al, 1987;
Kamimoto et al, 1989) and in immunohistochemical detection of P-
glycoprotein in rat hepatocellular carcinomas (Volm et al, 1990). The
transcript size detected in the liver membrane vesicles was ~ 160 kD which
was smaller than the 170 kD CH^C5 cell line P-gp standard, used in the
study (Kamimoto et al, 1989).
The immunoreactivity of C219 with the rat membrane vesicles
prepared from the Wistar rat livers, treated with different xenobiotics, is
shown in Figure 5.7.
Table 5.3 shows the relative expression of P-gp, following each
treatment, as defined by high, moderate or slight induction.
The molecular weight of the protein detected by C219 was calculated
and found to be 150 kD. Dex also induced a lower protein of 60 kd not
detected by any other treatment. The band of 150 kD on the immunoblot
appeared to represent two reactive proteins migrating very closely together.
C219 does not distinguish between the various classes of P-gp and
will therefore detect all the rat mdr transcript products, which contain the
highly conserved epitope VQAALD.
From Figure 5.7, it can be seen that Dex, Ara, 2-AAF and pyrazole
induced the expression of P-pg in Wistar rat liver to a high extent. 3-MC and
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FIGURE 5.7 EXPRESSION OF P-GLYCOPROTEIN AND
CYP1A1, CYP2B1, CYP2E1 AND CYP3A1 IN WISTAR RAT LIVER
TREATED WITH VARIOUS COMPOUNDS
Wistar rats were treated, as described in Table 5.1, and the liver microsomal protein was
Western blotted using the monoclonal antibody C219 and cytochrome P450 polyclonal
antibodies.
DEX dexamethasone PYZ pyrazole
ARA Araclor CTC carbon tetrachloride
ETOH ethanol LEAD NIT lead nitrate
2-AAF 2-acetylaminofluorene 4-AAP 4-acetaminophen
CO corn-oil AFB1 aflatoxin B1
3-MC 3-methylcholanthrene 4-NQO 4-nitroquinoline N oxide
CF clofibric acid
oc/p-NF a/p-napthoflavone





CYP 1A1 • m J)






CYP 3A1 52.5 kD
Livers from each treatment group (2 rats per group) were pooled. This blot represents the
results obtained from one experiment.
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TABLE 5.3 INDUCTION OF P450 ENZYMES AND P-
G LYCOPROTEIN IN WISTAR RAT LIVER
P450 FAMILY
Chem 1A1 2B1 2E 3A1 PGP
Dex NC ++ NC +++ +++
Ara +++ +++ NC +++ +++
Eth NC NC NC NC NC
2-AAF NC ++ NC NC +++
3-MC +++ NC NC - ++
Clo NC NC NC - +
oc-NF NC ++ NC NC NC
(3-NF +++ NC NC ++ +
Pyz + + +++ NC +++
Car Tet NC NC NC - NC
Lead Nit NC NC NC NC NC
4-AAP NC NC NC NC NC
AFB-| NC NC NC + ++






AFB-) both induced P-gp to a moderate level. Clofibrate and (3-
naphthoflavone ((3-NF) induced the expression of P-gp only slightly above
control levels. Both corn-oil and PBS control rat liver cross-reacted with the
C219 antibody to show the presence of P-gp in these samples occurred to
the same extent, but were themselves not inducing the level of protein to any
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extent. The induction of P-gp by certain compounds is occurring post-
transcriptionally. Although 2-AAF and AFB-) caused an increase in both
mRNA and protein, the other P-gp inducers failed to increase the level of
mRNA for the rat mdr genes.
FIGURE 5.8 EXPRESSION OF P-GLYCOPROTEIN IN
TREATED FISCHER RAT LIVER
Fischer rats were treated, as described in Section 5.2.1, and the liver microsomal protein was








Figure 5.8 shows the result of blotting the Fischer rat liver microsomes
treated with 3-MC, 2-AAF and AFB-| with the C219 antibody.
A membrane fraction of CHRC5 (50 pg), the mdr Chinese hamster cell line,
was also examined to compare the relative sizes of the immunoreactive
protein identified. The molecular weights of the proteins recognised by
C219 against CHRC5 and the rat liver microsomes were 160 kD and 150
kD respectively.
Both 2-AAF, at day 5, and AFB-j, at day 2, did induce P-gp expression
significantly above controls.
Figure 5.6 shows that 3-MC did not cause an increase in P-gp mRNA
in Fischer rat liver and this is reflected in the immunoblot results (Figure 5.8).
5.2.4 ANALYSIS OF RAT CYTOCHROME P450 AND GST
EXPRESSION FOLLOWING XENOBIOTIC TREATMENT
(a) NORTHERN BLOT ANALYSIS
The cDNA probes described in Section 2.7 were used to determine
the mRNA levels in the Wistar and Fischer rat livers. The CYP2B and
CYP4A cDNA clones used were of rat origin. CYP2A and CYP3A were
human cDNA clones. Human CYP2A7 displays 85% homology to the rat
CYP2A3. The CYP2C cDNA is of mouse origin but is also highly
homologous to the rat sequence.
The effect of various xenobiotic treatments on hepatic cytochrome
P450 and GSTa mRNA levels in Wistar rats is shown in Figure 5.9. Table 5.4
summarises the results of Figure 5.5.and 5.9.
The actin mRNA levels were assessed and DEN treatment appeared
to increase actin levels substantially. The reason for this may be due to the
necrotic effect of acute administration of DEN on the liver tissue. Liver
regeneration can be induced by any acute treatment, surgical or chemical,
that removes or kills hepatic parenchyma. Loss of parenchyma induces cell
proliferation to restore the total mass of the liver (Michalopolous, 1990).
Several chemical treatments including DEN and carbon tetrachloride cause
necrosis around the central zone of the hepatic lobule. mRNA levels for
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FIGURE 5.9 EXPRESSION OF CYTOCHROME P450s,
a-GST AND ACTIN mRNA IN TREATED WISTAR RAT LIVER.
Wistar rats were treated as described in Table 5.1. RNA was extracted from each individual rat
and Northern blotted using cDNA probes for CYP2A, CYP2B, CYP2C, CYP3A, CYP4A, GST
a and actin, as described in Section 2.11.
PBS phosphate buffered saline a/pNF
DEX dexamethasone CARBON TET
ARA Araclor LEAD NIT
EtOH ethanol 4-AAP
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Livers from each treatment group (2 rats per group) were pooled. This blot represents the
results obtained from one experiment.
TABLE 5.4
EFFECT OF XENOBIOTIC TREATMENT ON P450, cc-GST, MDR
AND ACTIN HEPATIC mRNA LEVELS IN WISTAR RATS
P450 families
CHEMICAL 2A 2B 2C 3A 4A GST-a MDR ACTIN
Dex + ++ ++ +++ NC NC NC NC
Ara + +++ +++ +++ NC ++ NC NC
Ethanol NC ++ +++ NC NC NC NC NC
2-AAF + ++ +++ ++ + NC +++ NC
DEN NC - NC - NC - +++ +++
3-MC + NC +++ NC NC NC NC NC
Clofibrate NC NC ++ + +++ ++ NC NC
cc-NF NC NC +++ NC NC NC NC NC
P-NF NC NC +++ + NC ++ NC NC
Pyrazole ++ +++ + ++ NC +
Car. Tet. NC NC +++ NC NC NC NC +
Lead Nitrate + NC +++ NC NC NC NC NC
4-AAP NC NC +++ NC NC - NC -
Starve o/n + ++ +++ NC NC - NC -
AFB-j + ++ +++ ++ ++ - +++ -






certain proteins such as actin, a- and (3-tubulin increase during liver
regeneration 12 -72 hours after partial hepatectomy (Friedman et al, 1984).
From microtome-cut sections of DEN treated Wistar rat liver it was observed
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that such necrosis had in fact occured in zone 3 and around the central vein,
as shown in Section 5.2.2. However, 2-AAF and AFB-| treated liver showed
no such necrotic areas. No increase in actin mRNA was observed for 2-AAF
or AFB-) (Figure 5.9).
Messenger RNA encoding the major cytochrome P450 families in rat
liver were determined, as shown in Figure 5.9, and found to be induced with
various treatments. CYP2A1 and CYP2A2 are only just detectable in the
liver (Matsuaga et al, 1988). CYP2A mRNA is induced by 3-MC as shown in
Figure 5.9. Dex, Ara, 2-AAF, lead nitrate and AFB-| also slightly induced the
level of CYP2A mRNA. Whether such induction represents CYP2A1 or
CYP2A2 is not clear from the probe used. Rat CYP2A3 is expressed only in
rat lung but is 71% and 73% homologous to CYP2A1 and CYP2A2 gene
expression cannot be determined from the CYP2A3 probe used.
The P450 2B sub-family mRNA was measured using the rat CYP2B1
full length cDNA clone. Rat CYP2B1 and CYP2B2 exhibit 97% amino acid
homology (Atchison and Adesnik, 1983) and have similar substrate
specificities. The two genes are coordinately regulated in liver by
phenobarbital (PB) due to an increased gene transcription rate (Atchison
and Adesnik, 1983). CYP2B2 is constitutively expressed whereas CYP2B1
is transcriptionally inactivated in untreated rats. CYP2B3 shares 77%
homology to CYP2B1 and CYP2B2, and is constitutively expressed as a
minor form in rat liver (Labbe et al, 1988). Figure 5.9 shows the induction of
CYP2B by Ara to a high extent. Dex and ethanol also induce CYP2B to a
moderate extent. 2-AAF, pyrazole, starvation overnight and AFB-) induced
CYP2B above control levels. DEN reduced CYP2B levels below control
values.
CYP2C genes are in most cases constitutively expressed. Two
members of the rat CYP2C family, designated CYP2C6 and CYP2C7 have
been isolated and sequenced (Haniu et al, 1984) and have 75% amino acid
similarity to each other. CYP2C11 is an adult male-specific form and is 70%
similar to the sequence of rat CYP2C6 (Yoshioka et al, 1987). Rat CYP2C12
and rat CYP2C13 have also been described.
The complexity of the rat CYP2C sub-families means that it is not
possible to exclude the possibility that the mouse Cyp2c probe used to blot
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rat CYP2C RNA levels are detecting more than one member of the CYP2C
sub-family.
A human cDNA CYP3A4 clone was used to probe the rat livers.
Humans have at least four CYP3 genes all of which having 90% or greater
similarity to each other. A cytochrome P450 inducible by the synthetic
steroid, pregnenolone 16a-carbonitrile (PCN) was purified from rat liver
(Elshourbagy and Guzelian, 1980) and was identified as a cytochrome P450
sub-family 3 gene. Both rat CYP3A1 and CYP3A2 have now been isolated
and share 90% nucleotide sequence identity. Rat CYP3A1 is inducible by
glucocorticoids such as Dex due to increased transcription rates (Simmons
et al, 1987) but the regulation is distinct from glucocorticoid regulated genes
such as tyrosine aminotransferase (Shuetz and Guzelian, 1984), since
CYP3A1 induction requires approximately 10 fold higher levels of steroid to
induce it.
Rat CYP3A was induced to a high extent by Dex and Ara. It was also
induced by 2-AAF and AFB-j to a moderate extent. DEN caused
suppression of mRNA levels for CYP3A.
CYP4A mRNA levels are increased in clofibrate- and aflatoxin B-|-
treated rat livers. Clofibrate activation occurs within one hour of
administration (Hardwick et al, 1987).
A wide range of chemicals, both natural and synthetic induce GST in
the rat, including PAHs (Igarishi et al, 1987). GST a (rat subunits 1 or 2) was
induced by Ara, 3-MC, (3-NF, pyrazole and substantially suppressed by DEN.
(b) IMMUNOBLOT ANALYSIS
The results of the cytochrome P450 analysis for the Wistar rats is
shown in Figure 5.7 and summarised in Table 5.3.
CYP1A1 is induced by Ara, 3-MC and (3-NF. CYP2B1 protein is
induced by Ara to the greatest extent but also by Dex, 2-AAF, a-
naphthoflavone (a-NF) and pyrazole. a-NF failed to cause an increase in the
mRNA level of CYP2B (Figure 5.9), therefore the increase in CYP2B1
protein with a-NF seems to be due to protein stabilisation or increased
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FIGURE 5.10 EXPRESSION OF VARIOUS P450s IN TREATED
FISCHER RAT LIVER
Fischer rats were treated, as described in Section 5.2.1, and the microsomal protein was
























CYP 2A1 54.5 kD
51.5 kD
CYP 2B1 54.5 kD
CYP 2C3 52.5 kD




Livers from each treatment group (2 rats per group) were pooled. This blot represents the
results obtained from one experiment.
FIGURE 5.11 EXPRESSION OF Yk, Yb and Yf GST IN
TREATED WISTAR RAT LIVER
Wistar rats were treated, as described in Table 5.1, and the cytosolic protein was Western
blotted using polyclonal antibodies against the glutathione S-transferases, as described in
Section 2.6.2.
CON control CAR TET carbon tetrachloride
DEX dexamethasone LEAD NIT lead nitrate
ARA Araclor 4-AAP 4-acetaminophen
ETOH ethanol AFB1 aflatoxin B1
2-AAF 2-acetylaminofluorene 4-NQO 4-nitroquinoleneoxide
3-MC 3-methylcholanthrene STD standard
P-NF p-napthoflavone
PYZ pyrazole
The standards are purified proteins for each respective isozyme.
Livers from each treatment group (2 rats per group) were pooled. This blot
represents the results obtained from one experiment.
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transcription efficiency. CYP2E1 protein is induced by pyrazole but appears
to be completely unaffected by dosing the rats with 1% ethanol for 10 days
although the cytochrome is known to be inducible by such a regimen (Koop
etal, 1982).
CYP3A1 induction by Dex, Ara, (3-NF and AFB-| at the mRNA level is
also reflected at the protein level. However, the increased mRNA in 2-AAF
treated rat is not reflected in the protein analysis, suggesting that increased
translation of the message is not occurring.
Figure 5.10 shows the results of the P450 immunoblotting following
treatment of adult male Fischer rats with 3-MC, 2-AAF and AFB-). 3-MC
clearly induced CYP1A1 and CYP2A1 but suppressed CYP2B1, CYP2C3
and CYP2E1 in the Fischer rat liver. AFB-| and 2-AAF induced CYP2C3
moderately.
Wistar rat cytosolic protein was immunoblotted with GST antibodies
against the Yk, Yb and Yf subunits. As shown in Figure 5.11, Wistar rat Yk
(a- class) GST is suppressed by acute administration of Dex, ethanol, 2-AAF
and 3-MC. Rat Yb (p-class) is suppressed by acute administration of Dex,
ethanol, 3-MC, carbon tetrachloride, 4-AAP and 4-NQO. In contrast the
negligible level of rat Yf (re-class) GST observed in control liver are induced
to some extent by all the treatment compounds.
Although it has been shown that hepatic mdr levels in rodent tissue
can be regulated, the specific genes affected or their role in drug resistance
is not yet known.
In order to examine a more well defined rodent model, it was decided
to examine the regulation of the hepatic mdr genes of mouse. All three gene
sequences have been published and the involvement of these genes in the
MDR phenotype has been elucidated.
5.3 XENOBIOTIC REGULATION OF MDR GENES IN MOUSE
In order to study mdr gene expression in mouse liver and other
tissues, cDNA probes specific for each gene was necessary. To establish the
specificity of the cDNA probes being used, it was decided to probe liver and
175
pregnant uterus (day 16 of gestation) of C57BL/6 mice.
The mdr 1 mouse gene is known to be localised to the luminal
surface of the secretory epithelium of the uterus during pregnancy (Arceci et
al, 1988). At day 16 of gestation, the mRNA is expressed at it's highest level.
Mdr 2 and 3 are not detected in this tissue.
Croop et al (1989) reported the high level of expression of mdr 2 in
normal mouse liver with lower levels of mdr 3 also expressed in this tissue.
Mdr 1, 2 and 3 mRNA species are 5, 4.5 and 6 kb respectively. The distinct
pattern of tissue-specific expression is shown in Table 5.5.
The actual cDNA probes used in this study are shorter than those
used by Croop, although they cover the same regon. The mdr probe used by
Croop was a 424bp fragment of ?iDR11 whereas a 165 bp fragment of
XDR11 was used in this study. The mdr 3 probe used by Croop was 373 bp
as opposed to 121 bp used in this study. The mdr 2 cDNA probe was the
same length as that used by Croop. The shorter probes distinguish between
the three genes to a greater extent and have been used in hybridisation
experiments to study the sub-chromosomal organisation of the mouse mdr
gene complex and identify the degree of specific gene amplification and
expression in a series of mdr cell lines (Raymond et al, 1990).
The specificity of the probes is shown in Figure 5.12.
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FIGURE 5.12 EXPRESSION OF MDR 1, MDR 2 AND MDR 3 IN
LIVER AND PREGNANT UTERUS
RNA (15 p.g) was prepared from C57BL/6 mouse liver and pregnant uterus (day 16 of












EXPRESSION OF MDR RNA IN VARIOUS MOUSE TISSUES
TISSUE mdr 1 mdr 2 mdr
Pregnant uterus +++++ - -
Uterus - - -
Adrenal ++++ ++ -
Kidney ++ - +
Liver + ++ +
Muscle + ++ +
Spleen + ++ +
Heart ++ ++ ++
Brain + - ++
Lung + - ++
Intestine - - +++
Spinal cord - - ++
Testes - - ++
Stomach - - +
Placenta +++ _ -
Symbols represent expression compared with that of the 3T3 cell line.




+++++ greater than 40 fold
no detectable levels
Adapted from Croop et al (1989).
178
5.3.1 TREATMENT OF C57BL/6 AND DBA 2/N MICE WITH PB, DEX AND
TCPOBOP
8 week old male and fem ale mice of the C57BL/6 and DBA2/N
strains (4 per group) were treated with the xenobiotic compounds
phenobarbital (PB), dexamethasone (Dex) and TCPOBOP in order to
determine whether known P450 inducers also affected mdr gene
expression.
PB (in PBS) and Dex (in corn-oil) were administered i.p. at 80 mg/kg
for three days and 100 mg/kg for four days respectively. Mice were sacrificed
24h after the final dose of treatment. One i.p. injection of TCPOBOP (3
mg/kg, in corn-oil) was administered and the animals killed four days after
treatment. Control animals received corn-oil.
Following sacrifice, the livers were removed, rinsed in cold PBS and
frozen rapidly on dry-ice before storage at -70°C.
The effect of TCPOBOP in DBA2/N male and female mice was
studied over a period of 12 weeks following a single injection of the
compound, as described above. Two mice of each sex were sacrificed at 4
dy, 4, 8 and 12 weeks following treatment.
5.3.2 ANALYSIS OF MOUSE MDR CONTENT FOLLOWING XENOBIOTIC
TREATMENT AND COMPARISON WITH CYTOCHROME P450 AND
GST 7i EXPRESSION
(a) NORTHERN BLOT ANALYSIS
Northern blots were performed on 15pg of hepatic RNA from the mice
treated as described in Section 5.3.1. The RNA was probed with the mouse
mdr 1, 2 and 3 genes previously described. The C57BL/6 mouse RNA was
also examined for Cyp2b and GST k mRNA expression.
The RNA samples were checked for equal loadings by staining with
ethidium bromide and probing with actin. The results of the analysis
following Dex, PB and TCPOBOP treatment of DBA2/N and C57BL/6 mouse
liver are shown in Figures 5.13(a) and 5.14(a) respectively.
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FIGURE 5.13 (a) MDR 1, 2, 3 , GST Pi AND ACTIN
mRNA LEVELS IN DBA2/N TREATED MICE
DBA2/N mice were treated, as described in Section 5.3.1, and the liver RNA (15 jig per
sample) was Northern blotted using mdr 1, mdr 2, mdr 3, glutathione S-transferase n and actin
cDNAs, as described in Section 2.11.
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Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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FIGURE 5.14 (a) MDR 1, 2, 3, Cyp2b1, GST Pi AND ACTIN
mRNA LEVELS IN C57BL/6 TREATED MICE
C57BL/6 mice were treated, as described in Section 5.3.1, and the liver RNA was Northern
blotted using mdr 1, mdr 2, mdr 3, Cyp2b1, glutathione S-transferase n and actin cDNAs, as
described in Section 2.11.
PU pregnant uterus T TCPOBOP-treated
C control M male















Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
MDR 2 ABSORBANCE RATIO FOR DEXAMETHASONE-,
PHENOBARBITAL- AND TCPOBOP-TREATED MICE.
FIGURE 5.13 (b) DBA2/N TREATED MICE
1 2 3 4 5 6 7 8
CON DEX PB TCPOBOP
FIGURE 5.14 (b) C57BL/6 TREATED MICE
5 -i
Mdr 2 absorbance ratio: Ratio of the integrals of the optical densities of hybridisation signals
on Northern blots probed with mdr 2 cDNA compared to actin cDNA.
1, 3, 5 and 7 represent male mice




TCPOBOP 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene
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CALCULATION OF THE ABSORBANCE RATIO (MDR 2
COMPARED TO ACTIN) FOR DBA2/N MICE
TABLE 5.6
DBA2/N MICE - MDR 2 LEVELS NORMALISED TO ACTIN
SEX TREATMENT ACTIN MDR 2 ABSORBANCE
RATIO
M CON 2471 23044 9.33
F CON 3065 18668 6.09
M DEX 4068 14757 3.63
F DEX 5400 14430 2.67
M PB 2783 13666 4.91
F PB 3510 13838 3.94
M TCPOBOP 8750 7384 0.84
F TCPOBOP 10188 10142 0.99
CALCULATION OF THE ABSORBANCE RATIO (
E 5.7 COMPARED TO ACTIN) FOR C57BL/6 MICE
.16 MICE - MDR 2 LEVELS NORMALISED TO ACTIN
SEX TREATMENT ACTIN MDR 2 ABSORBANCE
RATIO
M CON 4038 18573 4.59
F CON 4819 18389 3.82
M DEX 5088 10817 2.13
F DEX 5324 11017 2.07
M PB 6164 14452 2.34
F PB 8279 17049 2.06
M TCPOBOP 6476 2293 0.35
F TCPOBOP 9184 2111 0.23
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The values in columns 1 and 2 represent the integrals of peak areas derived from
densitometry readings, of one representative autoradiograph, using a Joyce Loebl scanner.
Semi-quantitation of the mRNA levels for mdr 2 were obtained by scanning
the blots using a densitometer. The autoradiographs used for scanning were
*
non-saturated.Tables 5.6 and 5.7 show the calculations for the absorbance
ratio of mdr 2 compared to actin, for both strains of mice following the various
treatments. The normalised results for DBA2/N and C57BL/6 are shown as
histograms in Figures 5.13(b) and 5.14(b) respectively.
The RNA from both mouse strains had slightly variable actin levels.
However, after taking these levels into account, the overall results do not
alter.
Mdr 1 could not be detected in control animals of either strain, but
was strongly detected in C57BL/6 pregnant uterine tissue as a mRNA
transcript of 5 kb.
Mdr 2 mRNA was detected at moderate levels in both strains of mice.
Control levels between male and female mice did not vary significantly
indicating no sexual difference in mdr mRNA 2 hepatic expression.
Treatment of both mouse strains with PB and Dex resulted in a slight
suppression of mdr 2 mRNA levels. However, treatment of the mice with a
single dose of TCPOBOP (75pg for a 25g mouse) caused a dramatic
suppression of mdr 2 levels in DBA2/N and C57BL/6 mice .
Mdr 3 mRNA levels were also measured in these samples and the
results were comparible to those for mdr 2. TCPOBOP again caused
substantial suppression of mRNA levels. Dex and PB also caused slight
suppression of mRNA in both strains of mice.
The influence of Dex, PB and TCPOBOP on GST k levels was also
assessed in these samples. Male and female control levels were
significantly different in both strains with females being much lower than
males. In male mice, the n class GST is known to dominate (McLellan and
Hayes, 1987) and expression has been demonstrated to be testosterone-
dependent. Male levels were not induced by Dex, PB and TCPOBOP.
Female mRNA levels were increased by Dex and PB. TCPOBOP caused no
increase in GST k mRNA levels in either species of mouse.
All three treatments induced the level of mouse Cyp 2b mRNA in
C57BL/6 mice (Figure 5.14 (a)). Female mRNA levels were higher than male
levels in each case. TCPOBOP induced both male and female mRNA levels
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to the greatest extent, although female levels were still greater than male.
Figure 5.15 (a) shows the Northern blot of DBA2/N mice sampled over a 12
week period, following a single i.p. injection of TCPOBOP.
Mdr 2, actin and Cyp2c mRNA levels were measured after 4 days, 4,
8 and 12 weeks. Actin levels were essentially equal for all time points.
Control male and female mdr 2 mRNA levels were similar to previous
DBA2/N controls, whereas mRNA levels for both male and female mice
were dramatically suppressed after 4 days following TCPOBOP
administration. Levels remained low even up to 12 weeks. In contrast,
Cyp2c1 mRNA levels rose above control at 4 days and remained high up to
12 weeks. At 12 weeks, both male and female Cyp2c1 mRNA levels were
starting to fall back to control but were still elevated.
Figure 5.15 (b) shows the semi-quantitation of the mdr 2 mRNA levels
after long-term TCPOBOP exposure, after normalising the absorbance ratio
of mdr 2 to actin as calculated in Table 5.8.
TABLE 5.8
LONG-TERM TCPOBOP - MDR 2 LEVELS NORMALISED TO
ACTIN
SEX TREATMENT ACTIN MDR 2 ABSORB RATIO
M CON 4272 15314 3.58
F CON 4387 13107 2.99
M 4 DY TCPOBOP 3242 1697 0.52
F 4 DY TCPOBOP 4012 1443 0.36
M 4 WK TCPOBOP 4785 297 0.06
F 4 WK TCPOBOP 7769 1188 0.15
M 8 WK TCPOBOP 5998 933 0.10
F 8 WK TCPOBOP 6811 290 0.04
M 12 WK TCPOBOP 6298 340 0.05
F 12 WK TCPOBOP 6811 559 0.07
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FIGURE 5.15 (a) EXPRESSION OF MDR 2, ACTIN AND Cyp2c1
AT 4 DAYS, 4, 8 AND 12 WEEKS FOLLOWING A SINGLE
INJECTION OF TCPOBOP
DBA2/N male and female mice were treated with a single injection (3 mg/kg) of TCPOBOP.
RNA was extracted from the mouse livers at various time points and Northern blotted using





4 D 4 days following treatment
4W 4 weeks following treatment
8 W 8 weeks following treatment
12W 12 weeks following treatment
mdr 2
4D 4W 8W 12W






Livers from each treatment group (2 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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FIGURE 5.15 (b) SUPPRESSION OF MDR 2 LEVELS UP TO
12 WEEKS WITH TCPOBOP
Mdr 2 absorbance ratio: Ratio of the integrals of the optical densities of hybridisation signals






















1, 3, 5 and 7 represent male mice




4dy 4 days following 3 mg/kg TCPOBOP
4/8/12 wk 4/8/12 weeks following treatment
(b) IMMUNOBLOTTING ANALYSIS
Microsomes were prepared from male and female mouse Dex, PB
and TCPOBOP treated liver as well as control. Microsomal protein (15 fig)
was immuno-blotted with antibodies against Cypla, Cyp2a, Cyp2c, Cyp3a
and Cyp4a. The analysis was performed to verify that the compounds had
induced the various cytochrome P450 enzymes as expected and also to
determine whether or not P-glycoprotein is coordinately regulated along with
them. The results are shown in Figure 5.16.
The control male and female liver expressed very low levels of all
cytochromes compared to treated animals; Cyp2a1 and Cyp2c showed the
highest control levels. PB induced all the cytochrome P450 subfamilies, but
induced male levels to a greater extent that female for Cyp3a1 and Cyp4a,
whereas Cyp1a2 , Cyp2a1 and Cyp2c were induced to an equivalent extent
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FIGURE 5.16 EXPRESSION OF VARIOUS CYTOCHROME
P450S IN DBA2/N MICE TREATED WITH PB, DEX AND TCPOBOP
DBA2/N mice were treated, as described in Section 5.3.1, and microsomal liver protein
Western blotted using polyclonal antibodies against cytochrome P450 isozymes, as
described in Section 2.6.2.
M male F female
con control PB phenobarbital
dex dexamethasone
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Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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by PB in males and females.
Dex, a syntheticglucocorticoid, induced all the cytochrome P450s
examined in the male and female livers with Cyp3a1 being induced to the
greatest extent.
TCPOBOP also induced females to a greater extent than males. This
difference was apparent in all five gene families analysed.
Dex and TCPOBOP showed a similar pattern of induction but
TCPOBOP induced female Cyp2a1 and Cyp2c to a greater extent than Dex
whereas dex induced Cyp3a1 to a slightly greater extent. Dex induced male
liver Cyp3a1 levels to a great extent whereas TCPOBOP did not. Both dex
and TCPOBOP induced Cyp4a to the same high level in female and to a
lower level in males.
TCPOBOP itself is highly hydrophobic and accumulates primarily in
adipose tissue and to a lesser extent in the liver (Poland et al, 1980). It is
metabolised slowly and hence exerts an effect over a long period of time
during which time it is released from the fatty tissue of the animal.
5.3.3 TREATMENT OF C57/ICRF AND DBA2/N MICE WITH OTHER P450
SUBSTRATES
8 week old C57BL6 mice (4 per group) were treated with the
compounds shown in Table 5.9. All animals were sacrificed by cervical
dislocation the day after their last dose of treatment, except mice treated with
TCPOBOP which were left for four days after a single dose of the compound.
Control mice were administered with corn-oil.
Immediately following sacrifice, the livers and kidneys were removed,
washed briefly in PBS and snap-frozen on card-ice. The tissues were then
stored frozen at -70°C until RNA, microsomal and cytosolic protein was
prepared from them.
DBA2/N male mice (4 per group) were also treated with 3-MC and




COMPOUNDS AND INDUCTION PROTOCOL USED FOR MOUSE
TREATMENTS (SECTION 5.3.3)
COMPOUND VECTOR ROUTE DOSE DAYS
Control corn-oil 'P - 3
Dexamethasone corn-oil ip 10Omg/kg 3
3-Methylcholanthrene corn-oil ip 200 mg/kg 3
Pyrazole PBS ip 200 mg/kg 3
Diethylnitrosamine PBS ip 200 mg/kg 3
P-Naphthoflavone corn-oil ip 80 mg/kg 3
Phenobarbitone PBS ip 80 mg/kg 3
2-Acetylaminofluorene corn-oil ig 50 mg/kg 4
TCPOBOP corn-oil ip 3 mg/kg 1
Aflatoxin B-| corn-oil ip 0.2 mg/kg 1




5.3.4 ANALYSIS OF MDR, CYTOCHROME P450 AND GST EXPRESSION
FOLLOWING TREATMENT WITH A RANGE OF P450
SUBSTRATES
From each treatment group described, total RNA was extracted from
both liver and kidney. RNA loading for Northern blots was assessed by
ethidium bromide staining and probing with actin.
Both cytosolic and microsomal fractions were also extracted from the
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mouse livers. 12% SDS PAGE gels were run on these fractions to check for
equal protein loading. Cytosolic and microsomal proteins were
electrophoresed using 12% and 9% gels respectively, and immunoblotted
for GST and cytochrome P450 isozymes.
(a) NORTHERN BLOT ANALYSIS
Mdr 1, 2 and GST k mRNA levels were assessed in each kidney and
liver sample (Figures 5.17, 5.18 respectively) using the probes previously
described in Section 2.7.
Actin levels were high in both the liver and kidney of mice treated with
DEN. PB and TCPOBOP increased actin levels slightly in mouse liver. Dex,
PB and TCPOBOP increased actin levels in C57BL/6 mouse kidney. PB is
known to cause massive proliferation of liver endoplasmic reticulum
membrane (Remmer and Merker, 1963). TCPOBOP has similar effects on
liver proliferation (Poland et al, 1980). Therefore, it is not surprising that
these compounds affect cell cycle regulated genes such as actin. DEN
causes increases in actin levels probably due to it's necrotic effects on liver
tissue, as discussed in Section 5.2.4(a).
Interestingly, PB did not cause an increase in the actin levels of DBA
mice treated with the compound.
Mdr 1 mRNA levels were measured in both kidney and liver. Kidney
has been previously reported to express mdr 1 to a moderate level (Croop
et al, 1989) using a specific 424 bp probe. Kidney mRNA levels in Croop's
study were much smaller than those detected in the pregnant uterus tissue,
which shows the highest expression of the mdr 1 gene.
Figure 5.17 shows the results obtained after probing the kidney RNA
from normal and treated mice with a 165 bp mdr 1 specific probe. Mdr1
mRNA in pregnant uterus control hybridised strongly whereas mdr 1 could
only be detected in the DEN treated mouse kidney RNA sample. Figure 5.19
shows a longer exposure of the DEN treated kidney mdr 1 mRNA expression
level. This experiment was repeated and blots washed at both 0.2 x and 2 x
SSC to determine whether or not stringency of washing would effect the
result. However, even at a lower stringency, the result was still negative for
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FIGURE 5.17 LEVELS OF EXPRESSION OF ACTIN AND MDR
1 mRNA IN C57BL/6 MOUSE KIDNEY TREATED WITH VARIOUS
COMPOUNDS
C57BL/6 male mice were treated, as described in Section 5.3.3, and kidney RNA (15 pg) was














Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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FIGURE 5.18 LEVELS OF EXPRESSION OF MDR 1, MDR 2,
GST Pi AND ACTIN mRNA IN C57BL MOUSE LIVER TREATED
WITH VARIOUS COMPOUNDS
C57BL/6 male mice were treated, as described in Section 5.3.3, and liver RNA (15 pg) was
Northern blotted using mdr 1, mdr 2, glutathione S-transferase n and actin cDNAs.
PREG UTER pregnant uterus (3-NF (3-napthoflavone
CON control PB phenobarbital
DEX dexamethasone 2-AAF 2- acetylaminofluorene
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Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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all other kidney samples. The samples appeared intact on ethidium stained
gels and after probing with actin. It was concluded that the kidney tissue from
these particular C57BL/6 mice contained extremely low levels of mdr 1
which could not be detected using such a system of Northern blotting.
Extraction of mRNA instead of total RNA from the kidney samples, or using a
longer probe might allow for better detection of the gene transcript.
Mdr 1 could not be detected in normal C57BL/6 mouse liver as
shown in Figure 5.18.
DEN treated mice did however induce the expression of mdr 1 in the
liver. Figure 5.19 shows the relative levels of expression of mdr 1 in the DEN
treated liver and kidney tissues are equivalent. Such induction may be
similar to the increase in mdr genes seen in rat liver treated with DEN and
may be due to the necrotic effects of DEN in the tissue.
PB treated mice demonstrated decreased mdr 2
transcript levels. Following actin adjustment, Dex, 3-MC, pyrazole, DEN,
TCPOBOP, 2-AAF, (3-NF and AFB-j treated C57BL/6 mouse livers had
equivalent levels of mdr 2 mRNA as control.
Burt and Thorgeirsson (1988) showed that both 2-AAF and AFB-|
induced the expression of mdr in C57BL/6 mouse liver, using the human mdr
cDNA probe, pADR-1. No mdr transcript was detected in the normal mouse
liver control. In this study, a 4.5 kb transcript was detected. Croop et al
(1989) described mdr 2 mRNA in mouse liver as being 4.5 kb. The mdr 2
transcript was found to be the major mdr RNA species in normal mouse liver.
From these studies, it is uncertain which mdr transcript was induced by 2-
AAF and AFB-| by Burt and Thorgeirsson (1988) since the probe was not
gene specific. However, their results for control mice do not suggest that the
transcript was mdr 2.
Figure 5.20 contrasts the results found with C57BL6 and DBA2/N
mice following treatment with 3-MC and PB. The actin levels following
treatment with PB were elevated in C57BL/6 mouse liver whereas no such
increase was found in the DBA2/N liver. All other actin mRNA levels were
approximately equivalent. Control levels for C57BL/6 and DBA2/N for mdr 2
mRNA were equivalent. PB treatment caused no decrease in mdr 2 mRNA
levels in DBA2/N mouse liver whereas C57BL liver showed a decline in the
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FIGURE 5.19 LEVELS OF MDR 1 EXPRESSION IN MALE
C57BL/6 LIVER AND KIDNEY TREATED WITH
DIETHYLNITROSAMINE, 2-ACETYLAMINOFLUORENE AND
AFLATOXIN B-,
Male C57BL/6 mice were treated, as described in Section 5.33, and liver RNA was prepared
from both liver and kidney. Northern blotting (15 pg samples) was performed using the mdr 1
cDNA, as outlined in Section 2.11.
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Livers and kidneys from each treatment group (4 mice per group) were pooled. This blot
represents the results obtained from one experiment.
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FIGURE 5.20 LEVELS OF ACTIN, MDR 2 AND GST Pi mRNA
IN C57BL/6 AND DBA2/N MOUSE LIVER
TREATED WITH 3-MC AND PB
Male C57BL/6 and DBA2/N mice were treated, as described in Section 5.3.3. Mice of both
species, treated with 3-methylcholanthrene and phenobarbital, were Northern blotted (15 pg





Livers from each treatment group (4 mice per group) were pooled. This blot represents the
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expression of this transcript. 3-MC caused a slight decline in the level of mdr
2 mRNA for DBA2/N mouse liver, whereas no change occurred in the
C57BL/6 mouse. GST n mRNA levels were also measured in these mouse
strains.
The level of GST k mRNA was higher in C57BL mice than DNA2/N
mice. PB induced GST k mRNA slightly in DBA2/N mice.
Figure 5.18 also shows the results of a range of treatments on GST n
mRNA levels.
DEN, J3-NF and PB caused a slight decrease in the mRNA levels in
C57BL6 mice; all other GST n levels were unaffected by the treatments.
(b) IMMUNOBLOTTING ANALYSIS
Immunoblotting of microsomal protein (15pg) and cytosolic protein
(30|ig) was performed on the mouse livers using cytochrome P450 and GST
antibodies respectively. Rat CYP4A1 and CYP4A2/3 specific monoclonals
were also availabe for use. CYP4A1 shares -65% sequence similarity with
CYP4A2 and CYP4A3. Polyclonal antibodies used against CYP4A do not
differentiate between CYP4A1 (51.5 kD), CYP4A2 (51.1 kD) and CYP4A3
(52 kD).
Monoclonal antibodies were raised against two different CYP4A
preparations from clofibrate treated male Sprague-Dawley rat liver.
Immunoglobulins purified from the clones were characterised by isoelectric
focusing and immunoblotting and were found to cross-react with the
antigens used for immunisation (Henderson et al, 1991).
The results of the treatments on both C57BL/6 and DBA2/N mouse
liver cytochrome P450 protein levels is shown in Figure 5.21 and
summarised in Table 5.10.
The control level of C57BL/6 protein was found to be higher than
DBA2/N for each cytochrome P450 family examined. Both intra- and inter¬
species variations in the activities and enzyme expression for the P450s has
been found (Gonzalez et al, 1989).
C57BL/6 and DBA2/N mouse livers show a difference in response to
the CYP1A1 inducer 3-MC, which indicates that the C57BL6 mouse strain
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FIGURE 5.21 LEVELS OF EXPRESSION OF VARIOUS
CYTOCHROME P450S IN C57BL/6 MICE FOLLOWING
TREATMENT WITH INDUCING COMPOUNDS
Mice were treated, as described in Section 5.3.3, and liver microsomes prepared following treatment.
Microsomes were Western blottted (15 pg) using P450 polyclonal antibodies, as outlined in Section
2.6.2.
CON control PYZ pyrazole
DEX dexamethasone DEN diethylnitrosamine
3-MC 3-methylcholanthrene (3-NF (3-napthoflavone
TCBOP 1, 4-bis [2-(3,5-dichloropyridyloxy)] benzene




















































































Livers from each mouse strain (4 mice per strain) were pooled. This blot represents the results
obtained from one experiment.





















































































































has an intact Ah receptor whereas the 'non-responsive' DBA2/N mouse has
a much lower number of cytosolic Ah receptors, a qualitative defect in
receptor ligand binding or both (Okey et al, 1980). C57BL/6 mice showed a
high induction of Cyp1a-1 whereas DBA2/N showed no such elevation in
Cyp1a-1 protein levels. (3-NF also induced C57BL/6 Cyp1a-1 protein
to a high level. Both 3-MC and (3-NF operate via the Ah locus (for a review
see Eisen et al, 1983). PB induced both strains to a moderate extent. This
compound does not operate via the Ah locus but all PB-like compounds are
hypothesised to bind a common receptor.
DEN suppressed the expression of all the cytochrome P450 proteins
examined in C57BL/6 mouse liver, with the notable exception of Cyp2b.
Cyp2a was highly induced by 3-MC and moderately by (3-NF. PB also
induced Cyp2a in both mouse species to a moderate extent.
Both Dex and PB treated livers showed highly increased Cyp2b
protein. Dex is known to stabilise the CYP2B1 protein in rat (Simmons et al,
1987). TCPOBOP, the PB-like ligand, also highly induced Cyp2b protein
levels. 2-AAF and AFB-) are known to be weak inducers of cytochrome P450
gene families 1 and 2 (Astrom et al, 1986; Ishii et al, 1986). These
compounds induced Cyp2b slightly above control protein levels.
Cyp3a was moderately induced by Dex in this study. This has been
described previously by other investigators for the rat (Simmons et al, 1987).
PB increased DBA2/N Cyp3a expression levels to a much greater extent
than C57BL/6. TCPOBOP showed elevated protein levels to a similar extent
as Dex treatment in C57BL/6 mice and PB treatment in DBA2/N mice. In
mouse, TCPOBOP and Dex both induce Cyp2b and Cyp3a to similar
extents. PB also induces Cyp2b but fails to affect Cyp3a in C57BL/6 mice.
Both species of PB treated mice showed increased protein levels for the
Cyp4a family using the polyclonal antibody. However, using monoclonal
antibodies it was shown that the mouse orthologue of the rat CYP4A1 was
induced to a greater level than the mouse orthologue of the rat CYP4A2/3.
DEN decreased the levels of the mouse orthologues of the ratCYP4A1 and
CYP4A2/3 in C57BL/6 mice.
In addition to measuring the P450 protein levels, GST Ya-|, Ya2,Ya3,
Yb-| and Yf protein levels were assessed, as shown in Figure 5.22 and
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FIGURE 5.22 INDUCIBILITY OF GST ISOZYMES IN C57BL/6
AND DBA2/N MICE BY VARIOUS COMPOUNDS
Mice were treated, as described in Section 5.3.3, and liver cytosols prepared following
treatment. Microsomes were Western blottted (20 pg for Ya1, Ya2 and Ya3; 5 pg for Yb and Yf)
using glutathione S-transferase polyclonal antibodies, as outlined in Section 2.6.2.
CON control DEN diethylnitrosamine AFB1 aflatoxin B1
DEX dexamethasone (3-NF p-napthoflavone STD standard
3-MC 3-methylcholanthrene PB phenobarbital C C57/6
PYZ pyrazole 2-AAF 2-acetylaminofluorene D DBA2/N
TCPOBOP 1, 4-bis [2-(3,5-dichloropyridyloxy)] benzene
C57/BL6
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Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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summarised in Table 5.10.
Both Ya2 and Ya0 protein subunits were present at much higher
levels in DBA2/N mice compared to C57BL/6. No treatment caused
induction in either of these subunits. Ya-j control levels were equivalent in
C57BL6 and DBA2/N mice. 3-MC and PB caused an increase in the DBA2/N
Ya-| subunit protein. Pyrazole and, to a lesser extent,TCPOBOP treatment of
C57BL/6 mice elevated Ya-j protein levels. GST Yb-| C57BL/6 protein levels
remained unchanged following various treatments, whereas 3-MC and PB
treated DBA2/N mice exhibited elevated levels of Yb-| and Yf GST.
5.4 ANTICANCER DRUGS AND CYP3A SUBSTRATES AS
REGULATORS OF MDR GENES IN MICE
5.4.1 TREATMENT OF C57BU6 MICE WITH ANTI-CANCER DRUGS AND
CYP3A SUBSTRATES
8 week old male C57BL mice (4 per group) were treated with the
compounds listed in Table 5.11. Figure 5.23 shows the structures of these
compounds and also includes the structure of butylated hydroxyanisole
(BHA).
All compounds were administered intraperitoneal^ except
progesterone which was given sub-cutaneously. Control mice were injected
with corn-oil.
All mice were sacrificed 24h following the last dose of treatment.
Livers, lungs and kidneys were removed, washed briefly in PBS and snap-
frozen on card-ice. Tissues were stored at -70°C until required. RNA was
extracted from the liver and kidney. Microsomal and cytosolic protein was
fractionated from liver, lung and kidney.
Liver RNA samples were probed using mdr 1, mdr 2 , GST k and
actin cDNAs. Kidney RNA was probed with mdr 1. Samples were assessed
for equal loading using ethidium bromide staining and actin level
measurements. Cytosolic and microsomal fractions from liver, lung and
kidney tissues were immunoblotted against GST and cytochrome P450
antibodies respectively.
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The compounds outlined in Table 5.11 can be broadly divided into
two groups. Triacetyloleandomycin (TAO), rifampicin (RIF), erythromycin
(ERY), clotrimazole (CLOT) and progesterone (PROG) are all Cyp3a
substrates whereas adriamycin (ADR), etoposide (VP-16), vincristine (VINC)
and vinblastine (VINB) are all used as anti-cancer drugs in clinical medicine.
It is likely that multiple Cyp3a proteins are expressed in liver, as
suggested by cDNA cloning (Beaune et al, 1986a; Gonzalez et al, 1988;
Molowa etal, 1986). CYP3A is expressed in human fetal liver to significant
levels (Kitada etal, 1985). CYP3 expression varies in human liver which
TABLE 5.11
COMPOUNDS USED IN SECTION 5.4.1 AND INDUCTION
PROTOCOL
COMPOUNDS VECTOR ROUTE DOSE DAYS
Control corn-oil ip 3
T riacetyloleanomycin corn-oil ip 500 mg/kg 3
Rifampicin corn-oil ip 200 mg/kg 3
Erythromycin corn-oil ip 500 mg/kg 3
Clotrimazole corn-oil ip 50 mg/kg 3
Adriamycin PBS ip 4 mg/kg 3
VP-16 (Etoposide) corn-oil ip 12 mg/kg 3
Vincristine corn-oil ip 0.3 mg/kg 3
Vinblastine corn-oil ip 3 mg/kg 3
Progesterone corn-oil sc 1 mg/kg 11
ip intraperitoneal
sc sub-cutaneous
could have important clinical implications since CYP3A metabolises a
variety of drugs including the calcium channel blocker nifedipine (Gonzalez
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FIGURE 5.23 STRUCTURES OF THE P450 SUBSTRATES
AND ANTI-CANCER DRUGS USED TO TREAT C57BL/6 MICE
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et al, 1988), progesterone (Schwab et al, 1988), the immunosuppressant
cyclosporin (Kronbach et al, 1988) and the antibiotic erythromycin (Watkins
et al, 1985). It is extremely interesting to note that all of these CYP3A
substrates are also substrates for P-gp.
TAO is a macrolide antibiotic and an inducer of Cyp3a1 (Wrighton et
al, 1985). The TAO metabolite binds strongly to the reduced iron of the haem
prosthetic group of this cytochrome resulting in the formation of a persistant
metabolic intermediate complex (Pessayre et al, 1981). The rabbit CYP3A6
mRNA is stabilised by TAO (Dalet et al, 1986) as are the rat CYP3A1 and
CYPpf3A2 proteins (Watkins et al, 1986). Dex however transcriptionally
activates the rat CYP3A1 gene (Simmons et al, 1987).
CYP3A6 catalyses erythromycin N-demethylation and is induced
significantly by rifampicin (Murray and Reddy, 1990). Clotrimazole can also
induce the expression of CYP3A1.
5.4.2 ANALYSIS OF MOUSE MDR, CYTOCHROME P450 AND GST
EXPRESSION FOLLOWING TREATMENT WITH ANTI-CANCER
DRUGS AND CYP3A SUBSTRATES
Treated mouse liver RNA samples (15pg), including a C57BL/6
mouse pregnant uterus control for mdr 1, were blotted. Liver, kidney and
lung microsomes were immunoblotted using polyclonal antibodies raised
against rat CYP2A1, CYP2B1, CYP2C3, CYP2E1, CYP3A1 and CYP4A.
Monoclonal antibodies raised against rat CYP4A1 and CYP 4A2/A3 were
also used to immunoblot the microsomal samples. Liver, kidney and lung
cytosolic protein was immunoblotted using polyclonal antibodies against
Ya^, Ya2, Ya0, Yb-| and Yf GST subunit proteins.
Yf is the most highly expressed GST subunit in male mouse liver and
Yb-| is also highly expressed.
(a) NORTHERN BLOT ANALYSIS
The results obtained following Northern analysis on the liver RNA
samples of treated mouse livers is shown in Figure 5.24.
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FIGURE 5.24 LEVELS OF EXPRESSION OF MDR 1, MDR 2,
GLUTATHIONE S-TRANSFERASE Pi AND ACTIN mRNA IN MALE
C57BL/6 LIVER FOLLOWING TREATMENT WITH ANTI-CANCER
DRUGS AND CYP3A SUBSTRATES
Mice were treated, as described in Section 5.4.1, and RNA was prepared from the liver
following treatment. Northern blotting (15 pg of each sample) was performed, as described in
Section 2.11, using mdr 1, mdr 2, glutathione S-transferase Pi and actin cDNA probes.
PREG UT Pregnant uterus ADR adriamycin
CON control VP 16 etoposide
TAO triacetyloleandomycin VINC vincristine
RIF rifampicin VINB vinblastine













Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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Actin levels were approximately equivalent in all the samples.The mdr 1
cDNA detected a strongly hybridising 5 kb transcript in the pregnant uterus
control but detected no other transcript in control or treated mice.
The mdr 2 cDNA probe strongly detected a 4.5 kb transcript in both control
and treated mice. Rifampicin, etoposide (VP-16) and vincristine substantially
induced mdr 2 mRNA levels to above control levels and progesterone
increased mdr 2 mRNA slightly. No other Cyp3a substrates or anti-cancer
drugs examined in this study altered mdr 2 mRNA levels. GST k mRNA
levels were suppressed in both erythromycin and vinblastine treated mice .
Vincristine treated mice had normal GST n expression. The difference in the
expression of mdr 2 and GST n in vinblastine and vincristine treated mice
was somewhat surprising since these compounds are remarkable similar in
structure (Figure 5.23). Progesterone only slightly induced mdr 2 mRNA
levels although it is a known substrate for rat CYP3A and mdr 1 (Waxman et
at, 1988; Yang et at, 1989).
From the results shown in Figure 5.24, it is evident that progesterone
does not induce the expression of mdr 1 mRNA in mouse liver although it
has been shown to induce the gene to high levels in mouse uterus.
VP-16 is a DNA topo II inhibitor and causes an increase in mdr 2
expression. Since topo II is a common drug target, down-regulation in
expression of topo II and a concomitant rise in mdr expression could protect
the cell against the toxic effects of these drugs. Chin et aI (1990) found a
coordinated response of mdr and topo II was found in rat and mouse cell
lines challenged with several anti-tumour drugs. Agents that caused an
elevation of mdr RNA levels promoted a rapid decline in topo II RNA levels.
The lack of regulation of mdr 2 mRNA levels by
triacetyloleandomycin, erythromycin and clotrimazole indicates that not all
Cyp3a substrates act as regulators of mdr 2 mRNA expression.
(b) IMMUNOBLOTTING ANALYSIS
To assess the induction characteristics of the compounds used in this
study, the microsomes and cytosols prepared from liver were probed with
cytochrome P450 and GST antibodies respectively.
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FIGURE 5.25 INDUCTION OF CYTOCHROME P450
ISOZYMES IN C57BL/6 MOUSE LIVER FOLLOWING TREATMENT
WITH VARIOUS COMPOUNDS
Male C57BL/6 mice were treated, as described in Section 5.4.1, and liver microsomes were prepared.
Western blotting (30 pg per sample) was performed, as described in Section 2.6.2, using P450
polyclonal antibodies.
CON control ADR adriamycin
TAO triacety (oleandomycin VP 16 etoposide
RIF rifampicin VINC vincristine
ERY erythromycin VINB vinblastine
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The standards are purified proteins for each respective isozyme.
Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
FIGURE 5.26 INDUCTION OF GST ISOZYMES IN C57BL/6
MOUSE LIVER FOLLOWING TREATMENT WITH VARIOUS
COMPOUNDS
Male C57BL/6 mice were treated, as described in Section 5.4.1, and liver cytosols were prepared.
Western blotting (20 pg for Ya-| and Ya2; 5 p.g for Yb-| and Yf) was performed, as described in Section
2.6.2, using glutathione S-transferase polyclonal antibodies.
CON control ADR adriamycin
TAO triacetyloleandomycin VP 16 etoposide
RIF rifampicin VINC vincristine
ERY erythromycin VINB vinblastine
CLOT clotrimazole PROG progesterone
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Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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As shown in Figure 5.25, triacetyloleandomycin, rifampicin, erythromycin,
clotrimazole and progesterone all induced the mouse orthologue of rat
CYP3A1 above control levels,. The anti-cancer drugs did not induce
CYP3A1. Clotrimazole and progesterone induced the mouse orthologue of
rat CYP2A1, CYP2B1 and CYP4A above control levels. Vincristine and
vinblastine varied slightly in their induction pattern. Vinblastine induced th
emouse orthologue of rat CYP2A1, CYP2E1 and CYP4A2/A3, whereas
vincristine only induced CYP4A2/A3. Metabolism of these compounds would
therefore appear to vary in mouse liver and hence differences in the
regulation of mdr genes by these compounds might be expected. As a
general observation, the anti-cancer drugs induced the mouse ortholgue of
rat CYP4A most significantly in mouse liver. The results of the GST
immunoblotting is shown in Figure 5.26.
Progesterone caused dramatic induction of Ya-| GST mRNA levels as
well as a moderate increase in the Yb-j GST mRNA. The other compounds
had little effect on GST mRNA levels in the mouse liver.
To assess the effects of these compounds in extra-hepatic tissue,
both kidney and lung tissues from the treated mice were probed with the
P450 and GST antibodies.
As shown in Figure 5.27, mouse kidney orthologues of rat CYP2B1,
CYP4A1 and GST isozymes Ya-|, Ya3, Yf and Yb-|were largely unaffected by
these compounds apart from the slight induction of CYP2B1 by rifampicin
and clotrimazole. The CYP4A1 orthologue did not appear to be induced by
the anti-cancer drugs to any extent in mouse kidney.
All isozymes measured remained unchanged by treatment in mouse
lung (Figure 5.28).
Table 5.12 summarises the immunoblotting results for the P450 and
GST protein expression in mouse liver.
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FIGURE 5.27 INDUCTION OF CYTOCHROME P450s AND
GST ISOZYMES IN MALE C57BL MOUSE KIDNEY FOLLOWING
TREATMENT WITH VARIOUS COMPOUNDS
Male C57BL/6 mice were treated, as described in Section 5.4.1, and both microsomes and
cytosols were prepared from the kidney. Western blotting (30 pg of microsomal and cytoslic
protein) was performed, as described in Section 2.6.2, using P450 and glutathione S-
transferase polyclonal antibodies.
CON control ADR adriamycin
TAO triacetyloleandomycin VP 16 etoposide
RIF rifampicin VINC vincristine
ERY erythromycin VINB vinblastine






























Kidneys from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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FIGURE 5.28 INDUCTION OF CYTOCHROME P450s
AND GST ISOZYMES IN MALE C57BL/6 MOUSE LUNG
FOLLOWING TREATMENT WITH VARIOUS COMPOUNDS
Male C57BL/6 mice were treated, as described in Section 5.4.1, and both microsomes and
cytosois were prepared from the lungs. Western blotting (50 pg of microsomal and cytoslic
protein) was performed, as described in Section 2.6.2, using P450 and glutathione S-
transferase polyclonal antibodies.
CON control ADR adriamycin
TAO triacetyloleandomycin VP 16 etoposide
RIF rifampicin VINC vincristine
ERY erythromycin VINB vinblastine
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Lungs from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
212










































































5.5 EFFECT OF BHA ON MDR EXPRESSION IN MOUSE LIVER
5.5.1 TREATMENT OF BALB/C MICE WITH BUTYLATED
HYDROXYANISOLE (BHA)
8 week old female Balb/c mice were fed the monofunctional anti-
carcinogen BHA (7.5 g/kg) for 14 days, as described by Pearson et al
(1988). Following treatment, both RNA and cytosolic protein were prepared
from the snap-frozen liver tissue. Control mice were fed a standard
laboratory chow diet. Untreated DBA2/N mouse RNA was included in the
Northern blot analysis to act as a control for the mdr 2 probe.
BHA is a phenolic anti-oxidant and is known to activate the
transcription of the GST Ya subunit gene, through the antioxidant responsive
element (ARE) (Rushmore and Pickett, 1990).
5.5.2 ANALYSIS OF MDR 2 AND GST EXPRESSION IN MOUSE LIVER
(a) NORTHERN BLOT ANALYSIS
RNA (15pg) from Balb/c control and BHA treated mouse liver as well
as control DBA2/N mouse liver was probed with actin and mdr 2 cDNAs.
RNA amounts were standardised using ethidium bromide staining.
As shown in Figure 5.29, actin levels were found to be approximately
equivalent, although the BHA treated mice were slightly higher.
After adjustment for this slight discrepancy in actin levels, mdr 2
mRNA for BHA treated Balb/c mice liver was still found to be induced two
fold over the control.
Control DBA2/N mice had far greater expression of mdr 2 mRNA than
control Balb/c mice. Such a difference will be further discussed in Chapter 6.
GST a protein levels in BHA treated mice were much higher than
controls as expected. GST n protein levels were also slightly increased by
BHA treatment.
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FIGURE 5.29 LEVELS OF ACTIN AND MDR 2 mRNA AND
ALPHA AND PI GST ISOZYME EXPRESSION IN BHA TREATED
BALB/C MICE
Male C57BL/6 mice were treated, as described in Section 5.5.1, and hepatic RNA and
cytosolic protein prepared following sacrifice. Northern blotting (15 pg RNA per sample)was
performed, as outlined in Section 2.11, using mdr 2 and actin cDNA probes. Western blotting
(20 pg of protein for alpha; 5 pg of protein for pi) was performed, as outlined in Section 2.6.2,
































Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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5.6 SUMMARY OF RESULTS AND DISCUSSION
From previous studies on rat and mouse, it appeared that both rodent
groups respond to xenobiotics by inducing the expression of mdr genes
(Burt and Thorgeirsson, 1988).
The compounds chosen to study the inducibility of mdr levels in rat,
as shown in Table 5.1, were grouped into P450 inducers, hepatotoxins and
carcinogens. The compounds do not strictly adhere to these groupings, for
example 2-AAF is both a hepatotoxin and hepatocarcinogen. Much is
already known about the effects of these compounds on P450 and GST
expression and their mechanism of action.
3-MC is a classical inducer of a major xenobiotic regulated P450
family. Among the enzymes actively induced by 3-MC, is aryl hydrocarbon
hydroxylase (AHH) activity (Conney et al, 1956). The mechanism of 3-MC
induction of AHH activity was found to be under the control of the Ah locus or
TCDD receptor. Poland et al (1986) synthesised a specific photoaffinity
ligand that binds to the TCDD receptor and showed that it has a molecular
mass of 95-126 kD (Poland and Glover, 1987). An extensive review of this
receptor has been published by Whitlock (1987).
The regulatory pathway by which 3-MC and other polyaromatic
hydrocarbons (PAHs) affect the expression of specific genes has been well
documented (Eisen et al, 1983). A possible model for regulation of CYP1A1
gene expression by the Ah locus might be as follows. PAHs form a ligand
complex with the Ah receptor which is translocated to the nucleus and
interacts with the xenobiotic responsive element (XRE) leading to
transcriptional activation of the P450 gene. The XRE core sequence,
5' - T - GCGTG - 3'
3' - A - CGCAC - 5'
is found in multiple copies of the 5' flanking region of the CYP1A1 structural
gene (Whitlock, 1987). For the GST Ya gene, two regions of the 5' flanking
sequence have regulatory elements involved in the regulation of gene
expression by poly-aromatic compounds (Rushmore et al, 1990; Paulson et
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at, 1990). One of the regions is identical to the consensus sequence shown
above but the second region has no identity to such a sequence and is
responive to p-NF and 3-MC as well as contributing to the maximal basal
level of expression of the Ya subunit gene. This element is also responsive
to phenolic anti-oxidants in cells that lack functional Ah receptors, and is
known as the antioxidant responsive element (ARE). However, response of
this element to p-NF requires a functional Ah receptor and functional
CYP1A1 protein (Rushmore and Pickett, 1990).
Dexamethasone induces the steroid inducible CYP3A1 gene in a
non-classical glucocorticoid manner. Either such activation depends on
other factors or differences exist between classical glucocorticoid-regulated
genes and CYP3A1 in their affinity for receptor ligand binding to cis-acting
DNA control elements.
Araclor induces cytochromes in a manner similar to PB. PB induces
CYP2B1, CYP2B2 and also CYP3A1. Data regarding the specific PB
receptors or cis-acting DNA sequence elements in this induction process are
lacking. The PB-like ligand, TCPOBOP, is 660 fold more potent than PB as
an inducer in mice but is ineffective in rats (Poland et al, 1981).
Such P450 inducing agents as discussed above were studied to
examine their effects on rat mdr levels in order to examine whether common
induction of any P450 or GST genes occurs in association with the mdr
genes. Burt and Thorgeirsson (1988) suggested that induction of rat mdr
genes and P450 1 and 2 gene families by these compounds represent a
coordinated response to harmful xenobiotics in the rat liver regulated
through the Ah locus. Compounds known to regulate expression via the Ah
locus,were administered to rats in order to clarify this hypothesis.
3-methylcholanthrene and p-NF both failed to induce the levels of
Wistar rat mdr mRNA. Also in Fischer rats, 3-MC caused no increase in mdr
mRNA above control values. In both strains of rat, 2-AAF and AFB-j did
however induce mdr mRNA. 2-AAF induction has not been shown to be
mediated via the cytoplasmic Ah receptor. Receptor mediation has been
suggested as a mechanism for AFB-] induction but convincing results to
prove such a mechanism are still lacking.
From these results, it is doubtful whether the Ah receptor is involved
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in mdr induction. However, a receptor or class of receptors, similar to the Ah
receptor, may regulate xenobiotic mediated induction of mdr expression.
Such receptors may activate genes in order to protect the cell from
xenobiotic insult.
The induction of rat mdr by 2-AAF is known to occur by increased
gene transcription in rats exposed to the compound in vivo from studies
done using nuclear run-on assays.
Whether or not AFB^ and DEN cause increased transcription or
stabilisation of the message is not known.
Marino et al (1990) reported that increased expression of the mdr
gene in regenerating rat liver appears to be regulated by a post-
transcriptional event such as message stabilisation. The mdr 1 gene is
normally a rapidly turned over message, with a half life of 30-60 minutes
(Chin et al, 1990). The 3' non-coding region of the gene contains the Shaw
and Kamen motif ATTTA, is AT rich and is capable of forming stem and loop
structures.
Therefore both increased transcription and message stabilisation
may contribute to the increase in mdr 1 mRNA in treated rat livers.
Both 2-AAF and AFB-) cause an increase in P-gp protein as assayed
using the C219 monoclonal antibody.
C219 reacts with an epitope on the cytoplasmic face of P-gp (Riordan
et al, 1985). It recognises a region which is highly conserved in all P-gps
analysed and represents a universal probe for the protein (Kartner et
al, 1985). This antibody has been used extensively in studies designed to
detect the localisation of P-gp in different tissues in order to elucidate it's
normal function. Tobe et al {1990) used C219 to assay rat renal brush border
membranes (BBM) and basolateral membranes and glomeruli by
immunoblotting. He found that the apparent molecular weight of P-gp in
CHO cells was 170 kD, whereas C219 bound to a protein of 155 kD in BBM.
In the immunoblots shown in Figure 5.7 and Figure 5.8 the Mr of the protein
detected by C219 in rat liver is 150 kD.
Dex, pyrazole and Ara also strongly induced the expression of P-gp
in rat liver. However, these compounds did not increase the level of mdr
transcription as measured by Northern blotting. This suggests that the RNA
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from rat livers treated with Dex, Ara and pyrazole is more efficiently
translated and/or the protein translated is more stable.
Many examples exist whereby challenging hepatic enzymes with
various chemicals results in increased protein but decreased mRNA levels
compared to untreated animals. Rats treated with pyridine display induced
expression of CYP2E protein but a decline in CYP2E mRNA expression
(Kim and Novak, 1990). This also occurs in rabbits treated with acetone
(Porter et al, 1989). The reason for this is thought to be due to increased
translatability of the message caused by transfer of RNA to larger
polysomes.
In the mouse, DEN induced mdr 1 in the liver and kidney (Figure
5.19), whereas it suppressed all cytochrome P450 families at the protein
level with the exception of Cyp2b1 (Figure 5.9).
The damaging effects of DEN on rat liver and kidney was assessed
(Figure 5.2 - 5.4). The necrotic areas around the cental vein in liver and in
the kidney tissue indicated extensive and acute damage to the tissues. Actin
levels were also induced to a high extent in rat (Figure 5.9) and mouse
(Figure 5.17).
Short-term exposure of the liver to a high dose of DEN causes a
decrease of P450 enzymes and an increase in mdr genes in a very short
period of time. P450 isozymes decrease due to a decline in the number of
hepatocytes which express P450 enzymes to a high extent, with the
development of necrotic areas around the central vein. P450 and GST
expression is normally found in these cells (Figure 5.30). Such zonal
expression of P450s is decreased in DEN treated liver compared to normal
liver as shown in Figure 5.30. In contrast, P-gp expression is induced in the
DEN treated rat liver. The hepatotoxic nature of the compounds capable of
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FIGURE 5.30 EXPRESSION OF P450 AND GLUTATHIONE S-
TRANSFERASES IN NORMAL AND DEN TREATED RAT LIVER
Male Wistar rat was treated with diethylnitrosamine, as described in Section 5.3.3. Control rats were
treated with corn-oil. Following trreatment the livers wre removed and prepared for histological staining,





















inducing mdr 1 expression appears to be significant. DEN may initiate
regenerative changes and thus induce mdr 1. Liver regeneration is well
known to cause increases in mdr genes in the rat (Marino et al, 1990).
The cell population which is non-necrotic in the DEN treated liver
may be rapidly dividing. The increase in actin levels following DEN
treatment would suggest such a state. Rapid division of cells often results in
a less well differentiated phenotype. This may also partly explain the loss of
P450 expression in the liver tissue treated with DEN.
From the studies on xenobiotic induction in the rat, several
conclusions were reached.
1. Hepatocarcinogens such as 2-AAF, AFB-) and DEN quickly induced
mdr mRNA levels, whereas other well known P450 inducers such as 3-MC
and Dex failed to do so.
2. Compounds known to operate via the Ah locus, for example 3-MC
and (3-NF, did not induce mdr mRNA levels. This suggests that mdr induction
is not operating through this mechanism. The possibility of the induction
operating via another receptor however is not excluded.
3. The pattern of mdr induction does not mimic any particular P450
family and is therefore presummed to be part of the general response to
xenobiotic insult shown by P450 and GST isozymes.
TCPOBOP causes dramatic increases in the expression of all the
cytochrome P450 proteins in mouse liver. The mechanism of action of
TCPOBOP is unknown, but for any drug-induced response the presence of a
potent agonist suggest that the effect may be mediated through a receptor.
Some evidence for such a receptor exists (Kende et al, 1985; Kelley et al,
1985).
The suppression of mdr 2 and 3 mRNA levels by TCPOBOP may
represent an important and effective route by which P-gp expression levels
in tumours may be regulated to allow for for effective chemotherapy. Certain
anti-cancer drugs such as VP-16 and vincristine increase mdr 2 mRNA
levels in mouse liver. Both compounds induced the mouse orthologue of rat
CYP4A to a moderate extent. It can be concluded that mdr 2 expression is
effected by some anti-cancer drugs in mouse liver.
Cyp3a family substrates in general do not appear capable of
221
influencing the level of expression of mdr 2 mRNA in mouse liver. However,
rifampicin and to a small extent progesterone increased the level of mdr 2
mRNA above those of control.
Progesterone induced many P450 families including the mouse
orthologue of rat CYP2A1, CYP2B1, CYP3A1 and CYP4A. It also induced
the expression of GST Ya-j to high levels. Progesterone and
deoxycorticosterone cause an increase in labelled vinblastine accumulation
and a modest reversal of vinblastine resistance in mdr J7 VI-1 murine
macrophages (Yang et al, 1989). Progesterone also inhibits azidopine
photoaffinity labelling of endometrial P-gp (Naito et al, 1989). These studies
indicate that progesterone may be a substrate for the mdr 1 gene product, P-
gp. The regulation of mdr 1 mRNA by progesterone suggested the
possibility that steroid hormones may also be substrates for mdr 2. However,
progesterone only slightly elevated mdr 2 mRNA levels in mouse liver.
Progesterone also had no effect on mdr 1 mRNA levels in mouse liver.
Therefore, progesterone induction appears to be mdr 1 and uterus specific.
Butylated hydroxyanisole incresed mdr 2 levels by 3 fold in female
Balb/c mice. BHA is known to induce hepatic mRNAs that code for a, (i and n
class GST by 50, 15 and 2-5 fold respectively (Pearson et al, 1988). An
element known as the ARE has been shown to be required for the activation
of the Ya subunit gene, in the rat, by phenolic anti-oxidants (Rushmore and
Pickett, 1990). The induction of the mdr 2 gene by this compound may be
due to a similar type of control mechanism.
To examine the transcriptional regulation of the mdr 2 gene, it will be
necessary to characterise the 5' upstream region to identify regulatory
elements.The mechanism by which TCPOBOP down-regulates the




ENDOGENOUS REGULATION OF MULTIDRUG
RESISTANCE GENES IN MOUSE
6.1 INTRODUCTION
The endocrine system and the nervous system control adjustments in
the body to enable it to adapt to environmental changes. The endocrine
system operates through hormones which circulate in the blood and modify
the activity of target organs. Some hormones act on several tissues rather
than on a specific target tissue, for example, growth hormone (GH), thyroxine
and insulin, which implies that the receptors for these hormones are
widespread. Other hormones act on one tissue, for example, thyrotrophin,
adrenocorticotrophin (ACTH) and gonadotrophins are secreted by the
anterior pituitary and have specific target tissues, namely the thyroid gland,
adrenal cortex and gonads respectively.
Some of the principle endocrine glands and the hormones they
produce are shown in Table 6.1.
Regulation of hormonal release by the anterior pituitary is complex.
Modulation of pituitary secretion by hormones secreted from the target
endocrine gland is known as "direct negative feedback". Feedback control
can occur via the hypothalamus and may be positive or negative. "Short-
loop" feedback also occurs, in which the pituitary hormone regulates it's own
secretion.
GROWTH HORMONE
Growth hormone (somatotropin, GH) is a protein hormone produced
in somatotrophs in the pituitary gland. GH has many different metabolic
effects and stimulates the synthesis of proteins and nucleic acids in a wide
range of tissues. Predominant among these is somatomedin C/insulin-like
growth factor (SmC/IGF-1) which is stimulated in many tissues, especially
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the liver (D'Ercole et al, 1984, McConaghey and Sledge, 1970) and
probably mediates the actions of GH. Specific binding sites for GH are found
in high concentrations in the liver and have been studied in many species
TABLE 6.1
PRINCIPLE ENDOCRINE GLANDS AND THE HORMONES
PRODUCED
GLAND HORMONE




Growth hormone releasing hormone
Prolactin inhibiting factor (Dopamine)





Posterior Pituitary Vasopressin (antidiuretic hormone)
Oxytocin








Adapted from Gould et al {1982).
224
and cultured cell lines (Wallis, 1980).
The nature of somatomedins is now well understood. Somatomedin C
stimulates cartilage growth in vitro, DNA synthesis and proliferation. It acts
as a growth factor for many cells in culture and appears to synergise with
platlet derived growth factor (PDGF) to promote growth (Stiles et al, 1979).
In the hypophysectomised rat, circulating levels of somatomedin C
are lowered to 5 - 10% compared to those in the intact animal (Maes et al,
1986; D'Ercole etal, 1984). Greater then 50% of circulating somatomedin C
in the rat is produced by the liver (D'Ercole et al, 1984) and this is a major
target organ for the effects of GH on the production of the polypeptide.
GH also stimulates somatomedin C levels in a variety of other
species, including mouse and man (Copeland etal, 1980). In man and other
species, shortage of GH due to pituitary deficiency lowers somatomedin
levels. From studies done by Mathews et al (1986) on the GH deficient (lit/lit)
mouse and Roberts et al(1986) on hypophysectomised rat, it was concluded
that GH causes a transcriptional increase in somatomedin C in the liver.
THYROTROPHIN
Thyrotrophin releasing hormone produced by the hypothalamus
stimulates the synthesis and release of thyrotrophin by the pituitary
thyrotrophs. Thyrotrophin or thyroid stimulating hormone (TSH) is bound to a
specific receptor on the thyroid follicular cell surface and activates release of
the thyroid hormones, thyroxine (T4) and triiodothyronine (T3).
With hypothyroidism, the concentrations of T4 and T3 are diminished.
ADRENOCQRTICQTRQPHIC HORMONE (ACTH1
ACTH is a 39 amino acid peptide synthesised and secreted by the
anterior pituitary and acts on several target tissues including the adrenal
cortex where it stimulates the synthesis of steroids. ACTH interacts with a
receptor in the adrenocortical plasma membrane and activates cAMP which
in turn activates a protein kinase within the cortical cells (Schimmer, 1980;
Bost and Black, 1986).
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The short-term action of ACTH on the adrenocortical cell is the
stimulation of the conversion of cholesterol to glucocorticoid,
mineralocorticoid or androgen precursor steroids and is catalysed by
enzymes in the endoplamic reticulum and mitochondria (Hornsby, 1988).
As well as short-term effects, ACTH also exerts long-term effects on
the synthesis of enzymes involved in steroidogenesis. All the cytochrome
P450 enzymes involved are inducible by ACTH, acting via cAMP (Waterman
and Simpson, 1985; Zuber et al, 1986). The mode by which ACTH causes
such induction is not fully understood. John et al (1986) showed using
nuclear run-off experiments that increased transcription of steroid enzyme
genes accounts for increased protein.
REGULATION OF XENOBIOTIC METABOLISING ENZYMES BY
HORMONES
A major mechanism by which the organism regulates xenobiotic
metabolism is hormonal control. The control is directed mainly at the liver
with most of the pituitary regulated hormones (adrenal, thyroid and sex
hormones) involved (for a review see Skett, 1987).
The expression of constitutively expressed cytochrome P450 genes is
regulated by hormones in various ways. During development, P450 gene
expression is activated. Immediately following birth in rats, CYP2E1,
CYP2D1 and CYP2D2 mRNA levels are elevated (Gonzalez et al, 1987;
Song et al, 1986). Changesin the methylation state of the CYP2E1 gene
correlates with transcriptional activation (Umeno et al, 1988).
The role of pituitary hormones in the regulation of sex-specific P450s
has been thoroughly investigated. In rats, pituitary growth hormone secretion
in male and female varies, with male rats having a pulsatile pattern of
secretion whereas females have a more constant secretory pattern. These
patterns are determined by neonatal androgen exposure and adult
testosterone levels (Jansson et al, 1985). CYP2C11 expression in males is
dependent on pulsatile growth hormone secretion and hypophysectomy
reduces it's expression (Kato et al, 1986). Growth hormone secretion is also
involved in the regulation of the female specific CYP2C12 (Mode et al,
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1987). Mice have also been investigated for developmental and sex-specific
regulation of P450 enzymes. A female specific testosterone 16a-
hydroxylase in the Cyp2b subfamily has been characterised (Noshiro and
Negishi, 1988).
Certain male and female P450 forms are suppressed on reaching
puberty. The expression of CYP3A2 mRNA in female rats decreases and
leads to loss of testosterone 6(3-hydroxylase expression at puberty
(Gonzalez et al, 1986a). The developmental decrease was found to be due
to the continuous levels of GH found in adult females (Kato et al, 1986).
Waxman (1988b) also suggested that such suppression could be the result
of decreased circulating corticosteroid. The actions of GH on hepatic
metabolism appear to be inextricably intertwined with those of other
endocrine systems notably the thyroid gland and adrenal cortex (Skett,
1987.
Inducibility of genes is also developmentally regulated. TCCD
induces the expression of the mouse Cyp1a1 gene at 10 days of gestation
whereas Cyp1a2 is not activated until after birth (Ikeda et al, 1983). In rat,
both CYP1A1 and CYP1A2induction occurs one week after birth. Therefore,
a species specific difference in developmental control occurs one week after
birth (Giachelli and Omiecinski, 1987). In general, most P450 enzymes are
not expressed or induced prior to birth.
Cytochrome P450 expression is also tissue specific. Most P450
genes are expressed in hepatocytes, but more specialised steroid
hydroxylases, for the biosynthesis of aldosterone and Cortisol are found in
such tissues as the adrenal gland, ovary and testis. Extrahepatic expression
is considerably lower than in the liver.
Changes in GST gene expression during development has been
studied most closely in the liver. Before birth, overall GST activity is low
whereas after birth the levels increase. At maturity the a family is more highly
expressed in the female and the p. family is more abundant in the male
(Igarashi et al, 1987). In mouse, the Yf (n) subunit is expressed in male liver
at levels approximately 10 fold higher than in the female and constitutes
~70% of the total hepatic GST content whereas in the female it represents
only a minor form (McLellan and Hayes, 1987). In rat, GST n occurs at high
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concentrations in preneoplastic nodules in both males and females
(Kitahara et al, 1984). Very little is known about developmental changes in
mouse GST isozymes apart from male hormone-dependent expression of
the k class in liver (McLellan and Hayes, 1987). Variations in the CDNB-
dependent GST activity in female mice have been shown to vary with age in
liver, lung and intestinal tissue (Fujita et al, 1985).
In rat, growth hormone was found to be most active of the pituitary
hormones in influencing steroid metabolism (Wilson, 1976). Growth
hormone was discovered to be the factor responsible for the pattern of drug
and steroid metabolism in males and females (Mode et al, 1983).
Administration of oestrogens to male rats feminises the pattern of GH
secretion whereas androgens masculinise the GH pattern in female rats
(Mode et al, 1982).
Many hepatic proteins are sexually differentiated including epidermal
growth factor (Ekberg et al, 1989), insulin-like growth factor 1 (Maitler et al,
1989), prolactin and oestrogen (Norstedt, 1982) and are under control of the
GH secretory pattern. In the mouse, a similar system operates. The
production of the mouse major urinary proteins (MUPS) and metabolism of
hexobarbital is regulated by the pattern of GH release (Macleod and
Shapiro, 1989).
The role of thyroid hormones in the control of hepatic drug
metabolism was reviewed by Skett and Weir (1983) and Leaky et al {1982).
The overall conclusions are rather confusing but thyroidectomy does result
in substrate- and sex-specific effects on cytochrome P450 drug metabolism.
The role of the thyroid gland on Phase II metabolism has also been studied.
Moscioni and Gartner (1983) did show however that a thyrotoxic dose of T3
could decrease bilirubin gluconyl-transferase and increase p-nitrophenol
gluuronyl tranferase activity in the rat. Decreased glutathione tranferase
activity towards CDNB and decreased levels of glutathione transferase A (3-
3), AA (2-2) and L (1-1) were found after thyroid hormone treatment in the rat
(Beckett et al, 1986; Beckett et al, 1988).
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AIMS
From studies on the endogenous regulation of both cytochrome P450
and GST drug metabolising hepatic isozymes, it was decided to examine
such regulation for the mdr genes in mouse. In light of the findings for other
hepatic enzyme systems, the possible role of the pituitary was investigated.
The first line of consideration was to examine the effects of removing
the pituitary by hypophysectomy and thereby ablating the effects of all
pituitary hormones. Subsequent studies relied on the use of animal models
to examine the effects of deleting specific pituitary hormones on the
expression levels of the hepatic mdr genes. These various models are
discussed below.
HYPOPHYSECTOMY
Hypophysectomy involves the removal of the pituitary gland, which is
the main regulator of the endocrine system. The hypothalamus releases
various factors which control the function of the pituitary. Removal of the
gland leads to the functional paralysis of the adrenal, thyroid and gonads.
Many diverse processes are governed by the anterior pituitary and removal
of such a gland is an extremely crude way of examining hormonal control
but can provide useful information as an initial study.
However, to determine which hormones are acting directly to regulate
specific effects and which are acting permissively, a more subtle approach
must be taken.
"LITTLE MOUSE" MODEL
Mutant mouse strains are commonly used to examine endocrine-
related phenomena. The "little" mouse mutant was derived from the C57BL/6
strain and has a specific autosomal recessive defect in GH synthesis and
secretion. Growth hormone releasing hormone (GHRH) is secreted from the
hypothalamus and stimulates GH synthesis and secretion from pituitary
somatotrophs via a specific receptor on the surface of these cells. In the
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mutant (lit/lit) mouse, GH is neither synthesised nor released in response to
GHRH, due to defective cell receptors (Clark and Robinson, 1985; Jansson
et al, 1986).Homozygous mice are -60% of the size of normal mice. Pituitary
GH content and GH mRNA levels in "little mice" was measured to be 4-8% of
normal levels (Cheng et al, 1983; Clark and Robinson, 1985). Other pituitary
functions are however normal which makes it an excellent model for the
study of GH regulation in gene expression.
TRANSGENIC HYPOTHYROID MOUSE MODEL
In the anterior pituitary, many hormones including thyrotropin, are
produced by different specialised secretory cells (see Section 6.1). Since
cells with different specialised functions are often physically close to and
interspersed with each other, it is almost impossible to produce an
experimental animal with a single hormone deficiency using surgery. In
order to study the involvement of thyroxine in the regulation of mdr genes in
the liver, a model in which to explore complete thyroid deprivation was
required.
The thyroid gland contains two known types of secretory cell; follicle
cells which produce thyroxine and C-cells which secrete calcitonin. The
gland is in close contact with the parathyroid gland which secretes para¬
thyroid hormone (PTH). The C-cells lie in clusters between the thyroid
follicles. Surgical removal of the thyroid results in the loss of the parathyroid
and the thyroid C-cells as well as the follicle cells. Drugs which have been
used to inhibit thyroxine production, such as methimazole and
propylthiouracil, do not consistently inhibit thyroxine and have toxic side-
effects in some cases. However, genetically hypothyroid mice retain
significant levels (10%) of circulating thyroxine (Stein et al, 1989).
A mouse model employing the technique of transgenic ablation was
utilised in this study. The model was kindly provided by Dr. R. Al-Shawi,
University of Edinburgh. The basis of such a technique has been well
established. Behringer et al {1988) targeted the expression of diptheria toxin
A-protein to the pituitary with the GH promoter which resulted in the specific
destruction of the pituitary somatotrophs and lactotrophs. An alternative
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approach was examined by Borrelli et al (1989) and is based on the
properties of herpes virus thymidine kinase (HSV1-TK). The expression of
the herpes virus gene (HSV-tk) was targeted to the pituitary by means of the
GH promoter. Following treatment of the transgenic mice with 1-(2-deoxy-2-
fluoro-p-D-aribinofuranosyl )-5-iodouracil (FIAU), the somatotrophs and
lactotrophs of the pituitary were completely and selectively ablated. Removal
of FIAU resulted in regeneration of these cells.
FIAU and Ganciclovir (9-[1,3-dihydroxy-2-propoxy(methyl)]-guanine;
DFIPG) are phosphorylated by FISV1-TK but not by cellular nucleoside
kinases. These compounds are lethally toxic when phosphorylated.
In the model used in this study (Wallace et al, 1991), transgenic mice
were examined in which HSV-TK expression was targeted to the thyroid
follicle cells by coupling the HSV-tk gene to the bovine thyroglobulin
promoter (deMartynoff et al, 1987). Expression was largely confined to the
thyroid follicle cells. Female mice were used since transgenic HSV1-tk
reporter genes are expressed in the testis irregardless of the promoter used,
resulting in male sterility (Al-Shawi et al, 1988).
Mature female mice were infused with DHPG which resulted in
complete loss of thyroxine production. The thyroid glands regressed and
follicle cells were destroyed. Serum levels of circulating thyroxine fell below
the limit of detection within 14 days while the level of PTH was unaffected
and calcitonin levels were reduced by less than 50%. Following withdrawal
of DHPG, thyroxine levels remained negligible for at least 60 days. The
production of mouse major urinary protein (MUP), known to require
thyroxine (Knopf et al, 1983) ceased in the hypothyroid mice but was
restored by thyroxine administration (Wallace et al, 1991).
As part of the thesis aims, developmental regulation of expression
was briefly examined in order to assess whether or not mdr genes are
expressed in a similar manner to P450 and GST hepatic enzymes both pre-
and post-natally.
Finally, four rodent species were compared to determine the extent of
variation of mdr 2 gene expression.
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6.2 PITUITARY REGULATION
6.2.1 HYPOPHYSECTOMISED MOUSE MODEL - ANIMAL TREATMENT
Male and female C57BL/6 mice were obtained from Charles River
Laboratories, Willmington, Massachusetts, USA. These animals were
hypophysectomised at eight weeks of age. Control animals were sham-
operated. Mice were allowed to recover from the operation for two weeks
before treatment. Animals (four per group) were treated with phenobarbital
(80 mg/kg, 3 dy, i.p.) and dexamethasone (100 mg/kg, 3 dy, i.p.). Control
animals received corn-oil. Animals were sacrificed by cervical dislocation 24
hr after the final treatment. The liver was removed immediately after sacrifice,
frozen on dry ice and stored at -70°C.
Changes in body weight and measurements of triiodothronine (T3)
levels were used to measure the success of the operative proceedure.
Completely hypophysectomised mice have a stable or gradually decreasing
body weight whereas incompletely hypophysectomised animals have an
increase in body weight. T3 decline is also indicative of successful surgery.
These measurements had been previously recorded and it was concluded
that thehypophysectomy procedure had been successful on these animals
(Dolan, 1990).
6.2.2 ANALYSIS OF MDR AND GST k GENE EXPRESSION FOLLOWING
HYPOPHYSECTOMY
RNA was prepared from male and female hypophysectomised
(hypox) and sham-operated (sham) C57BL/6 male and female control,
dexamethasone (100 mg/kg, 3 dy) and phenobarbital (80 mg/kg, 3 dy)
treated. Dexamethasone and phenobarbital treated mice had been
previously used to study the expression of GST Pi following
hypophysectomy. The known results of such treatment acted as an internal
control for the experiment. RNA (15pg) from each treatment was probed with
mdr 2, mdr 3, GST % and actin (Figure 6.1).
The actin levels for the hypox animals were consistently higher that
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FIGURE 6.1 LEVELS OF GST Pi, ACTIN, MDR 2 AND MDR 3
IN SHAM AND HYPOX MALE AND FEMALE C57BL/6 MICE
TREATED WITH DEXAMETHASONE AND PHENOBARBITAL
Male and female mice were treated, as described in Section 6.2.2, and RNA was prepared
from the liver following treatment. Northern blotting (15 pg per sample) was performed, as
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Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
the sham operated animals, although the ethidium bromide staining of the
ribosomal RNA was equivalent. Actin may be regulated to some extent by
pituitary factors which are removed after hypophysectomy.
Following hypophysectomy a sharp decline in the levels of GST k in
the male mouse occurs. In the female, a slight elevation in hepatic Yf was
noted after removal of the pituitary. Treatment with the compounds
phenobarbital and dexamethasone had little effect on sham male mice but
induced Yf mRNA levels in female mice substantially.
Dexamethasone and phenobarbital may fail to induce Yf levels in
male mice due to the already high levels of expression seen in untreated
animals. Following hypophysectomy, the male control level falls due to
removal of the positive regulation by GH (McLellan and Hayes, 1987).
Dexamethasone and phenobarbital are then observed to induce Yf levels
above those of the greatly suppressed control levels. Phenobarbital induces
mRNA levels to a greater extent than dexamethasone. In female mice by
contrast, the control levels rise following hypophysectomy probably due to
release of suppression by GH and perhaps other hormones. The induction
of Yf levels by phenobarbital and dexamethasone appears to be maintained
following hypophysectomy, with phenobarbital inducing Yf mRNA levels to a
greater extent than dexamethasone.
The mdr 2 and mdr 3 mRNA levels show a similar pattern following
hypophysectomy and xenobiotic treatment. In both male and female mice,
the levels of mdr 2 and mdr 3 mRNA are decreased in hypophysectomised
mice compared to sham-operated mRNA levels. The actin levels for sham-
operated dexamethasone treated females are low in comparison to the
sham-operated control and phenobarbitone treated female mice. Following
adjustment for actin, control, dexamethasone and phenobarbital treated
sham-operated female mice samples have similar mdr 2 and mdr 3 levels of
expression, as the sham-operated male mice. Following hypophysectomy,
male control, phenobarbital and dexamethasone treated mice mdr 2 and
mdr 3 mRNA levels are all significantly reduced. Phenobarbital treated mice
show greatly reduced levels of both mdr 2 and mdr 3 mRNA expression.
Such a result may indicate that the suppression caused by phenobarbital in
hypophysectomised male C57BL mice is normally masked by the pituitary
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factor(s) maintaining the levels of mdr 2 and 3 expression observed in the
control male animals. Following hypophysectomy, control, dexamethasone
and phenobarbital treated female mice mRNA mdr 2 and mdr 3 levels were
again significantly reduced in agreement with the male pattern. However,
phenobarbital does not have the same effect in suppressing mdr 2 and mdr
3 levels in hypox female animals as it does in hypox male mice. Therefore
the effect of phenobarbital on mdr 2 and mdr 3 expression appears to be
male specific. This finding does however require to be verified by further
treatment of more animals.
6.2.3 "LITTLE MOUSE" MODEL - ANIMAL TREATMENT
Male and female "little"mice (lit/lit) and controls (+/+) were obtained
from Charles Rivers Laboratories, Willmington, USA at the age of eight
weeks. The mice were acclimatised for two weeks before treatment
commenced. Phenobarbital (80 mg/kg, 3 dy) and dexamethasone (100
mg/kg, 4 dy) were administered to the mutant and normal mice. The animals
were sacrificed 4 days following the start of treatment. Livers were removed,
snap-frozen and stored at -70°C until required.
6.2.4 ANALYSIS OF MULTI-DRUG RESISTANCE GENE EXPRESSION IN
"LITTLE MICE"
Northern blot analysis was performed on the above animals using
RNA (15|ig) extracted from the liver. Both mdr 2 and mdr 3 levels were
examined.
As shown in Figure 6.2, no difference was observed between male
+/+ (control) and male lit/lit (GH-deficient) treated with dexamethasone.
Female +/+ and lit/lit treated with dexamethasone and phenobarbital
showed equivalent mRNA levels. A slight increase was observed in lit/lit
male mice compared to +/+ male mice treated with phenobarbital. Since
hypophysectomy caused a marked decrease in the expression of mdr 2 and
3 mRNA in phenobarbital treated male mice, such a result does not agree
with the hypothesis that growth hormone is suppressing mdr 2 mRNA levels
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FIGURE 6.2 LEVELS OF EXPRESSION OF MDR 2 AND MDR
3 IN +/+ AND LIT/LIT MICE
Male and female +/+ and lit/lit mice were treated, as described in Section 6.2.3, and RNA
prepared from the liver following treatment. Northern blotting (15 pg per sample) was
performed, as described in Section 2.11, using mdr 2 and mdr 3 cDNA probes.
+/+ growth hormone sufficient D
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Livers from each treatment group (4 mice per group) were pooled. This blot represents the
results obtained from one experiment.
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in these mice. These observations may be due to a slight variation in actin
levels. Mdr 3 mRNA levels were much lower than those seen for mdr 2, but
were equivalent between +/+ and lit/lit mice.
6.2.5 TRANSGENIC HYPOTHYROID MOUSE MODEL - ANIMAL
TREATMENT
Transgenic mouse lines were established by injecting the HSV-tk
thyroglobulin construct into either pronucleus of C57BL/6 x CBA/CaF2
embryos (Al-Shawi, 1988). Transgenic offspring were identified and four
lines were established. Transgenic female mice, 12-18 weeks of age, were
implanted with mini-pumps to administer DHPG (4.5 mg/dy for 14 days).
Control animals were given saline.
6.2.6 ANALYSIS OF MDR GENE EXPRESSION IN HYPOTHYROID MICE
RNA was prepared from both hypothyroid and control mice and
probed with actin, mdr 2 and GST a.
The results, shown in Figure 6.3, demonstrate that the actin levels
between control and hypothyroid mice were equivalent. Mdr 2 mRNA levels
were also unchanged between hypothyroid and normal mice, which
indicated the lack of involvement of thyroid hormones in the pituitary
regulation of hepatic mdr 2 mRNA levels. Interestingly, the expression of the
a class GST increased in the hypothyoid animal compared to control. The
levels of Ya-| has been shown to increase in hypox mouse liver (Dolan,
1990). Such an increase may be due, in part, to diminished levels of thyroid
hormone affecting the transcriptional expression of the gene.
6.2.7 REGULATION OF ADRENOCORTICOTROPIC HORMONE BY
DEXAMETHASONE AND TCPOBOP - ANIMAL TREATMENT
In order to establish whether or not adrenal hormones are involved in
the regulation of hepatic mdr 2 and mdr 3 gene expression, adult male
C57BL/6 mice (4 per group) were treated with dexamethasone (200 mg/kg,
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FIGURE 6.3 LEVELS OF ACTIN, MDR 2 AND GST-a IN
HYPOTHYROID COMPARED TO NORMAL MICE
Transgenic mice were obtained, as described in Section 6.2.5, and RNA was prepared from
the livers of hypothyroid animals and control animals. Northern blotting was performed, as
described in Section 2.11, using actin, mdr 2 and glutathione S-transferase alpha cDNA
probes.
Livers from each treatment group (4 mice per group) were pooled. This blot represents the
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3 dy) and TCPOBOP (3 mg/kg, 1 dy). Control animals (6 mice) were given
injections (0.2 ml, 3 dy ) of corn-oil.
The mice were sacrificed 4 days following the start of treatment.
Cardiac punture was performed on each animal to collect the serum for
measurement of corticosterone levels. Livers were also collected from these
animals and frozen at -70°C. RNA was prepared from the tissue to assess
whether or not the treatments had effected mdr expression levels.
6.2.8 MEASUREMENT OF CORTICOSTERONE LEVELS IN
DEXAMETHASONE AND TCPOBOP TREATED MICE
Corticosterone levels were measured in the three groups of mice
described above, as outlined in Section 2.13.2.
The standard curve data and graph for the assay is shown in
Appendix 2. From the assay, the percentage binding for the control,
dexamethasone and TCPOBOP treated mice was found to be 3=1.4%, 41.1%
and 36.6% respectively. From the standard curve, the corticosterone levels
were calculated as 380 nmol/l (control), 200 nmol/l (dexamethasone treated)
and 660 nmol/l (TCPOBOP-treated).
The control value was as expected. Normal rat corticosterone levels
vary between 100-300 nmol/l. Dexamethasone treatment decreased normal
corticosterone levels by -50% and TCPOBOP increased levels by -70%.
Dexamethasone is a known synthetic glucocorticoid and would be
expected to exert negative feedback on ACTH release and thereby reduce
plasma glucocorticoid concentrations.
In this study, dexamethasone administered for a period of 3 days did
suppress corticosterone levels but the response was not large.
TCPOBOP has been shown to be a potent inducer of mouse
microsomal monooxygenase activity (Poland et al, 1980). The effects of
TCPOBOP in mouse hepatocarcinogenesis have also been well studied.
The compound was shown to be a hepatic neoplasm promoter when
administered at 3 mg/kg, once a week for 5 months after an initiating dose of
diethylnitrosamine; hepatic enzymes involved in drug metabolism were also
shown to be induced by TCPOBOP (Dragini et al, 1985, 1987).
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In this study, TCPOBOP was shown to cause -70% increase in
corticosterone levels. The pathway in the adrenal cortex leading from
cholesterol to glucocorticoids (corticosterone in the case of mice) is known
to involve several different forms of cytochrome P450 enzymes. Such P450
enzymes in the adrenal may be induced by TCPOBOP to cause an increase
in overall corticosterone production. This hypothesis is an interesting one
and requires further examination, but is outwith the scope of this study.
6.2.9 ANALYSIS OF MDR GENE EXPRESSION IN ANIMALS WITH
ELEVATED AND DEPLETED CORTICOSTERONE LEVELS
Animals were treated as described in Section 6.2.7. Following
sacrifice, livers were removed and RNA was prepared from the three groups.
RNA (15pg) was probed with mdr 2 and actin.
As shown in Figure 6.4, the actin level for dexamethasone-treated
mice were slightly raised above control levels. Following visual adjustment
for actin, it was concluded that TCPOBOP significantly decreased mdr 2
levels compared to the control value whereas dexamethasone caused only
a slight decrease to mdr 2 mRNA levels. The effects of dexamethasone on
corticosterone levels were not considered great enough to be significant in
terms of causing changes to hepatic enzymes. The effect of TCPOBOP on
C57BL6 mice mdr 2 mRNA expression in this study was significant and the
corticosterone levels were increased substantially.
The effect of dexamethasone treatment following hypophysectomy on
mdr 2 and mdr 3 mRNA expression was negligible (see Figure 6.1). The
effects of corticosterone administration on hepatic drug metabolism in vivo
are manifested in hypophysectomised rats (Bousquet et al, 1965). Therefore
adrenocortical steroids can exert effects on hepatic microsomal enzymes
independent of the pituitary gland.
The changes in corticosterone levels by TCPOBOP treatment are




Since many hepatic enzymes are developmental^ regulated,
including cytochrome P450s and GSTs (see Section 6.1), it was of interest to
determine whether or not the mdr genes were likewise regulated.
FIGURE 6.4 LEVELS OF MDR 2 AND ACTIN IN
DEXAMETHASONE- AND TCPOBOP-TREATED C57BL/6 MICE
Mice were treated with dexamethasone and TCPOBOP, as described in Section 6.2.7, and
RNA prepared from the liver following treatment. Northern blotting was performed, as
described in Section 2.11, using mdr 2 and actin cDNA probes.
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Livers from each treatment group (4 mice for dexamethasone and TCPOBOP and 6 mice for
control) were pooled. This blot represents the results obtained from one experiment.
In order to examine expression both before birth and pre- and post-
pubertally, a time course from 15 days of gestation to 8 week old adult
mouse was examined.
6.3.1 TIME COURSE OF EXPRESSION - ANIMAL TREATMENT
Untreated C57BL/6 male mice (2 per group) were sampled at 1, 2, 4,
6 and 8 weeks of age. Liver at day 15 of gestation was also obtained from
fetal mice (4 animals pooled).
All livers were removed quickly following sacrifice, washed in PBS
and snap-frozen on card-ice. Tissue was stored at -70°C until RNA was
prepared from it.
6.3.2 ANALYSIS OF MDR GENE EXPRESSION IN EMBRYONIC AND
ADULT MOUSE LIVER
Hepatic RNA was extracted from mice at all time points and RNA
(15|ig) was examined with actin and mdr 2 cDNA probes. Figure 6.5 shows
the results of such analysis on mdr 2 expression during development.
In the 15 day fetal liver, mdr 2 mRNA levels are just detectable but
very low. Following birth, the levels of mdr 2 begin to increase and at 2
weeks the mdr 2 mRNA reaches maximal levels. Figure 6.5 also shows the
actin measurements for the same blot. The levels were equivalent for the
RNA from 1-8 weeks inclusive. The 15 day fetal liver RNA had been
overloaded compared to the other liver samples. Following adjustment for
actin, the mdr 2 levels in the liver appear to be negligible before birth and
rise rapidly post-natally.
MacFarland et a/(1991) investigated the levels of expression of mdr 1
in fetal tissue. In the fetal brain and testis, the polyclonal antibody MRK16,
specific for mdr 1, gave strong staining. In the testis the strongest staining
was in the interstitial calls (Leydig ceils) which actively secrete testosterone.
In the brain the cell surface of the Ependimal cells, which line the central
canal and ventricular surface between the brain cells and cerebrospinal fluid
were stained most strongly. In liver mdr 1 staining was found on the microvilli
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FIGURE 6.5 LEVELS OF MDR 2 AND ACTIN IN 15 DAY
EMBRYO AND 1-8 WEEK OLD C57BL/6 MICE
Male C57BL/6 mice were sampled at various ages, as described in Section 6.3.1, and RNA
was prepared from the liver. Northern blotting (15 pg per sample) was performed, as described
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Livers from each time point (2 mice per group) and from embryonic liver (4 mice per group)
were Dooled. This blot represents the results obtained from one experiment.
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of the bile canaliculi and in cytosolic granules in some sinusoidal
cells.However, the P-gp staining was much weaker in the liver than in other
tissues such as the brain. The levels of the mdr 2 gene product has not
been examined using immunohistochemistry since a peptide specific
antibody is not yet available.
6.4 VARIATION IN RODENT MDR GENE EXPRESSION
In order to assess whether variation in expression of the mdr 2 gene
occurs between different strains of mice, C57BL/6, C57BL (ICRF strain),
DBA2/N and Balb/c mouse liver was examined. Mdr 2 and actin mRNA
levels were measured. All animals (4 per strain) were adult when sacrificed.
Livers were collected, snap-frozen and stored at -70°C until RNA was
prepared from it.
Although the actin levels varied, with C57BL/6 being greater than the
rest, it was still evident that the Balb/c mice showed negligible levels of mdr
2 gene expression compared to other strains examined (Figure 6.6).
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FIGURE 6.6 LEVELS OF MDR 2 IN C57BL/6 (CHARLES
RIVER STOCK), C57BL (ICRF STOCK), DBA2/N AND BALB/C
MICE
Male mice from different strains were obtained, as descibed in Section 6.4, and RNA was
prepared from the liver. Northern blotting was performed, as outlined in Section 2.11, using
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Livers from each mouse strain (4 mice per strain) were pooled. This blot represents the results
obtained from one experiment.
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6.5 SUMMARY OF RESULTS AND DISCUSSION
From the results in this chapter, it was concluded that mdr 2 and mdr 3
gene expression in mouse liver is controlled by the pituitary.
Removal of the pituitary by hypophysectomy resulted in a decrease in
mdr 2 and mdr 3 gene expression in both male and female animals (Figure
6.1).
However, from analysis of animal models with depleted growth
hormone (Figure 6.2) and thyroid hormone (Figure 6.3), neither of these
hormones appeared to effect mdr expression when their release was
impaired. The growth hormone model has previously been used to show the
involvement of this hormone in GST expression and the effects of GH
depletion was assessed by measuring weight gain and T3 levels in these
animals (Dolan, 1990).
The thyroid hormone model was confirmed as being valid for the
study of hypothyroid mice by measurement of MUP and T3/T4 levels.
Histological examination of follicular cell was also performed. All these
parameters confirmed the hypothyroid state of the animals (Wallace et at,
1991).
Adrenal hormone status was also examined by using compounds
which elevated and depleted corticosterone levels. Depletion of
corticosterone levels by dexamethasone was not considered to be
substantial enough to mimic the effects of adrenalectomy. Further studies in
this regard would require removal of the adrenal gland to ensure complete
down-regulation of corticosterone production. However, the effects of
glucocorticoids on hepatic mdr 2 and mdr 3 expression is dubious since
dexamethasone given to mice following hypophysectomy did not cause an
elevation in mdr 2 or mdr 3 mRNA levels (Figure 6.1). TCPOBOP
administration caused an elevation in corticosterone levels and a significant
decrease in mdr 2 gene expression in C57BL/6 mice. The findings from this
preliminary investigation would merit further experimentation. This increase
in corticosterone is the opposite effect to that seen following pituitary
removal and hence does not explain the effect seen with hypophysectomy.
The regulation of mdr 2 and mdr 3 gene expression by pituitary
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hormones other than GH, thyroid hormone and adrenal hormones seems
unlikely since no male/female sex difference in mdr expression exists in
normal untreated mice. Pituitary hormones such as FSH and LH are known
to affect the gonads. Prolactin stimulates milk productin and breast
development in females and facilitates reproductive function in males.
The models used in this study do not allow for interaction between
different types of hormones in a regulated manner. However it is known that
certain hormones act synergistically, for example GH and thyroid hormone.
Knopf et al (1983) reported that transcription of the MUP genes in mouse
liver depends on both thyroxine and GH, which appear to act synergistically.
Thyroxine stimulates GH gene transcription (Evans et al, 1982). Thyroxine
deprivation influences MUP expression directly and indirectly through GH.
GH deprivation reduces growth by up to 50% for up to at least eight and a
half weeks after birth due to GH deficiency and partly due to consequential
IGF-I deficiency (Behringer et al, 1990). There are many interactions
between hormones and it is difficult in vivo to dissect out the individual
effects of the various hormones. Some hormones, for example
glucocorticoids, are permissive agents for the actions of other hormones
(Skett et al, 1987).
Another approach to the study of hormonal control is by
supplementing hormones to hypophysectomised animals. However, such
supplementation must mimic the normal pattern of hormone secretion. The
use of osmotic mini-pumps can be employed to overcome this problem.
Such a system can be readily adapted to allow two (or more) hormones to
be administered simultaneously. Using this approach, the interaction
between different hormones could be used to assess their role in the
regulation of mdr gene expression in the liver.
The examination of mdr 2 gene expression in the liver showed that
the expression was very low before birth; was maximal at two weeks
following birth and thereafter remained unchanged. In mice, puberty occurs
at ~4 - 6 weeks of age and therefore mdr 2 gene expression is not affected
by changes in sex hormone expression occurring at puberty.
Such elevation in expression following birth is commonly observed
for many hepatic enzymes and may be due to an increase in xenobiotic
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metabolism which occurs concomitantly with birth.
The differences in mdr 2 mRNA expression noted between the Balb/c
mouse strain and other strains examined was of interest. Differences in the
expression of mdr 2 transcripts was also noted in a study by Teeter et al
(1990) in which he noted that individual variations in the levels of mdr gene
expression within the same strain was apparent and especially true for mdr
2. Whether the low level of mdr 2 gene expression in the Balb/c mouse strain
is due to strain variation or individual variation is not known, since these
observations are still preliminary ones, made on a small group of animals.
Further studies are required to determine whether the variation in mdr
2 gene expression in different mice is genetically determined. Animal
models with different levels of mdr 2 gene expression may be useful in
studies on the physiological role of the mdr 2 gene product.
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CHAPTER 7 OVERALL CONCLUSIONS OF THE THESIS
AND DISCUSSION
Considerable evidence has accumulated to indicate that P-gp plays
a central role in both intrinsic and acquired resistance to cancer
chemotherapy. Inhibition of P-gp may aid in overcoming such resistance. An
attractive approach to inhibit the function of P-gp is to modulate or suppress
P-gp at the transcriptional level. It was presumed that P-gp, like enzymes
such as cytochrome P450s may be part of an adaptive response system
against environmental toxins. Therefore in an analagous way to the P450
system, P-gp may be subject to regulation by foreign chemicals and
hormones. To circumvent the resistance conferred by P-gp, an
understanding of how it is regulated is of obvious importance.
The major aim of the work presented within this thesis was to
determine the factors which contribute to the regulation of expression of
rodent mdr genes. The findings presented strongly suggests that both
xenobiotic and hormonal controls are involved in such regulation.
In conjunction with in vivo xenobiotic regulation studies in rat and
mouse, in vitro studies using established cell lines of hamster origin were
performed to investigate whether or not carcinogens act as substrates for P-
gp without prior metabolism by cytochrome P450 enzymes. It was concluded
that unmetabolised carcinogens failed to act as substrates for P-gp in cell
lines which express the protein to high levels.
7.1 XENOBIOTIC REGULATION
At the outset of the project, both C219 and MRK16 monoclonal
antibodies were available to study the regulation of mdr proteins. However,
both antibodies were of limited usefulness for different reasons. Monoclonal
antibody C219 was considered to cross-react with proteins, other than P-gp,
which were not involved in drug efflux. Thiebaut et al (1989) concluded that
the antibody cross-reacted with muscle myosin. This conclusion was re¬
iterated by Wishart et al (1990) following immunohistochemical studies
using C219 on frozen sections of skeletal and granulation tissue, known to
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contain myosin. However, more recent findings are not consistent with this
proposal. Bradley et al (1990) demonstrated the specific expression of the
class III hamster P-gp isoform, homologous to mouse mdr 2, in cardiac
muscle fibres and a subset of striated muscle fibres using C219. To prove
that specific staining was achieved, the antibody was competed with excess
of the C219-epitope peptide; staining which was non-specific was not
removed by co-incubation with the peptide. This study demonstrated that
C219 did not cross-react non-specifically with myosin as previously
reported.
Monoclonal antibody MRK16, generated against human
myelogenous leukemia K-562 cells resistant to adriamycin (K562-Adm),
was found to be species specific (Hamada and Tsuruo, 1986). Such an
antibody was therefore of no use in the investigation of rodent P-gp
expression.
In order to study the expression of P-gp in rodent liver, it was decided
to raise polyclonal antibodies for use in Western blotting and
immunohistochemistry. The method chosen for raising antibodies was to
immunise rabbits with peptide conjugates. The peptides represented 5
sequences of between 5 and 15 amino acids in length covering different
parts of the human mdr 1 gene (Chen et al, 1986). This strategy was
employed in an effort to raise antisera against specific regions of P-gp which
were considered to be highly conserved, extracytoplasmic or potentially
immunogenic. Such a strategy for raising antibodies was also adopted and
reported subsequently by Marquadt et al (1990) and Tanaka et al (1990).
Marquadt et al (1990) prepared antisera against peptides that corresponded
to the deduced sequence of human mdr 1 and found these to be highly
reactive with P-gp contained in HL60 cells, isolated for resistance to
vincristine. Tanaka et al (1990) generated antibodies against the amino-
and carboxy-terminal halves of P-gp using recombinant protein fragments
produed in E. Coli. These antibodies specifically immunoprecipitated ^H-
azidopine-labelled P-gp from mdr KB-C1 cells.
This type of strategy for raising antibodies differs from the ones
employed by Kartner et al (1985) and Hamada and Tsuruo (1986). Kartner
raised the C219 monoclonal antibody by immunizing mice with purified
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plasma membranes from CHRB30 and CEM VLB500 P-gp expressing cell
lines. In contrast, Hamada and Tsuruo immunized mice with intact K-
562/ADM cells to raise the MRK16 antibody.
In the present study 2 antibodies of high titre were rasied following
immunisation of rabbits with mdr peptide conjugates. Both these antibodies
cross-reacted with P-gp in mdr hamster and human cell lines. Polyclonal
antibody 21 detected P-gp in bovine adrenal medulla and adrenal cortex
microsomes to the same level found in the CHO colchicine resistant cell line
CH^CS. Immunoreactivity was shown to be specific by competing the PA21
antibody with an excess of the PA21 epitope peptide; staining that remained
following co-incubation with excess peptide was considered non-specific.
Similar high levels of P-gp expression have been reported in the hamster
adrenal cortex (Bradley etal, 1990) and the mouse adrenal gland (Croop et
at, 1989) as those found in bovine adrenal in the present study. Due to the
high levels of expression found in bovine adrenal and the suggested role of
P-gp in steroid transport (Thiebaut etal, 1987), primary bovine adrenal cell
culture would be a potentially useful model to study the regulation of P-gp
expression. The relatively large size of the adrenal in this mammalian
species would facilitate these kinds of study using primary cell culture.
Polyclonal antibody 21 failed to detect P-gp in normal rat liver and
kidney microsomes. Since the sequence of the rat P-gp protein has not yet
been published, it is not known whether the epitope (1273-1280 of human
mdr 1) against which the peptide antibody was raised is conserved in this
rodent species. Low sequence homolgy in this region of the mdr protein may
account for the lack of cross-reactivity in liver and kidney. In contrast, PA61
detected P-gp in normal rat and mouse liver as well as the mdr hamster cell
line CH^S. This antibody was raised against a peptide region which
mapped to the putative ATP binding site of human mdr 1. From the known
mouse and hamster sequences, homology to the human mdr 1 sequence
was compared and found to be between 80-100%. This probably explains
the strong inter-species cross-reactivity shown by PA61.
Unfortunately, neither PA21 nor PA61 were effective in detecting
differences between P-gp expression levels in the mdr cell line CH^S and
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its parental sensitive cell line AuxB1 in immunohistological studies. Both the
antibodies cross-reacted with other proteins present in the membrane and
cytosol. This is not unexpected since the antibodies were raised against
short peptide sequences which could potentially cross-react with many
proteins. Antibodies raised against the entire purified P-gp would have an
advantage in this respect. Pre-adsorption of the antibodies with pre-immune
serum may have increased the specifity of the two antibodes. In retrospect, it
would have been more useful to raise antibodies specific for particular
rodent proteins, for example the products of mouse mdr 1, 2 or 3. Mouse
liver is known to express the products of mdr 1, 2 and 3 with mdr 2
expression being highest. Gene specific antibodies would have been more
useful in differentaiting between the gene products in liver tissue, and would
have allowed an examination of the factors regulating the expression of
particular mdr gene products at the protein level.
The expression of 3 hamster P-gp isoforms have been studied in
normal hamster tissues by immunohistochemical analysis using isoform-
specific monoclonal antibodies (Bradley et al, 1990). It was shown that each
isoform is expressed in small distinct cell groups and is tightly regulated, in
some cases by hormonal control. These distinct patterns of expression of P-
gp has relevance to chemotherapy. An understanding of the expression of
distinct isoforms in normal cells may elude to the basis of P-gp expression in
malignant cells.
Since it was already established that certain well-known
hepatocarcinogens induced the mRNA levels of P-gp in rat liver (Burt and
Thorgeirsson, 1988), studies were conducted to examine the possibility of
carcinogens acting as substates for P-gp. It has been previously established,
from examination of rodent cytochrome P450 drug metabolising enzymes,
that compounds which act as inducers of different cytochrome P450
isozymes also act as substrates for those enzymes (see review of Gonzalez,
1989). Co-induction of P-gp and cytochrome P450 1 and 2 gene families,
representing a coordinated response of rats against harmful xenobiotics,
has been suggested by other studies (Burt and Thorgeirsson, 1988). On the
basis of potential overlapping regulation of cytochrome P450s and mdr
genes, the possibility of carcinogens acting as P-gp substrates was studied.
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The mdr cell line CH^C5 and it's parental cell line AuxB1 were used in a
tissue culture assay to determine whether or not carcinogens could compete
with P-gp for efflux of colchicine, a well known P-gp substrate. The
carcinogens studied included 2 acetylaminoflourene and aflatoxin B1.
These have previously been shown to induce P-gp expression in rats in
vivo (Burt and Thorgeirsson, 1988). These compounds are also known to be
metabolised by and weak inducers of cytochrome P450 gene families 1 and
2 (Astrom et al, 1986; Ishii et al, 1986). Benzo(a)pyrene, also studied as a
potential substrate for P-gp, is also actively metabolised by cytochrome
P450 1A1 (Goldstein et al, 1982).
Both cell lines were grown exponentially for 4 days in the presence of
a non-toxic dose of carcinogen and a range of colchicine concentrations.
The cell lines showed a differential response to colchicine; CH*\)5 cells
were 21 fold more resistant than AuxB1 cells.
The assay was designed to show whether or not the unmetabolised
carcinogens could compete with colchicine for P-gp efflux and hence
increase the toxic effect of colchicine in the P-gp expressing cell line.
However, the compounds used in the assay failed to increase the toxicity of
colchicine towards the P-gp expressing cell line.
It was concluded from the study that unmetabolised carcinogens
could not compete for P-gp efflux and hence do not act as substrates for P-
gp. The results from this work may be due to the lack of phase I metabolism
in the immortalised mdr cell line. The requirement for cytochrome P450
metabolism of the carcinogens in order to interact with P-gp correlates well
with the hypothesis proposed by Burt and Thorgeirsson (1988) which
suggested the coordinated response of mdr and cytochrome P450 families 1
and 2 against xenobiotics. Such a coordinate response may be due to the
requirement for P450 metabolism of compounds before they can act as P-gp
inducers.
Xenobiotic regulation of P-gp was studied in vivo using rodent
species. Two rat strains, Wistar and Fischer, and two mouse strains, DBA2/N
and C57BL/6, were examined. Regulation of mdr gene expression by
xenobiotics in these rodent species were shown to vary considerably.
However, inter-strain variation was negligible.
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In order to determine the type of compounds capable of inducing mdr
expression, rats were treated with a range of compounds known to be
inducers of specific cytochrome P450 isozymes, hepatotoxins and
carcinogens. Following treatment of the animals using standard dosing
regimes the expression of the inducible cytochrome P450 enzymes was
examined at both the mRNA and protein level. The compounds were found
to induce specific cytochrome P450 enzymes, as reported in the literature
(for a review see Gonzalez, 1989). At the mRNA level, the carcinogens 2-
acetylamino fluorene (2-AAF), diethylnitrosamine (DEN) and aflatoxin B1
(AFB1) induced the expression of rat mdr. It has been previously proposed
that mdr genes may respond to the same set of inducers as cytochrome
P450s 1 and 2. Since polyaromatic hydrocarbons are known to affect gene
expression via the cytoplasmic aromatic hydrocarbon (Ah) receptor (Eisen
et al, 1983), it was suggested that various ligands, such as AFB1, on binding
the Ah receptor, may result in induction of cytochrome P450 1 or mdr (Burt
and Thorgeirsson, 1988). The results from the present studies disagree with
such a hypothesis. 3-methylcholanthrene and p-napthoflavone, both known
to potently induce CYP1A1 via the Ah locus, failed to induce mdr mRNA
levels whereas 2-AAF and AFB1, which are weak inducers of CYP1A1,
successfully induced mdr mRNA. These results strongly suggest that the
regulation of mdr is not via the Ah locus. The original hypothesis was
subsequently retracted following further studies conducted in an isolated
hepatocyte system using the very potent cytochrome P450 1A inducer TCDD
(Thorgeirsson et al, 1991). TCDD is the definitive compound for the Ah
receptor and it was expected to be the most potent inducer of mdr. At
concentrations of TCDD found to cause maximal induction of CYP1A,
induction of mdr expression was very poor, therefore the proposed
involvement of the Ah receptor in mdr regulation was disproved. However,
an alternative receptor (mdr-R) sharing overlapping substrate specificity with
the Ah receptor and involved in xenobiotic induction of mdr expression was
hypothesised (Thorgeirsson et al, 1991). Experiments conducted to show
that inhibition of protein synthesis in primary rat hepatocytes induced mdr
mRNA levels also suggested the involvement of a distinct trans-acting
regulatory protein (Thorgeirsson et al, 1991). If such a receptor for mdr
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induction exists, antagonists for this receptor could potentially overcome
resistance.
Results of mdr induction in the rat differed from the mRNA level to the
protein level. 2-AAF and AFB1 induced both mdr mRNA and protein levels.
However some compounds which did not induce mdr mRNA, such as
dexamethasone, arachlor and pyrazole, did induce mdr protein levels.
These findings suggest that the regulation of mdr by xenobiotics may occur
by both transcriptional and post-transcriptional mechanisms depending on
the compound. AFB1, for example, may induce mdr protein levels by
increasing transcription rates or improving message stability whereas
dexamethasone may induce mdr protein levels by increasing the
translatability of the mdr message. In future, to assess whether or not mRNA
levels are induced by increased transcription rates or increased message
stability, nuclear run-off assays could be done.
Diethylnitrosamine decreased the mRNA expression of cytochrome
P450 enzymes but induced mdr mRNA levels. On this basis, the induction of
mdr mRNA levels by diethylnitrosamine appeared to differ from that of 2-AAF
and AFB1. DEN caused widespread necrosis in the liver leading to a
decrease in cytochrome P450 expression. However, at the start of animal
dosing, DEN may have initially induced cytochrome P450 enzymes, in a
manner similar to 2-AAF and AFB1. Therefore, it cannot be concluded
whether or not DEN induces mdr mRNA by the same or different
mechanisms as 2AAF and AFB1. By dosing rats with DEN at a less toxic
level it could be determined whether or not cytochrome P450 and mdr
expression is co-ordinated following administration of DEN.
The regulation of mdr mRNA levels by cytotoxic agents was recently
studied in rodent cells (Chin et al, 1990). It was found that mdr levels in
immortalised rodent cells increased substantially following exposure of
these cells in vivo to chemotherapeutic agents such as adriamycin,
duanomycin, m-AMSA and mitoxantrone. From nuclear run-off experiments,
the increase in mRNA was suggested to be due to both transcription and
post-transcriptional mechanisms. This was concomitant with a down-
regulation of topoisomerase II. This type of concerted response was
hypothesised to be a mechanism by which cells could protect themselves
255
against the toxic effects of these drugs.
In this thesis, the overall findings of mdr regulation by xenobiotics in
rats were as follows:
1. Hepatocarcinogens (for example 2-AAF, DEN and AFB1) induced two
rat mdr genes (5.3 kb and 4.3 kb). The identification of these genes is
unknown, although a recent report regarding the cloning and
sequencing of the first rat mdr cDNA suggests that the 4.3 kb
transcript may represent the homologue of the mouse mdr 1 gene
(Silverman etal, 1991).
2. P450 inducers known to operate via the Ah locus failed to induce mdr
mRNA levels. This mechanism of mdr regulation was therefore
refuted. An alternative receptor with overlapping substrate
specificity, as suggested by Thorgeirsson et a/(1991), is a
viable alternative hypothesis.
3. The induction of mdr mRNA and protein in the rat does not appear to
mimic the induction of a specific cytochrome P450 gene family or
families as previously proposed (Burt and Thorgeirsson, 1988).
Xenobiotic regulation of mdr induction in mouse was also studied in
the course of the thesis. Gene-specific probes for mouse mdr 1, 2 and 3,
were reported to correspond to discrete regions showing low sequence
homology among the 3 genes (Raymond et at, 1990). It has previously been
established that mouse mdr 1 cDNA can convey the mdr phenotype when
expressed in the drug-sensitive Chinese Hamster LR 73 cells (Gros et al,
1986). However, mdr 2 mouse cDNA failed to confer drug resistance
folowing similar transfection experiments (Gros et al, 1988). Using these
gene specific clones, it was shown that mdr expression was associated with
the independent expression of mdr 1, mdr 3 but not mdr 2 (Raymond et al,
1990). The characterisation of the mouse genes has also involved studies
into the tissue-specific expression of these genes in normal mouse tissues
(Croop et al, 1989). It was found that the expression level of each mouse
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mdr gene was dramatically different from tissue to tissue. Specific mRNA
transcript sizes of 4.5, 5 and 6 kb for mouse mdr 1, 2 and 3 respectively were
detected. Mouse liver was shown to express all 3 genes to some extent,
although mdr 2 was identified as the major mdr RNA species in the tissue.
Kidney was found to express mdr 1 more strongly than liver.
Since the liver is the major organ of detoxification it was decided to
study the expression of mouse mdr genes in this tissue. Foreign compounds
are known to both induce and suppress cytochrome P450 gene expression.
In order to determine whether or not this was the case for the mouse mdr
genes, mice were treated with a wide range of compounds including known
modulators of cytochrome P450 as well as chemotherapeutic drugs and
carcinogens. Most of the compounds, including the anti-cancer drugs, did
not alter the expression of either mouse mdr 2 or 3. Similar to the findings in
rat, the polycyclic aromatic hydrocarbons known to operate via the Ah locus,
for example 3-methylcholanthrene, had no effect on mouse mdr expression.
Of the compounds tested, DEN alone induced mdr 1 mRNA levels and mdr 2
mRNA was induced by vincristine (~2 fold), etoposide (~2 fold),
progesterone (~2 fold) and the phenolic antioxidant butylated
hydroxyanisole (BHA) (~3 fold). A profound effect on hepatic mdr expression
was seen with the phenobarbital-like inducing agent 1,4 bis [2-(3-
dichloropyridyloxy)] benzene (TCPOBOP). TCPOBOP is a herbicide
contaminant and is known to be an extrememly potent modulator of gene
expresion (Poland et al, 1980). Phenobarbital and dexamethasone had
similar but less marked effects.These 3 agents had the effect of suppressing
the expression of mdr 2 and mdr 3 mRNA in mouse liver. TCPOBOP
suppressed the level of mdr 2 well below that of control animals.
To determine the duration of the effect of the TCPOBOP response,
mice were sampled for up to 3 months following a single injection (75og) of
TCPOBOP and the effects on cytochrome P450 and mdr expression were
studied. Cytochrome P450 enzyme levels, in all the xenobiotic inducible
cytochrome P450 families, were still highly induced following this period.
This effect has been previously reported and is explained by the fact that
TCPOBOP is not metabolised or excreted but stored in adipose tissue
(Poland et al, 1981).
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The mechanism by which TCPOBOP is effective is unknown at
present. Since dexamethasone can also induce the expression of similar
cytochrome P450s as TCPOBOP, it was suggested that the effects may
involve the glucocorticoid receptor. This has now been shown not to be the
case (C. R. Wolf, personal communication). However, this does not exclude
the possibility that TCPOBOP may be a ligand for a hitherto unidentified
receptor. Nebert (1990) proposed that chemicals, such as TCPOBOP, that
can activate particular cytochrome P450s are ligands for receptors in the
nuclear receptor super-family.
The effects of TCPOBOP on gene expression in mice are the
opposite of those associated with the development of drug resistance in rat
liver preneoplastic lesions (Sato, 1989) and in a variety of drug resistant cell
lines (Cowan et al, 1986). Under these circumstances, cytochrome P450
gene expression is suppressed whereas mdr is induced. It may be possible
to use TCPOBOP to reverse the expression of mdr genes and induce
cytochrome P450 gene expression in tumour cells. Following treatment of
tumourous tissue with an anticancer drug, treatment with TCPOBOP may
increase the metabolism of anti-cancer compounds by increasing
cytochrome P450 expression but decreasing the efflux of the drug from the
tumour cells by suppressing mdr expression, and hence improve the
usefulness of treatment. To study whether or not TCPOBOP can induce
cytochrome P450 genes and suppress mdr gene expression in tumours, it
will be necessary to treat human tumour xenografts in nude mice with the
compound and measure both gene and protein expression.
The mechanism by which TCPOBOP can regulate gene expression is
obviously of great interest and importance. Studying and comparing the
regulatory elements of the genes which the compound can induce or
suppress may determine the important elements involved in such regulation.
The regulation of mdr 1 gene expression in the mouse has been examined
by Raymond and Gros (1990). They concluded that the regulation of
expression of mdr 1 may be conferred through interaction of a combination
of positive and negative cis-acting factors with regulatory trans-acting
factors. It was theorised that negative trans-acting factors could suppress the
basal transcription of cells in which mdr 1 is not expressed.
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In a similar manner, TCPOBOP may be able to effect the expression
of trans-acting factors involved in mdr gene regulation and cause gene
transcription to be suppressed. Alternatively, TCPOBOP may be able to alter
the methylation state of the mdr gene and in this way suppress transcription
of mRNA.
In future, to determine the regulatory elements involved in TCPOBOP
regulation of the mdr 2 and 3 genes, chimeric genes containing 5' deletions
in the mdr 2 or mdr 3 promotor region could be constructed. These
constructs, fused to the bacterial chloramphenicol acetyltransferase (CAT)
reporter gene (Gorman et al, 1982), could be transfected into cells and used
in transient expression assays. This system could measure the level of gene
expression in the constructs and allow an assessment of the elements
involved in basal and TCPOBOP inducible expression of the mouse mdr 2
and mdr 3 genes.
7.2 HORMONAL REGULATION
Studies conducted into the regulation of the mdr genes were based
on the premise that the products of these genes, like cytochrome P450
enzymes, may be part of an adaptive response to toxic insult. Therefore, as
found with the cytochrome P450 system, P-gp may be regulated by
hormones (Skett,1987). Hormonal control of both phase I (cytochrome P450)
and phase II (glutathione S-transferase) drug metabolising enzymes has
been previously studied.
In the present study, it was found that both mdr 2 and mdr 3 gene
expression is regulated by pituitary hormones. However, such regulation
was considered to be complex since depletion of growth hormone, thyroid
hormone and changes in the status of adrenal hormones failed to influence
the expression of these genes. No significant differences between male and
female mdr gene expression was detected. The substantial increase in mdr
2 expression in the liver following birth tends to suggest that mdr 2 may play
a significant role in the adaptive response of an organism to toxic compound
exposure which increases at this time. Cytochrome P450s and other drug
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metabolising enzymes are known to be elevated in response to increased
xenobiotic metabolism during development (Gonzalez et al, 1987).
7.3 CONCLUDING REMARKS
The original premise on which the studies in this thesis were based
was that P-gp, like enzymes such as cytochrome P450 dependent
monooxygenases, may be part of an adaptive response system against
environmental toxins. By analogy to cytochrome P450s, it was proposed that
P-gp may be subject to regulation by hormones and foreign chemicals.
From the main findings of the thesis it can be concluded that
xenobiotic compounds can both induce and suppress the expression of mdr
genes in the rodent species.
In the rat, compounds known to be weak inducers of the cytochrome
P450 1 gene family were shown to induce rat hepatic mdr expression.
However, the involvement of the Ah locus in the regulation of such
expression, as suggested by Burt and Thorgeirsson (1988), was disproved,
in agreement with subsequent literature (Thorgeirsson et al, 1991). The
hepatotoxic compound DEN induced rat mdr expression liver.
From these findings it was concluded that mdr and cytochrome P450
genes may be co-regulated and that regulation of gene expression may
operate via common regulatory elements. A model for xenobiotic induced
regulation of mdr gene expression in rat was suggested by Thorgeirsson et
al (1991) and is suitable for explaining the results obtained in this thesis with
regard to induction of rat mdr with foreign compounds.
The model proposes that a receptor (mdr-R) is involved in the
induction of mdr gene expression and shares overlapping substrate
specificity with the Ah locus. The model also suggests the presence of a
trans-acting regulatory protein involved in the regulation of mdr gene
expression, distinct from the proposed receptor.
The compounds shown to induce mdr in the rat (2-AAF, AFB1 and
DEN) may complex with the proposed receptor and induce mdr expression
as well as cytochrome P450 gene expression. Due to the high dose of DEN
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used to treat the rats in the present study, induction of cytochrome P450
cannot be measured following DEN treatment due to the necrosis of cells
normally expressing cytochrome P450 genes to high levels.
In the mouse, the phenobarbital-like cytochrome P450 inducing
compound TCPOBOP induced cytochrome P450 gene expression to high
and sustainable levels with concomitant decreases in mdr 2 and mdr 3 gene
expression. It is proposed that a receptor for TCPOBOP may be able to form
a substrate/receptor complex which can induce cytochrome P450 genes but
suppress mdr gene expression. Similar inducers such as phenobarbital and
dexamethasone, which are known to induce similar cytochrome P450
enzymes, also suppressed the expression of mdr genes.
Various experimental findings support a receptor mechanism for
TCPOBOP induction. Poland efa/(1980, 1981) identified TCPOBOP as a
potent agonist exhibiting a graded response which was tissue and species
specific. Furthermore, Kelley et al (1985) conducted studies into the
induction of cyctochrome P450s in mice by ten structural analogues of
TCPOBOP and found that these analogues had distinct strucure-dependent
potencies. These findings showed that any changes in the pyridyloxy or
benzene ring of the compound affected enzyme induction activity. These
studies provide evidence for a receptor-mediated response although such a
receptor has not yet been identified.
These data regarding the induction and suppression of mdr gene
expression in the rat and mouse respectively, via cytochrome P450 inducing
agents, show that distinct rodent species display differences regarding the
regulation of mdr gene expression. In the rat, regulation of mdr gene
expression appears to be via a receptor similar to the product of the Ah
locus. Compounds which can induce mdr gene expression appear to belong
to cytochrome P450 inducers which operate via such a receptor. However, in
the mouse mdr mRNA levels are suppressed by phenobarbital-like
compounds. These cytochrome P450 inducers are considered to operate via
a phenobarbital-like receptor. Mdr mRNA levels in the mouse are induced by
butylated hydroxyanisole (BHA) and some chemotherapeutic agents. BHA is
a phenolic antioxidant and known to induce glutathione S-transferase gene
expression via xenobiotic regulatory sequences (XREs). Mouse mdr gene
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expression has also been shown to be positively regulated by pituitary
hormones. Regulation of mouse mdr genes appears to be somewhat
complex and may involve both positive and negative regulatory elements.
Further studies into the regulatory elements contained in the
promoters of the mouse mdr genes should shed light on the mechanisms
involved in both xenobiotic and hormonal regulation.
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